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Dedicated to the memory of my mother, Judith Arron 
and to Sarah 
The value the world sets upon motives is often grossly unjust and inaccurate. Consider, 
for example, two of them: mere insatiable curiosity and the desire to do good. The latter 
is put high above the former, and yet it is the former that moves one of the most useful 
men the human race has yet produced: the scientific investigator. What actually urges 
him on is not some brummagem idea of Service, but a boundless, almost pathological 
thirst to penetrate the unknown, to uncover the secret, to find out what has not been found 
out before. His prototype is not the liberator releasing slaves, the good Samaritan lifting 
up the fallen, but a dog sniffing tremendously at an infinite series of rat-holes. 
H. L . Mencken 
The right answer to a trivial question is also trivial, but the right question, even when 
insoluble in exact form, is a guide to major discovery. 
Edward O. Wilson 
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1. A B S T R A C T 
This thesis describes the investigation of the mechanisms of signal transduction activated 
by tumor necrosis factor (TNF) superfamily proteins. Ligands of the TNF family engage 
TNF receptor (TNFR) family proteins, leading to a wide variety of cellular effects, and 
these interactions are implicated in inflammation, immune regulation, bone homeostasis, 
and development. TNFR proteins lack intrinsic enzymatic activity, and are coupled to 
intracellular signaling cascades by TNFR associated factor (TRAF) proteins, which are 
cytoplasmic adaptor molecules. The roles of TRAF1, TRAF2, and TRAF6 are 
investigated structurally and functionally in the activation of NF-kB, AP-1, and Src-
family kinases. Cbl proteins are identified as positive and negative regulators of TRAF-
mediated Src-family kinase signaling. The molecular structure of TRAF6 is determined 
and structure-function relationships between TRAF6 and the receptors to which it binds 
are examined. A physiological role for TRAF1 is identified in the regulation of TRAF2. 
This finding elucidates the role of translocation into lipid rafts in TRAF signaling and 
regulation. The implications of these findings are considered primarily in the reciprocal 
regulation of immunity and bone homeostasis by TRAF-mediated signaling pathways. 
2. General Introduction 
2. GENERAL INTRODUCTION 
2.1 TNF/TNFR Superfamilies 
Lymphotoxin (1) and tumor necrosis factor (TNF) (2) were first identified in the late 
1960s and early 1970s as factors produced by immune cells that induced the death of 
various types of tumor cells. As molecular cloning became commonplace, it became clear 
that the genes that encoded these factors were part of a large family of genes, the 
identification of which continues to expand to this day. The TNF superfamily consists of 
a wide variety of proteins, some cell-bound and others secreted, that regulate a wide 
variety of cellular processes. In particular, TNF family proteins regulate the life and death 
of not only tumor cells, but of activated cells of the immune system. They modulate the 
activation state of immune cells, and as we are increasingly becoming aware, they 
mediate the signals that these cells send to each other. TNF family proteins have been 
implicated in areas outside of inflammation and immunity, including bone homeostasis, 
lymph node organogenesis, hair follicle development, and mammary gland development 
(3). A holistic view of the TNF family clearly demonstrates that, through TNF family 
proteins, these myriad biological processes are inextricably linked, and the widespread 
sequelae of inflammatory processes can be explained through the actions of the TNF 
family. 
TNF family proteins mediate cellular effects by binding to their cognate cellular 
receptors, members of the TNF Receptor (TNFR) superfamily (3-6). TNF family proteins 
are expressed as type II transmembrane proteins that form trimers and may interact with 
their cognate receptors as cell-bound or soluble forms (7). TNFR family proteins are type 
I transmembrane proteins with conserved cysteine-rich domains (CRDs) that typically 
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consist of three conserved disulfide bridges (8). These domains form elongated receptor 
chains that intercalate with protomers of ligand trimers (9). It has been suggested that 
encounter with a ligand trimer induces the trimerization of a receptor, which leads to 
intracellular signaling, although recently it has been shown that TNFR proteins self-
assemble in the absence of ligand, undergoing conformational changes upon ligand 
engagement that lead to signaling (10). While the extracellular ligand-binding domains of 
TNFR proteins are similar, there are three divergent subgroups of TNFR proteins that can 
be classified by motifs (or lack thereof) in their cytoplasmic tails: death receptors, decoy 
receptors, and activating receptors. Since TNFR proteins appear to lack intrinsic 
enzymatic activity, their intracellular signals are mediated by cytoplasmic adaptor 
proteins. 
2.1.1 Death Receptors 
Apoptosis, or programmed cell death, is a necessary feature of embryonic development, 
lymphocyte homeostasis, CD8+ T cell-mediated killing of virus-infected or tumor cells, 
and the maintenance of "immune privileged" sites such as the eye (11,12). As opposed to 
death through necrosis, which is a response to physical injury to cells, apoptosis is a 
highly regulated process in which a cell "commits suicide." Morphological characteristics 
of apoptosis include membrane blebbing, cytoplasmic, nuclear, and chromatin 
condensation, and DNA fragmentation. The cell is reduced to fragments termed apoptotic 
bodies, which have intact membrane structures that contain surface markers that signal 
phagocytic cells to engulf them (13). This orderly process prevents the release of 
inflammatory stimuli that characterizes necrosis. During development, as tissues and 
structures differentiate, it is essential for certain cells to die in order to generate proper 
morphology. For example, in limb development, if there is a defect in apoptosis, the 
tissues in between digits may persist, resulting in webbing. During a cellular immune 
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response, there is massive proliferation of activated lymphocytes. While these activated 
lymphocytes are necessary to clear the infectious agent, they can cause collateral damage 
through nonspecific inflammation, and if they persisted, the body would eventually be 
overrun by lymphocytes. Indeed, mice and humans with mutations in Fas or FasL have 
autoimmune syndromes characterized by massive accumulation of activated lymphocytes 
and greatly enlarged lymph nodes (14). Thus, activated lymphocytes are extremely 
sensitive to apoptotic stimuli and lymphocyte homeostasis is maintained through the 
process of apoptosis (4). Death receptors such as TNFR1 and Fas contain a conserved 
intracellular "death domain" (DD) that can interact with intracellular DD containing 
adaptor proteins such as TRADD and FADD (15-17). FADD couples Fas and the 
TNFR1-TRADD complex to caspase-8 activation, which results in the orderly sequence 
of proteolytic events of apoptosis. 
2.1.2 Decoy Receptors 
Decoy receptors of the TNFR superfamily include osteoprotegerin (OPG) (18), DcRl 
(19,20), DcR2 (21-24), and DcR3 (25). Their function is to negatively regulate the effects 
of various TNF family ligands by preventing their interaction with cell-bound receptors 
that mediate the dominant signals activated by those ligands. OPG is a soluble decoy 
receptor for TRANCE (discussed in more detail in section 2.3). DcRl is a GPI-linked 
decoy receptor for the pro-apoptotic TNF family member TRAIL, DcR2 is a 
transmembrane decoy receptor for TRAIL, and DcR3 is a soluble decoy receptor for 
FasL. The expression of decoy receptors plays an important role in tempering the potent 
effects of TNF family members. Another mechanism of generating decoy receptors is 
through the proteolytic cleavage of cell-bound TNFR family proteins, rendering them 
soluble. This has been shown in the case of TNFR1, TNFR2, CD27, CD30, CD40, and 
Fas (26). A third mechanism of generating decoy receptors is through alternative splicing 
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of TNFR family proteins, generating membrane-bound receptors with no cytoplasmic 
tails, which has been shown for Fas (27) and CD40 (28). 
2.1.3 Activating Receptors 
Activating TNF receptors mediate their intracellular signals through a different set of 
adaptor proteins termed TNF receptor associated factors, or TRAFs. While DD 
containing receptors interact with cytoplasmic adaptor molecules that activate the pro-
apoptotic caspase cascade, receptors that interact with TRAF proteins activate a variety 
of signal transduction pathways that mediate a large number of cellular effects, including 
survival, proliferation, differentiation, activation, and migration, to name but a few. 
TRAF proteins will be discussed in greater detail in the next section. Table 2.1 lists 
known TNFR family proteins (by standardized TNFRSF nomenclature), their ligands, 
intracellular adaptor molecules with which they interact, and known physiological 
functions (adapted from (3)). 
2. General Introduction 
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2.2 TRAF proteins 
There are six known mammalian TRAF proteins, of which TRAF1, 2, 3, 5, and 6 have 
been shown to interact directly or indirectly with members of the TNFR superfamily (29-
31). In addition, TRAF6 mediates signaling from several other receptors that are not 
TNFR family proteins, including IL-1R, IL-18R, and Toll-like receptors (TLRs). The 
physiological role and binding partners of TRAF4 are presently unclear. TRAF proteins 
are characterized by a highly conserved C-terminal domain called a TRAF domain that 
mediates interactions of TRAFs with other proteins. The N-terminal domains of TRAFs 
are slightly more divergent, but each TRAF contains one or more zinc-binding domains 
that enable the activation of signaling cascades. TRAF proteins have been implicated in 
the activation of several kinase cascades, including MAP kinases, IkB kinases, and Src-
family kinases, resulting in the ultimate activation of transcription factor complexes 
including AP-1, NF-kB, Elk-1, ATF2, and others. Thus, TRAF proteins exert their 
function by linking TNFR family proteins to these kinase cascades and subsequent 
regulation of gene expression. 
2.2.1 TRAF identification, genetics, and expression 
TRAF1 was first identified through the biochemical purification of intracellular factors 
interacting with TNFR2, and TRAF2 was cloned via a yeast two-hybrid system using 
TNFR2 as bait (32). TRAF3 (also called CD40bp, LAP-1, and CRAF1) was identified as 
an intracellular factor interacting with CD40 and LMP1 (33-35). TRAF4 was identified 
by differential screening of a cDNA library generated from tumor cells (36). The 
existence of multiple TRAFs suggested a larger family of proteins with a conserved 
domain (the TRAF domain), and degenerate PCR strategies were employed to clone 
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TRAF5 and TRAF6, which were also independently identified by yeast two-hybrid 
screening using CD40 as bait and the screening of an EST expression library (37-40). 
Since the identification of TRAF6 over 5 years ago, no other proteins strictly defined as 
belonging to the TRAF family have been identified, although some TRAF-like proteins 
that may have divergent functions have been identified recently (41). Evolutionary 
conservation of TRAFs is suggested by the identification of a TRAF in the nematode C. 
elegans (42) and two TRAFs in Drosophila (dTRAFl and dTRAF2, (43)). To date, all 
six mammalian TRAFs have been deleted in mice by gene targeting, revealing various 
physiological roles for each (to be discussed further in section 2.2.5). Of the six 
mammalian TRAFs, sequence conservation analysis has shown that TRAFs 1, 2, 3, and 5 
are closely related, while TRAFs 4 and 6 are more evolutionarily divergent. Of these 
evolutionary relations, TRAF1 and TRAF2 appear to have arisen after duplication of a 
common precursor, while TRAF3 and TRAF5 are derived from a different common 
precursor (44). 
Expression patterns of TRAF proteins are widely variable. TRAF2, 3, and 6 are 
expressed in most cell and tissue types (32-35,39,40). The expression patterns of TRAF1, 
4, and 5 are more restricted. The highest levels of endogenous TRAF1 expression have 
been found in tonsils, spleen, lung, and testis (32), while TRAF5 is expressed in spleen, 
lung, and thymus (37,38). The expression pattern of TRAF4 underscores its apparent lack 
of function in the arena of other TRAF proteins (inflammation and immunity), as it is 
predominantly expressed during embryogenesis and in certain neural tissues (36). While 
the expression of TRAF2, 3,5, and 6 appears to be largely constitutive in the cells that 
express those TRAFs, the expression of TRAF 1 is tightly regulated. Most cells with the 
potential to express TRAF1 express it at very low levels in a resting state. However, 
inflammatory stimuli including TNF family proteins, IL-1, LPS, and lymphocyte receptor 
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engagement induces rapid upregulation of TRAF1 expression (45). Promoter analysis of 
the trafl locus shows the presence of NF-kB and AP-1 sites (46), thus, intriguingly, 
transcription factors activated by TRAF-dependent signals upregulate the expression of 
TRAFL 
2.2.2 Structural features of TRAFs 
The domain organization of TRAFs comprises a modular structure characteristic of 
adaptor proteins whose function is to link structurally dissimilar factors. As shown in 
Figure 1, the C-terminal TRAF domain (32) can be further divided into two sections, 
TRAF-N and TRAF-C. The TRAF-N section is helical and adopts the form of a coiled 
coil, mediating oligomerization of TRAF proteins. The TRAF-C domain also contributes 
to oligomerization as well as to interactions with TNFR family proteins and other 
cytoplasmic factors (47). The N-terminal halves of TRAF proteins are somewhat more 
divergent, but all TRAFs except for TRAF1 contain a RING finger motif at their N-
termini. The RING finger comprises a set of four closely spaced Zn fingers, which, in 
turn, consist of two residues that can chelate a single Zn2+ ion (generally cysteines, but 
occasionally histidines or acidic residues). C-terminal to the RING finger in TRAF2, 3, 5, 
and 6 are five Zn fingers, while in TRAF1, there is a single Zn finger, and in TRAF4, 
there are seven Zn fingers. In addition to the Zn binding motifs in TRAF4 are two 
potential nuclear localization signals (NLS), which may direct TRAF4 localization to the 
nucleus (36), while TRAF1, 2, 3, 5, and 6 are chiefly cytoplasmic in their distribution. 
While nearly all known interactions between TRAFs and other proteins such as TNFRs 
and cytoplasmic factors are mediated through the TRAF domain (31), the RING and Zn 
fingers appear to be necessary for the ability of TRAFs to activate kinase cascades (47). 
Accordingly, deletion of the N-terminal domains of TRAFs renders them dominant 
negative for signal transduction. 
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Figure 2.1. Domain organization of mammalian TRAF proteins. 
The structures of the T R A F domains of TRAF2 and TRAF3 have been determined by x-
ray crystallography, and have provided important insights into the mode of interaction 
between TRAFs and other proteins (48-51). Much as T N F family ligands are trimeric, 
and their binding to T N F R family receptors dictates receptor trimers, the binding of 
T R A F proteins to the cytoplasmic tails of TNFR proteins is also trimeric. The TRAF 
domains of TRAF2 and TRAF3 adopt a mushroom-shaped structure, with the coiled-coil 
TRAF-N domains forming the stalk and the TRAF-C domains forming the cap. The 
receptor-binding portion of the TRAF-C domain of TRAF2 forms a groove in which 
receptor sequences bind symmetrically in an extended conformation (51). The interaction 
of TRAF2 with T R A D D , which couples TRAF2 to TNFR1, comprises a more extended 
binding interface, and suggests that T R A D D may compete with other receptor sequences 
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for TRAF2 (52). The thermodynamic properties of TRAF2-receptor interactions show 
significantly lower affinity of TRAF2 monomers for receptor peptides than is the case 
with trimeric TRAF2 (53). This suggests an oligomerization-driven affinity or avidity 
enhancement of TRAF-receptor binding interactions, which may illuminate a mechanism 
of action for TRAF proteins. It has been shown that induced multimerization of the N-
terminal halves of both TRAF2 and TRAF6 can activate signaling, which suggests that, 
in vivo, receptor-induced TRAF trimerization is necessary for the activation of signal 
cascades (54). 
2.2.3 TRAF-interacting proteins 
As adaptor proteins for TNFR family members, TRAFs mediate the assembly of 
cytoplasmic signaling complexes at the receptor. They have been shown to interact with a 
wide variety of cytoplasmic factors, either directly or indirectly, in addition to the TNFR 
family proteins listed in Table 2.1. In addition to forming self-associated homotrimers, 
some TRAF proteins can hetero-oligomerize with each other. Specifically, TRAF2 has 
been shown to form hetero-oligomers with TRAF1 and TRAF5 (32,55) while TRAF3 can 
form hetero-oligomers with TRAF5 (56,57). Interestingly, the hetero-oligomerization 
pairs of TRAF 1/2 and TRAF3/5 mirror the evolutionary origin of those pairs of TRAFs 
(44), which suggests that hetero-oligomerization is a product of closely related structures. 
This may provide a further layer of regulatory roles for TRAFs - the regulation of other 
TRAFs. TRAF proteins bind to and mediate the function of several general types of 
intracellular factors, including kinases, regulators of signaling pathways, structural 
proteins, and other adaptor molecules (31). TRAFs are well-characterized activators of 
MAP kinase signaling pathways, and have been shown to interact with and activate these 
cascades at the level of MAP3Ks and MAP4Ks, including ASK1 (58,59), TAK1 (60), 
MEKK1 (54), NIK (61), and GCK3 (62). Some other kinases implicated in TRAF 
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signaling are Src-family kinases (63,64), IRAK (39), and PKC (65). Most of the 
interactions demonstrated for TRAF proteins with kinases are mediated via the TRAF 
domain. However, the TRAF domain alone acts as a dominant negative, thus the N-
terminal RING and Zn fingers appear to play a vital role in the activation of these kinase 
cascades (47,66). Known interactions of TRAFs and intracellular factors are listed in 
Table 2.2 (adapted from (31)). 
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Table 2.2. TRAF-interacting cytoplasmic proteins and their functions 
Cytoplasmic factor 
RIP (Receptor interacting protein) 
RIP2 
IRAK (IL-1 receptor associated 
kinase) 
IRAK2, IRAK-M 
NIK (NF-icB inducing .kinase) 
ASK1 (apoptosis signal -regulating 
kinase-1 
TAK1 (TGF-P associated kinase-1) 
MEKK1 (MEK/ERK Kinase-1) 
IRE1 
GCK (Germinal center kinase) 
CDK9 (cyclin dependent kinase 9) 
PKC^ (protein kinase C, i\ isoform) 
TBK1/NAK 
c-Src 
cIAP-1 (cellular inhibitor of 
apoptosis-1) 
cIAP-2 
TRIP (TRAF inhibitory protein) 
TANK/I-TRAF 
A20 
T R A D D (TNFR associated D D 
containing protein) 
FLASH (FLICE-associated huge 
protein) 
ABIN (A20 binding protein) 
ECSIT 






































Activation of IKK, assembly of T N F R 1 complex 
Simile to RIP 
With M y D 8 8 or TIRAP/MAL, mediates signaling 
from IL-1R and TLRs to T R A F 6 
Similar to IRAK 
MAP3K-like kinase upstream of IKK activation 
MjAP3K upstream of J N K activation 
M.AP3K upstream of IKK, J N K 
M A P 3 K upstream of J N K 
ER-associated stress kinase 
M A P 4 K upstream of J N K 
Cell cycle regulation 
Mitogenic signaling 
Upstream of IKK activation 
Multifunctional tyrosine kinase 
Anti-apoptotic adaptor 
Similar to cIAP-1 
Inhibitor of T R A F signaling 
Regulator of T R A F signaling 
Antiapoptotic, anti-inflammatory regulator 
Mediates assembly of T N F R 1 complex, associates 
with RIP, F A D D , A20 
Assembly of apoptosis-inducing complex with 
caspase-8, possible role in IKK activation 
Inhibits IKK activation 
Enhances IKK activation 
Inhibits T6-IRAK interaction 
Competes with T R A F 6 for C D 4 0 binding, 
inhibitor of T R A F signaling 
Actin-binding protein 
Binds to microtubules 
Required for formation of caveolae 
Mediates nuclear entry 
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2.2.4 Signaling pathways activated by TRAFs 
TRAFs are defined by their ability to couple TNFR family proteins to signaling pathways 
that result in the cellular effects mediated by TNF family ligands. The most well-studied 
signaling pathways activated by TRAF proteins are those leading to the activation of the 
transcription factors NF-kB and AP-1. NF-kB describes a set of five transcription factor 
subunits: p50, p52, RelA, RelB, and cRel (67,68). An active complex of NF-kB consists 
of two of these subunits, either as a homodimer or a heterodimer. NF-kB complexes are 
maintained in the cytoplasm in an inactive state by an inhibitory protein, IkB, of which 
there are several variants (a, (3, y,and e among them). When a cell receives an NF-kB 
activating stimulus, a large, multiprotein complex of IkB kinases (IKK) phosphorylates 
IkB on two serine residues (69). Phospho-lKB is then recognized by ubiquitin-
conjugating enzymes, which quickly ubiquitinate it, resulting in its degradation. The 
released NF-kB subunits then translocate to the nucleus, where they bind to specific 
promoter sites, activating transcription of a wide variety of genes, including cytokines, 
adhesion molecules, transcription factors, and survival factors. Most TNF family-induced 
NF-kB activation has been associated with cell proliferation, survival, and differentiation 
signals. Oligomerization of TRAF proteins in a receptor complex results in the 
recruitment and activation of various kinases upstream of IKK, including RIP (70), NIK 
(61), TAK1 (60), MEKK1 (54), and MEKK3 (71). It is likely that no single one of these 
kinases is essential for TRAF-mediated NF-kB activation, but rather they may have 
overlapping or cell type-specific roles (72). Recently, in vitro biochemical studies have 
suggested that the mechanism of TRAF-mediated IKK activation involves the ability of 
the RING finger of TRAF6 to act as an E3 ubiquitin ligase, mediating non-classical K63-
linked polyubiquitnation of TRAF6 as well as of the IKK complex (73,74). 
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AP-1 describes a dimeric transcription factor complex comprising combinations of Jun 
(v-Jun, c-Jun, JunB, or JunD), Fos (v-Fos, c-Fos, FosB, Fral, or Fra2), or activating 
transcription factor (ATF2, ATF3, or B-ATF) proteins. c-Jun is activated by JNK, a 
stress-related MAP kinase (75). TRAF proteins, in particular TRAF2, activate JNK by 
activating upstream MAP3Ks including ASK1 (58,59), MEKK1 (54), TAK1 (60), and 
the MAP4K GCK (62). These kinases in turn activate MAPKKs such as MKK4 and 
MKK7, which phosphorylate JNK (76). As is the case with IKK kinases, genetic deletion 
of several of the MAP3Ks upstream of JNK has not revealed an absolute requirement for 
any one of these kinases in TRAF-mediated JNK activation, implying that there may be 
some redundancy in TRAF-mediated JNK activation (71,77,78). In lymphocytes, JNK 
activation appears to be associated with proliferation and survival signals, while in some 
other cell types, it is associated with apoptotic signals and stress responses (75,76). 
Notably, JNK is activated in response to physical and osmotic stress as well as in 
response to irradiation and DNA damage (79). In addition to JNK, other MAPKs are 
activated by TRAF signaling, including ERK and p38. ERK activates the transcription 
factor Elk-1, which is involved in cell activation and survival signals. p38 activates the 
AP-1 component ATF2, which has been implicated in stress and activation responses 
(76,79). Recently, we (63) and others (64) have shown that TRAF6-mediated signals can 
activate c-Src family tyrosine kinases. c-Src is essential for TRANCE-mediated 
osteoclast activation, and Src family kinase-mediated PI3-K activation results in the 
activation of Akt, a kinase associated with survival signals. 
Some typical examples of TRAF-mediated signaling pathways are illustrated by those 
activated by TNF-a, TRANCE, and IL-1. TNF-a has two known transmembrane 
receptors, TNFR1 and TNFR2. TNFR1 is a DD-containing receptor, and does not 
directly bind to any TRAF proteins, while TNFR2 has no DD and can directly bind to 
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TRAF1 and 2 (and possibly TRAF5) (32). While TNFR1 is expressed on most cell types, 
the expression of TNFR2 is restricted to hematopoietic cells (80,81). Additionally, while 
TNFR1 can be stimulated by cell-bound or soluble TNF-a, TNFR2 is only responsive to 
cell-bound TNF-a (82). Upon ligand engagement, TNFR1 recruits TRADD and RIP to 
the receptor complex via DD interactions (17,70). There are two essential pathways that 
can be activated at this point - TRADD can recruit FADD, which activates the caspase 
cascade, resulting in apoptosis, or it can recruit TRAF2, which activates NF-kB and AP-1 
signaling, which results in survival or proliferation (17). TNFR2, on the other hand, lacks 
a DD, and can bind to TRAF2, activating survival pathways (32). Interestingly, TNFR2 
stimulation has been shown to potentiate TNFR 1-mediated apoptosis, and this may be 
accomplished through the depletion of available TRAF2 (83). Thus, the available pool of 
TRAF2 may serve to regulate the balance of life and death in TNF signaling. Figure 2.2 
diagrams some features of TNF signaling. 
TRANCE-R, unlike TNFR1, lacks a DD, and its cytoplasmic tail can recruit TRAF1, 2, 
3,5, and 6 (84). The TRAF6 binding sites are distinct from the binding site for the other 
TRAFs in TRANCE-R. The TRAF1/2/3/5 sites are associated with the activation of NF-
kB and JNK similar to TNFR2, as are the TRAF6 binding sites. In addition, TRAF6 has 
been implicated in MAPK activation and c-Src activation (63). IL-1 is not a TNF family 
protein, and its receptor is not a TNFR family protein, although it signals through 
TRAF6, but indirectly. IL-1 binding to IL-1R, which is associated with an accessory 
protein (IL-lRAcP), induces the formation of a receptor complex that includes the 
cytoplasmic factors MyD88 and Tollip. MyD88 and Tollip then associate with the 
cytoplasmic factor IRAK. IRAK binds to TRAF6, enabling the activation of similar 
downstream signals as from TRANCE-R (39,85-89). IRAK is also a key intermediate in 
Toll-like receptor (TLR) signaling (90-92). TLRs recognize repetitive sequences such as 
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bacterial and viral products, and are associated with innate immunity. Thus, by mediating 
signals from both TNFR family proteins and TLRs, TRAF6 serves as a molecular bridge 
between adaptive and innate immunity. TRAF6-dependent signaling mechanisms from 
TRANCE-R and IL-1R are shown in Figure 2.3. 
TNF 
TNFR1 










JNK, p38, ERK 
lTRAF3 NF-kB 
s i V 
Figure 2.2. Signaling pathways 
activated by TNF. Soluble TNF-
a acts primarily on TNFR1 while 
membrane-bound TNF-a acts on 
TNFR2. TNFR1 associates with 
TRAF2 through TRADD and RIP, 
while TRAF2 binds directly to 
TNFR2. Death domains (DD) are 
shown in red. 
Figure 2.3. TRAF6-dependent 
signaling pathways. T N F R 
family members such as 
TRANCE-R and CD40 bind to 
TRAF6 as well as other TRAFs, 
activating various pathways 
including Src-family kinases. IL-
1R and Toll-like receptors are 
indirectly linked to TRAF6 
through MyD88, Tollip, and 
IRAK. 
NF-kB JNK 
2.2.5 T R A F knockout mice 
All six of the T R A F proteins have been deleted in mice by gene targeting, and the 
phenotypes of these mice reveal divergent roles for each T R A F . TRAF1-/- mice have no 
apparent developmental defects but appear to have enhanced inflammatory and T cell 
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responses to TNF (93). The biochemical function of TRAF1 in its regulation of TRAF2 is 
revealed in TRAF1-/- cells and will be discussed in detail in section 3.3. TRAF2 has been 
targeted by deletion as well as by overexpression of a dominant negative form of TRAF2 
in lymphocytes (94,95). TRAF2-/- mice appear relatively normal at birth but become 
progressively runted and cachectic and generally die within several weeks. This is most 
likely due to a "feed-forward" response of macrophages to TNF, as TRAF2-/-
macrophages produce large quantities of TNF in response to TNF stimulation, leading to 
systemic inflammation. TRAF2-/- cells show a lack of TNF-induced JNK activation but 
still have NF-kB activation, although they display an enhanced tendency toward TNF-
induced apoptosis relative to wild-type cells (94). Crossing of TRAF2-/- mice to TNF-/-
or TNFR1-/- mice greatly ameliorates the wasting phenotype (96). Overexpression of 
dominant negative TRAF2 (lacking the RING and Zn finger domains) in lymphocytes 
results in reduced JNK but not NF-kB activation in response to TNF and CD40L (95). 
The residual NF-kB activation may be explained by a redundant role of TRAF5, as 
TRAF2-/-TRAF5-/- cells have a complete lack of TNF-induced NF-kB activation (97). 
TRAF3-/- mice, like TRAF2-/- mice also appear normal at birth but become 
progressively runted and die within several weeks. Reconstitution of lethally irradiated 
mice with TRAF3-/- fetal liver cells produces lymphocyte, granulocyte, and erythroid 
lineages in those mice, but T cell responses are somewhat reduced, although CD40 
signaling does not appear to be compromised (98). TR..AF4 deletion results in tracheal 
malformation (99). Deletion of TRAF5 produces a relatively mild phenotype, with some 
defects in CD40-mediated B cell responses (100). TRAF6-/- mice have severe 
osteopetrosis, or thickening of bones, due to a defect in osteoclast function. Two separate 
deletions of TRAF6 have been reported, and one completely lacks osteoclasts (101), 
while the other has osteoclasts that are incapable of resorbing bone (102). In addition, 
both TRAF6-deficient strains have reduced responses to LPS, IL-1, and CD40. Thus, 
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despite the similarities in signaling pathways activated by different TRAF proteins, each 
appears to have a distinct physiological role. 
2.3 Physiological processes regulated by TNF family proteins 
TNF family proteins play vital roles in a wide variety of cellular processes, including 
development, inflammation, immunity, and bone homeostasis. As TNF/TNFR family 
proteins mediate communications between cells, they are important cellular organizers, 
mediating the formation of multicellular structures including inflammatory foci, 
lymphoid organs, bone, hair follicles, and lactating mammary glands (3). The signals 
transduced by TNFR family proteins that activate survival, death, differentiation, 
activation, and proliferation determine the dynamic organizing and reorganizing events 
that characterize the systems regulated by TNF/TNFR interactions. In particular, we shall 
consider the role of these interactions in immunity and bone homeostasis, which are both 
typified not by the permanence of any cellular structures but rather by the constant state 
of flux that ensures the robustness of each system. Additionally, it is becoming clear that 
the apparent divergence of the highly specialized cell types that constitute these 
apparently divergent systems is less obvious on a molecular level, and in fact, these 
systems are quite interdependent. In particular, the communication between these systems 
via TNF/TNFR family proteins is bridged by the processes and systemic metabolic 
requirements of inflammation. 
2.3.1 Dendritic cells 
Dendritic cells (DC) are essential organizers of immune responses. They are highly 
specialized cells that capture antigens in peripheral tissues, migrate to lymphoid organs, 
and organize T cell responses. The life cycle of the dendritic cell consists of several well-
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defined stages, including differentiation, maturation, activation, and apoptosis (103). All 
of these processes are regulated to some extent by the action of TNF family proteins on 
DCs, in particular TNF, CD40L, and TRANCE (104), while DCs can stimulate T cells 
via expression of OX40L, CD27L, and 4-1BBL (3). Additionally, extracellular signals 
not originating from TNF family proteins in DCs are still TRAF-dependent, as DCs are 
highly sensitive to bacterial and viral products that signal through TLRs (103), as well as 
to IL-1, which utilize TRAF6 in their signaling pathways. DC signals that influence T 
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Figure 2.4. DC-T cell cross-talk I. DCs mediate a wide variety of effects on T cells, in part through the 
actions of the TNF family proteins 4-1 BBL, CD27L, and OX40L. 
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Figure 2.5. DC-T cell cross-talk II. DCs respond to a wide variety of signals from their environment and 
from T cells with which they interact. TRAF-dependent factors that influence DCs include LPS, viral 
products, IL-1, TNF, CD40L, and TRANCE. 
DCs arise from multipotent precursors of the monocyte lineage. Autocrine TNF 
production is thought to contribute to differentiation to immature DCs (105). Immature 
DCs reside in peripheral tissues, sampling antigens. They are highly specialized for this 
task, efficiently internalizing particles from their environment. At this stage, the 
expression of T cell costimulatory molecules such as CD80, CD86, and MHC is low, as 
is the expression of TNFR family proteins such as CD40 and TRANCE-R. Many stimuli 
can induce the maturation of DCs, including microbial products that bind to TLRs, and 
inflammatory cytokines such as IL-1, TNF, and CD40L. As DCs mature, endocytosis 
decreases, and the surface expression of costimulatory molecules, CD40, and TRANCE-
R increases (106). Maturing DCs migrate to draining lymph nodes, where they encounter 
activated T cells, engaging in a sophisticated cross-talk with them. In the absence of 
external survival stimuli, mature DCs rapidly undergo apoptosis (107), which is a likely 
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regulatory mechanism preventing autoimmunity. A productive interaction between an 
antigen-bearing DC and an antigen-specific T cell involves signals influencing both the 
DC and the T cell. Stimulation of the TCR and costimulatory receptors such as CD28 
upregulate TNF, CD40L, and TRANCE on T cells, which provide survival and activation 
signals to the DC, so that it may engage more T cells in an ongoing immune response 
(104). Immature DCs are able to stimulate regulatory T cells leading to tolerogenic 
responses (108), thus the phenotype of DCs is an important regulator of the quality and 
intensity of a given immune response. 
TNF family members are important regulators of DC function. CD40L induces DC 
maturation, survival, and cytokine production (109). CD40L deficiency leads to a 
markedly reduced ability of DCs to stimulate T cell-dependent responses (110). 
TRANCE- and CD40L- mediated increases in DC survival have potent effects on 
antigen-specific T cell responses (107,111,112), suggesting that the persistence of 
antigen-bearing mature DCs in the lymph node is an important factor in determining the 
efficiency of T cell responses. TNF-deficient mice display reduced antiviral responses, 
which is likely to be due to a defect in maturation (113). The spontaneous apoptosis of 
mature DCs appears to be at least partially due to autocrine activation of TNFR1, as 
TNFR1-/- DCs are highly resistant to spontaneous apoptosis (114). While the importance 
of TNF family proteins to DC biology is indisputable, the signaling pathways activated 
by TNF family proteins in DCs have not been well documented. A deeper understanding 
of the roles of specific signals induced by TNF family proteins in DCs may provide tools 
to manipulate the quality and intensity of immune responses. 
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2.3.2 Osteoimmunology: cross-talk between bone and the immune system 
It has long been known that the cells of the immune system originate in the bone marrow. 
While the differentiation of lymphocytes and other cells of the hematopoietic system in 
bone marrow has been well described, relatively little attention has been paid to the 
effects that immune cells have on the bone itself. The possibility that immune cells can 
affect bone has been suggested in a variety of pathological conditions where normal bone 
growth and remodeling is disrupted, including autoimmune diseases and cancers of the 
hematopoietic system. The recent identification of some of the molecular mechanisms 
that govern bone physiology and immunity has revealed a striking amount of cross-talk 
between the two systems. It is rapidly becoming apparent that the fields of bone biology 
and immunology are inextricably intertwined. 
2.3.2.1 Bone disease and osteoclasts 
Rather than simply serving as a rigid, static frame on which to hang flesh and vital 
organs, skeletal bone is the result of a continuous, dynamic process of mineralization and 
resorption. These opposing actions are carried out by two cell types, osteoblasts and 
osteoclasts, and must be kept in balance to maintain skeletal integrity and systemic 
calcium metabolism. A disruption of this balance is most often observed when the rate of 
resorption by osteoclasts exceeds the rate of mineral deposition by osteoblasts, and bone 
mass is lost, as in osteoporosis (115). Increased bone resorption is observed in many 
inflammatory and autoimmune diseases, such as rheumatoid arthritis (116), periodontal 
disease (117), and Paget's disease (118). Bone destruction is also common secondary to 
many cancers, both those that reside in bone like leukemias and multiple myeloma, as 
well as breast and prostate cancers (119). A common clinical complication of cancer-
mediated bone resorption is humoral hypercalcemia of malignancy (120). 
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Osteoclasts differentiate from multipotent bone marrow-derived cells of the 
monocyte/macrophage lineage (121). The life of an osteoclast can be broken down into 
four sequential stages: differentiation from multipotent bone marrow progenitors into 
mononuclear osteoclasts, fusion into multinucleated cells, activation to resorb bone, and 
apoptosis. These stages are regulated by the interactions of osteoclasts and their 
precursors with osteoblasts and other stromal cells in bone tissue, which stimulate or 
inhibit osteoclastogenesis in response to various stimuli, such as parathyroid hormone 
(PTH), vitamin D3, and calcitonin. Deficiencies in normal osteoclast function lead to 
osteopetrosis, or a thickening of bone due to insufficient resorption, while hyperactivity 
of osteoclasts leads to osteoporosis, or loss of bone mass. 
Studies in osteopetrotic mice with spontaneous and engineered mutations have revealed 
some of the genetic factors responsible for each of the stages in the osteoclast life cycle. 
Two factors crucial for the differentiation of osteoclasts are M-CSF (macrophage colony-
stimulating factor) and TRANCE. Mice with a mutated M-CSF gene completely lack 
osteoclasts (122), as do mice with targeted deletions of TRANCE and TRANCE-R (123-
125). Not all osteopetrotic mice lack osteoclasts; those with targeted deletions of TRAF6 
(101,102) or the non-receptor tyrosine kinase c-Src (126,127) have osteoclasts, but they 
are incapable of being activated to resorb bone. Other mutant mice with osteopetrosis 
have demonstrated the importance of the transcription factors NF-kB (128) and AP-1 
(129) in osteoclast development. 
2.3.2.2 TRANCE/TRANCE-R/OPG regulation of osteoclasts 
Studies of TRANCE and its two receptors TRANCE-R and OPG has suggested that cells 
of the immune system and the cells that remodel bone may regulate each other's function. 
TRANCE is normally expressed on osteoblasts and activated T cells, and its activating 
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receptor TRANCE-R is expressed on myelomonocytic cells, including osteoclasts and 
DCs (104). Although TRANCE and CD40L appear to have largely overlapping functions 
in stimulating the activation, survival, and adjuvant properties of DCs (107,130,131), 
TRANCE has been shown to be essential for certain CD40-independent anti-viral T cell-
specific responses (112,132). In addition to its role in the regulation of osteoclasts and 
DCs, TRANCE is essential for lymph node organogenesis (133) and it regulates the 
function of activated T cells (134,135). OPG is a non-signaling soluble decoy receptor for 
TRANCE that negatively regulates its function by blocking the ability of TRANCE to 
bind to TRANCE-R on target cells (18,136). 
TRANCE-R signaling through TRAF6 is of particular interest in osteoclasts because 
TRAF6 plays a role in TRANCE-mediated NF-kB and JNK activation (84,137). TRAF6 
also provides a crucial link to the activation of c-Src, which activates the survival kinase 
Akt, prolonging the lifespan of activated osteoclasts (63,64). In addition, c-Src activation 
leads to the cytoskeletal changes such as membrane ruffling and actin ring formation 
necessary for osteoclasts to resorb bone (127). 
Since TRANCE is expressed on activated T cells, and is crucial for T cell-DC 
communication, one might expect massive bone resorption under most inflammatory 
conditions. Indeed, it has been shown that TRANCE on activated T cells could activate 
osteoclasts in an induced arthritis model, and blocking TRANCE with OPG abrogated 
bone destruction but not inflammation (138). Furthermore, the bacteria that cause 
periodontal disease induce TRANCE expression on T cells, leading to alveolar bone 
destruction (139). Under conditions of estrogen withdrawal similar those seen in 
postmenopausal osteoporosis, it was found that increased TNF production by T cells 
augments TRANCE-mediated osteoclastogenesis (140). In TRANCE-deficient mice, it 
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has been shown that some of the osteoclast defects could be rescued by transgenic 
overexpression of TRANCE on T lymphocytes (124), which suggests that T cells may 
have a role in osteoclast activation under non-pathologic conditions. Figure 2.6 
summarizes some key interactions between activated T cells, other inflammatory signals, 
osteoclasts, and osteoblasts. Our T cells are constantly working to fight off the universe 
of antigens in which we live, so what prevents them from causing extensive bone loss? 
Infection, 
Inflammation 
Survival, ^ / O C \ Calciotropi^ 
Cytokine production \ / \ ctimuli 







Figure 2.6. The interface between bone and the immune system. TRANCE on activated T cells 
stimulates DC as well as osteoclasts. Inflammatory mediators also affect OC function. 
2.3.2.3 Regulatory mechanisms for inflammation-induced bone loss 
Recently, a crucial counter-regulatory mechanism whereby activated T cells can inhibit 
TRANCE-mediated osteoclast development and activation through the action of the 
antiviral cytokine IFN-y was demonstrated (141). While the type of T cells involved in 
inflammatory responses express TRANCE, they also secrete IFN-y. IFN-y can block 
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TRANCE-mediated osteoclastogenesis in vitro, and in mice deficient for the IFN-y 
receptor, bone destruction in an autoimmune arthritis model is greatly exacerbated. 
As is shown in Figure 2.7, the mechanism for this strong blockade of TRANCE signaling 
by IFN-y in osteoclast precursors appears to be through activation of the ubiquitin-
proteasome pathway for protein degradation (142), specifically targeting TRAF6 for 
degradation. Osteoclast formation in the presence of IFN-y could be rescued by 
overexpression of TRAF6 in precursor cells, and IFN-y's suppressive effect on 
osteoclastogenesis was markedly decreased in mice lacking proteasome components. 
Moreover, TRANCE-R is not the only receptor that signals through TRAF6. Signals 
downstream of CD40 are also attenuated by IFN-y treatment. TRAF6 is an essential 
intermediate in signaling by LPS and IL-1, pathways associated with innate immunity 
(101,102). Given that IL-1 (143) and LPS (144) can induce osteoclastogenesis and bone 
resorption, it will be interesting to examine the effects of IFN-y on those pathways as 
well. Figure 2.8 diagrams some key signaling pathways involved in the balance between 
T cell-mediated osteoclast activation and inhibition. 
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Figure 2.7. IFN-y negatively regulates 
TRANCE-mediated osteoclastogenesis. 
Activated T cells express both T R A N C E 
and IFN-y. While T R A N C E can activate 
osteoclastogenesis in a TRAF6-dependent 
manner, IFN-Y upregulates pathways leading 
to the degradation of TRAF6. This may 
explain why inflammatory processes do not 
always lead to bone loss. 
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Figure 2.8. The osteoclast signaling axis. Factors promoting bone resorption by activating osteoclast 
function are shown in blue, and factors promoting bone mineralization by inhibiting osteoclast function are 
shown in red. 
-28-
2. General Introduction 
2.3.2.4 Other inflammatory regulators of osteoclasts 
Clearly, we are only beginning to scratch the surface of the relationship between bone 
biology and the immune system. Other immunomodulatory factors, including TNFa 
(145,146), IL-6, IL-11, IL-15, and IL-17 can positively modulate osteoclast function, 
while IL-4, IL-10, IL-13, IL-18, and TGF-p can inhibit bone resorption (147). The 
clinical sequelae of bone destruction in inflammatory diseases are significant, and some 
treatment initiatives targeting TNF (148) have shown promising preliminary results. 
However, systemically targeting TNF, TRANCE, or other immune mediators to prevent 
chronic bone loss may result in long-term immunodeficiencies. The future design of 
treatments for bone loss must incorporate greater sensitivity to the potential detrimental 
effects of those treatments on normal immune function. Cell type-specific inhibitors of 
various signaling intermediates in osteoclast activation such as c-Src present a step in the 
right direction (149), and further advances in understanding the differences in signaling 
pathways activated in osteoclasts and dendritic cells should lead to more therapeutic 
targets. 
The cells that resorb bone come from the same hematopoietic lineage as the cells that 
process and present antigens in the immune system. As is highlighted by the regulatory 
relationships between TRANCE, TRANCE-R, and OPG, immune cells and bone cells 
use similar molecular mechanisms in their normal functions. Increasingly, it is becoming 
evident that there is significant cross-talk between bone and the immune system under 
normal physiological conditions as well as in inflammatory pathological conditions. In 
light of recent advances in the treatment of both inflammatory diseases and osteoporosis, 
the challenge now is to carefully navigate the interface between bone (osteo-) and the 
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immune system. This challenge opens a new field of study, which we propose to call 
osteoimmunology (150). 
2.4 TNF/TNFR proteins and TRAFs in health and disease 
Beyond diseases of bone, there are many other clinical conditions in which dysregulation 
of TNF family proteins have been implicated, including Crohn's disease, stroke, multiple 
sclerosis, and Alzheimer's disease (151). Defects in CD40L expression results in X-
linked hyper-IgM syndrome, in which B cell isotype switching is impaired, and patients 
are susceptible to a variety of infections (152-155). Similar clinical findings have been 
linked to mutations in the CD40 gene (156). LMP1 is a viral protein expressed in 
Epstein-Barr virus-infected B cells, mimicking a constitutively active CD40 (35) and 
HVEM is a receptor for herpes simplex virus on T cells (157). While the basic 
underpinnings of TNFR family signaling are established, the precise mechanisms of 
action of TRAFs and their downstream targets are less clear. A greater understanding of 
TRAF-mediated signaling mechanisms, including: differentiating the mechanisms by 
which TRAFs activate different kinase cascades, determining the individual roles of each 
TRAF, elucidating structure-function relationships of TRAFs and interacting proteins, 
identifying modes of TRAF regulation, and dissecting the roles of combinations of 
TRAFs and specific receptors in a cell type-specific manner will be essential to 
understanding and manipulating these conditions in the future. The goal of this thesis is 
to address some of these issues pertaining to the mechanisms of TRAF signaling. 
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3.1.1 Summary 
TRANCE is a TNF family member essential for osteoclast differentiation, and it induces 
the activation and survival of osteoclasts and mature dendritic cells. We recently 
demonstrated that TRANCE activates Akt via a mechanism involving TRANCE-
R/RANK, TRAF6, and c-Src. Here, we show that TRANCE-R and CD40 recruit TRAF6, 
Cbl family scaffolding proteins, and the phospholipid kinase PI3-K in a ligand-dependent 
manner. The recruitment of Cbl-b and c-Cbl to TRANCE-R is dependent upon the 
activity of Src-family kinases. TRANCE and CD40L-mediated Akt activation is 
defective in Cbl-b -/- dendritic cells and CD40L-mediated Akt activation is defective in 
c-Cbl -/- B cells. These findings implicate Cbl family proteins as not only negative 
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regulators of signaling, but as positive modulators of TNF receptor superfamily signaling 
as well. 
3.1.2 Introduction 
Tumor necrosis factor (TNF) family proteins mediate diverse effects on cells of the 
hematopoietic lineage via their cognate receptors, members of the TNF receptor (TNFR) 
family (1). TNFR family proteins lack intrinsic enzymatic activity, but are linked to 
intracellular signaling cascades through TNFR associated factor (TRAF) proteins, and 
numerous TNF family proteins have been shown to activate nuclear factor-kappa B (NF-
kB) and mitogen-activated protein kinase (MAPK) cascades (2). TNF-related activation-
induced cytokine (TRANCE; also called RANKL, ODF, and OPGL) is a TNF family 
member expressed on activated T cells and osteoblasts that regulates the function of 
dendritic cells and osteoclasts through its cognate receptor, TRANCE-R (also called 
RANK) (3). Recently, we demonstrated that in addition to activating NF-kB (4) and c-jun 
N-terminal kinase (JNK) (5), TRANCE activates Akt, a serine/threonine kinase 
implicated in survival signals, through a mechanism involving TRAF6 and the 
nonreceptor tyrosine kinase c-Src (6). 
c-Cbl is a cytoplasmic adapter molecule that has been implicated in the negative 
regulation of signaling from a variety of receptor tyrosine kinases, including growth 
factor receptors and antigen receptors in lymphocytes (7,8). A highly related protein, Cbl-
b, has been identified (9). The domain structure of Cbl proteins consists of several 
functional domains, including an SH2-like phosphotyrosine-binding domain, a RING 
finger, a proline-rich domain, and a leucine zipper. Originally identified as a viral proto-
oncogene that acquires transforming potential with the 70z deletion (10), Cbl has been 
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implicated in the negative regulation of tyrosine kinase signaling by shortening the 
duration of activating signals (7). 
c-Cbl and Cbl-b have been shown to interact with a wide variety of activated signaling 
molecules including phosphatidylinositol 3-kinase (PI3-K), Src-family tyrosine kinases, 
Syk, and adaptor proteins Grb2 and She (11-14). One mechanism by which they may 
negatively regulate signaling is by acting as an E3 ubiquitin ligase, which results in the 
degradation of activated molecules by the proteasome (15-17). This E3 ubiquitin ligase 
activity has been localized to the RING finger of c-Cbl, and the RING finger has been 
associated with the negative regulation of a number of tyrosine kinases, including the 
epidermal growth factor receptor (EGFR) (18,19), syk (20), and CSF-1R (21), among 
others. Cbl-b has been associated with the negative regulation of Vav-mediated JNK 
activation (22) and EGFR signaling (23). 
Mice with targeted deletions in c-Cbl (24), and recently, Cbl-b (25,26) have been 
described; each displays a phenotype of decreased thresholds for lymphocyte activation 
and development of autoimmunity. Mice with a targeted deletion in c-Cbl display 
enhanced thymic positive selection, likely due to the persistence of activated 
costimulatory molecules that are ordinarily targeted for degradation by c-Cbl (24). Cbl-b-
/- mice demonstrate T cell hyperactivation and hyperproliferation in response to antigen 
receptor stimulation, uncoupling of T cell receptor (TCR) and CD28 stimulation, and 
develop spontaneous autoimmunity (25,26). 
In this report, we identify a mechanism by which the TNF family members TRANCE and 
CD40L activate Akt through their cognate receptors TRANCE-R and CD40. We 
previously demonstrated that, upon ligand engagement, TRANCE-R forms a complex 
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with c-Src and TRAF6 (6). We now show that PI3-K and Cbl proteins are also 
components of this signaling complex. Examination of the mechanism of the interaction 
of c-Cbl and Cbl-b with TRANCE-R shows a requirement for c-Src kinase activity, 
which may be regulated by TRAF6. Furthermore, a stable complex of TRANCE-R and 
Cbl-b is observable only in presence of a proteasome inhibitor, suggesting that Cbl-b may 
negatively regulate TRANCE signaling by downregulating one or more components of 
the TRANCE-R signaling complex. Finally, using cells derived from Cbl-b -/- and c-Cbl 
-/- mice, we show that Akt activation by TRANCE and CD40L in dendritic cells is 
dependent on Cbl-b, while Akt activation in B cells by CD40L is dependent on c-Cbl, 
suggesting a novel positive regulatory role for Cbl proteins in signaling. 
3.1.3 Experimental Procedures 
3.1.3.1 Reagents 
MG-132 was from Calbiochem; SAM68 was from Santa Cruz Biotechnology; PPI was 
from Alexis Biochemicals, soluble hCD8-TRANCE (TRANCE) was purified from insect 
cells as described (27); and soluble mCD8-CD40L (CD40L) was generated in insect cells 
and supernatant was used at a 1:100 dilution as described (28). 
Antibodies (Abs) specific for phospho-Akt (Ser-473), Akt, and IicB-a were from New 
England Biolabs; c-Src (N-16), TRAF6 (H-274), and Cbl-b (N-19) were from Santa Cruz 
Biotechnology; phosphotyrosine (4G10-HRP) and the p85 subunit of PI3-K (rabbit 
antiserum) were from Upstate Biotechnology Ine; c-Cbl (17) from Transduction 
Laboratories; HA (12CA5) from Boehringer Mannheim, and the Flag epitope (M2) were 
from Sigma. Anti-TRANCE-R (1E6.66) was previously described (29) and anti-CD40 
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(FGK-115) was purified from supernatants of hybridoma cells provided by Dr. Randolph 
Noelle (Dartmouth University, Hanover, NH). 
3.1.3.2 Primary Cells 
Mature dendritic cells were generated from bone marrow precursors as described (30). 
Osteoclasts were generated from bone marrow precursors as described (31). 
Lymphocytes were prepared from whole spleens by making single-cell suspensions 
followed by erythrocyte lysis and plating for lh on tissue culture plates to deplete 
adherent cells. 
3.1.3.3 Plasmids 
Expression constructs encoding FLAG-tagged wild-type mouse TRANCE-R (TR-wt), 
chicken c-Src, c-SrcKD (K295M), and HA-tagged human c-Cbl in pcDNA3.1 
(Invitrogen) have been described (6). TR-Y345F, Y440F, and Y468F were generated by 
the QuickChange method of site directed mutagenesis (Stratagene). HA-tagged human 
Cbl-b (WT and AN) constructs in the pCEFL vector were kindly provided by Dr. Stan 
Lipkowitz (National Cancer Institute, Bethesda, MD) and have been described (32). 
3.1.3.4 Cell Stimulation, Transfection, and Analysis 
In vitro differentiated mature dendritic cells and osteoclasts, and freshly isolated 
splenocytes were extensively washed to remove exogenous growth factors, cultured in 
medium with low serum (0.5% FCS, 2-4 h), then stimulated by adding TRANCE or 
CD40L as indicated. After stimulation, cells were washed with ice-cold PBS, lysed, and 
subjected to immunoprecipitation and western blotting as described (6). In order to 
control for equal loading of each timepoint, the protein concentration of each sample was 
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determined and samples were normalized for total protein content prior to further 
processing. 
293T cells were transfected by calcium phosphate precipitation as described (4). The 
amount of transfected DNA was held constant to 1 }J.g by addition of empty vector DNA 
where necessary. Cells were processed for analysis 24 h after transfection. Where 
indicated, MG-132 or an equivalent amount of vehicle (DMSO) was added to a final 
concentration of 10 ,uM 4 h prior to processing. Cells were processed and subject to 
immunoprecipitation and western blotting as described (6). All transfection experiments 
were repeated at least three times and representative results are shown. 
3.1.4 Results 
3.1.4.1 TRANCE-R and CD40 Interact with PI3-K and c-Cbl Upon Ligand 
Stimulation 
Since TRANCE activates Akt in dendritic cells (DC) and osteoclasts, and Akt activation 
is dependent on the activity of PI3-K, we investigated whether PI3-K was associated with 
TRANCE-R. In order to determine whether PI3-K is part of the TRANCE-R signaling 
complex in primary cells, we immunoprecipitated TRANCE-R from TRANCE-treated 
DC. The p85 regulatory subunit of PI3-K was recruited to TRANCE-R in a ligand-
dependent manner (Figure 3.1.1 A, top), which correlates with Akt phosphorylation in the 
whole cell extract (6). Since PI3-K has been shown to associate with the cytoplasmic 
scaffolding protein c-Cbl in a variety of cell types, we probed the TRANCE-R 
immunoprecipitates for c-Cbl and found that it associates with TRANCE-R in a 
TRANCE-dependent fashion. This correlates with a ligand-dependent increase in 
TRANCE-R-associated TRAF6 (Figure 3.1.1 A, top). Immunoprecipitation of c-Cbl from 
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dendritic cell lysates confirmed that TRAF6 inducibly associates with c-Cbl upon ligand 
stimulation (Figure 3.1.1 A, bottom). 
In order to determine whether other TNFR family members known to signal through 
TRAF6 behave similarly to TRANCE-R, we treated DC with CD40L, which, like 
TRANCE, promotes the survival and activation of myeloid dendritic cells (33). 
Immunoprecipitation of CD40 and western blotting showed that there was a ligand-
dependent increase in the p85 subunit of PI3-K and c-Cbl associated with CD40 (Figure 
3.LIB, top). As we have previously found with TRANCE-R (6), Src-family kinase 
activity co-precipitates with ligand-stimulated CD40 as assayed by the ability of the 
immunoprecipitates to phosphorylate recombinant SAM68, a known Src-family kinase 
substrate, in vitro (Figure 3.LIB, bottom). 
We previously observed a peak of TRANCE-induced Akt phosphorylation after 20 
minutes of stimulation (6). In order to determine if this activation correlates kinetically 
with PI3-K recruitment to TRANCE-R, we stimulated DC with TRANCE for up to 60 
minutes. Surprisingly, although PI3-K and c-Cbl continue to accumulate in the 
TRANCE-R complex in increasing amounts (Figure 3.1.1C, top), Akt activation 
decreases after 20 minutes of stimulation (Figure 3.1.1C, bottom. See also Figure 
3.1.4A). 
Since TRANCE-mediated Akt activation in DCs is dependent on the activity of Src-
family kinases and can be inhibited by the Src-family kinase inhibitor PPI (6), we 
endeavored to determine whether the association of c-Cbl and PI3-K is dependent on Src-
family kinase activity. We pretreated DCs with PPI or vehicle (DMSO), stimulated the 
DCs with TRANCE, and immunoprecipitated c-Cbl. In the absence of PPI, c-Cbl was 
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constitutively phosphorylated on tyrosine in unstimulated DCs, and its phosphorylation 
state was unaffected by TRANCE treatment. Pretreatment with PPI completely blocked 
all c-Cbl phosphorylation (Figure 3.LID, top). However, the phosphorylation state of c-
Cbl did not affect its binding to PI3-K, as PI3-K was constitutively associated with c-Cbl 
regardless of PPI treatment or TRANCE stimulation (Figure 3.LID, bottom). To ensure 
that TRANCE stimulation activated signaling by TRANCE-R, we probed whole cell 
extracts with antibodies to IkB-oc and observed equivalent TRANCE-dependent 
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Figure 3.1.1. PI3-K and c-Cbl are recruited to T R A N C E - R and C D 4 0 upon ligand stimulation in 
dendritic cells. 
A. Dendritic cells were treated for the indicated number of minutes with T R A N C E (2 |Jg/ml) and lysed. 
T R A N C E - R (top) and c-Cbl (bottom) were immunoprecipitated and the immunoprecipitates were probed 
with antibodies to PI3-K, c-Cbl, and T R A F 6 as indicated. 
B. D C were treated with soluble C D 4 0 L (1:100) for the indicated number of minutes and C D 4 0 was 
immunoprecipitated. The immunoprecipitates were probed with antibodies to c-Cbl and PI3-K (top and 
middle). An in vitro Src-family kinase assay was performed on the C D 4 0 immunoprecipitates (bottom) 
with recombinant S A M 6 8 as a substrate. 
C. D C were treated as in (A), T R A N C E - R was immunoprecipitated, and the immunoprecipitates were 
probed with antibodies to PI3-K and c-Cbl as indicated (top). Whole cell extracts ( W C E ) were 
immunoblotted with antibodies to phospho-Akt (Aktp) and PI3-K as indicated. 
D. D C were pretreated with vehicle ( D M S O ) or PPI (10 \xM) for 90 minutes, then stimulated and lysed as 
in (A). c-Cbl was immunoprecipitated and the immunoprecipitates were probed with antibodies to 
phosphotyrosine, c-Cbl, and PI3-K as indicated. 
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3.1.4.2 TRANCE-R and Cbl Proteins Interact only in the Presence of Active Src 
To further elucidate the mechanism of c-Cbl's interaction with TRANCE-R, we 
transiently transfected HEK 293T cells with constructs driving the expression of c-Cbl, c-
Src, or Flag-epitope tagged TRANCE-R from a CMV promoter. In the presence of 
overexpressed c-Src, an anti-c-Cbl antibody co-immunoprecipitated TRANCE-R (Figure 
3.1.2A, lane a). In the absence of overexpressed c-Cbl, endogenous c-Cbl was sufficient 
to demonstrate a c-Src dependent interaction with TRANCE-R (Figure 3.1.2A, lane c). 
Conversely, in the absence of overexpressed c-Src, neither overexpressed nor endogenous 
c-Cbl could co-precipitate TRANCE-R (Figure 3.1.2A, lanes b and d). To differentiate 
between catalytic and structural roles for c-Src in the TRANCE-R/c-Cbl complex, we 
cotransfected a kinase-inactive mutant of c-Src (c-SrcKD) with TRANCE-R and c-Cbl. 
While the wild-type c-Src construct used has been shown to phosphorylate c-Cbl in 
overexpression systems, c-SrcKD does not (34). Immunoprecipitation of TRANCE-R 
with the Flag antibody and western blotting revealed that the kinase-active form of c-Src 
was able to promote a strong interaction between c-Cbl and TRANCE-R (Figure 3.1.2B, 
lane a). The kinase-inactive form of c-Src, however, could not promote a strong 
interaction between c-Cbl and TRANCE-R (Figure 3.1.2B, lane b). 
To determine if Cbl-b, another Cbl family protein, could also interact with TRANCE-R, 
we cotransfected Cbl-b, TRANCE-R, and c-Src or c-SrcKD. Immunoprecipitation of 
TRANCE-R with the Flag antibody did not reveal the presence of Cbl-b protein in either 
case (Figure 3.1.2C, lanes a and b). However, in the presence of MG-132, a proteasome 
inhibitor (35), we were able to coprecipitate Cbl-b with TRANCE-R in a c-Src kinase-
dependent manner (Figure 3.1.2C, lanes c and d). This suggests that Cbl-b may 
downregulate one or more of the essential components of the TRANCE-R complex by 
ubiquitination, thus creating a transient interaction between TRANCE-R and Cbl-b. 
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Indeed, when we expressed TRANCE-R in the presence of c-Src and full-length Cbl-b, 
w e observed a marked decrease in the amount of T R A N C E - R protein in the cell extract 
(Figure 3.1.2D, lane a). However, w h e n w e either substituted a truncated form of Cbl-b 
with a deletion of the N-terminal S H 2 domain (Cbl-bAN, Figure 3.1.2D, lane b), omitted 
c-Src (lane c), or both (lane d), TRANCE-R expression was normal, which suggests that 
Cbl-b m a y mediate T R A N C E - R downregulation in a c-Src dependent manner. 
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Figure 3.1.2. c-Cbl and Cbl-b interact with 
T R A N C E - R in a c-Src kinase dependent 
manner. 
A. 293T H E K cells were transiently transfected 
with Flag-epitope tagged TRANCE-R (TR, 0.5 ng), 
c-Cbl (0.3 p,g), and c-Src (0.05 ng) as indicated, c-
Cbl was immunoprecipitated and the 
immunoprecipitates (IP) were probed with 
antibodies to Flag and c-Cbl as indicated. The 
whole cell extracts (WCE) were probed with 
antibodies to Flag and c-Src as indicated. 
B. As in (A), with either wild-type (WT, 0.05 
ng, lane a) or a kinase dead (KD, 0.1 ng. lane 
b) mutant of c-Src (K295M) transfected as 
indicated. T R A N C E - R was 
immunoprecipitated with an anti-Flag 
antibody. 
C. As in (B), but with transfection of Cbl-b 
(0.3 ng) instead of c-Cbl. MG-132, a 
proteasome inhibitor was added 4 h prior to 
cell lysis to a concentration of 10 \M where 
indicated (+, c and d) and an equivalent 
amount of D M S O (vehicle) was added to the 
other samples (-, a and b). 
D. 293T cells were transfected with TR, c-Src, 
and either wild-type Cbl-b (WT, lanes a and c) 
or a truncation mutant in which the N-terminal 
SH2 domain of Cbl-b has been deleted (AN, 
0.3 ng. lanes b and d) as indicated. Whole cell 
extracts (WCE) were probed with antibodies 
to Flag, H A (Cbl-b and Cbl-bAN), and c-Src. 




3.1.4.3 c-Src Phosphorylates TRANCE-R 
Since c-Cbl and Cbl-b interact with TRANCE-R only in the presence of active c-Src, we 
investigated whether this interaction is dependent on tyrosine phosphorylation of 
TRANCE-R. Sequence analysis of the cytoplasmic domain of mouse TRANCE-R 
revealed the presence of three tyrosine residues that could potentially serve as targets of 
c-Src: Y345, Y440, and Y468. Alignment with human TRANCE-R shows that while 
Y345 and Y468 are conserved, Y440 is not. There is an additional tyrosine in human 
TRANCE-R at position 422, corresponding to position 418 in mouse TRANCE-R (Figure 
3.1.3A). In order to determine if any of the tyrosine residues in mouse TRANCE-R are 
phosphorylated by c-Src, we employed site-directed mutagenesis to change each of the 
tyrosine residues to phenylalanine. We then cotransfected the tyrosine mutants of 
TRANCE-R with c-Src or c-SrcKD and immunoprecipitated TRANCE-R. Western 
blotting of the immunoprecipitates with an anti-phosphotyrosine antibody revealed that 
wild-type TRANCE-R is phosphorylated by or downstream of c-Src on Y468, as only the 
Y468F mutant was not phosphorylated in the presence of c-Src. Neither wild-type 
TRANCE-R nor any of its tyrosine mutants was phosphorylated on tyrosine when 
cotransfected with c-SrcKD, suggesting that Y468 is a specific target of c-Src activity 
(Figure 3.1.3B). We then cotransfected TRANCE-R constructs containing tyrosine 
mutations with c-Src and Cbl-b or c-Cbl and found that Cbl-b and c-Cbl co-precipitated 
with all of the Y-F mutants of TRANCE-R, which suggests that the interaction between 
TRANCE-R and Cbl is not dependent on the tyrosine phosphorylation of TRANCE-R 
(Figure 3.1.3C-D). There was no interaction between a mutant of TRANCE-R with the 
cytoplasmic tail deleted and c-Cbl or Cbl-b, indicating that the interaction is specific to 
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Figure 3.1.3. TRANCE-R is phosphorylated on 
tyrosine 468 by c-Src, but tyrosine 
phosphorylation of TRANCE-R is not necessary 
for association with Cbl-b and c-Cbl. 
A. Alignment of amino acid sequences of a 
portion of the cytoplasmic tails of human and 
mouse TRANCE-R. Mouse residues are 
numbered, and tyrosine residues are indicated 
in boldface. 
B. 293T cells were transfected with Flag-
tagged mouse TRANCE-R constructs with the 
indicated point mutations (WT, wild-type) and 
either c-Src or c-SrcKD. TRANCE-R was 
immunoprecipitated with an anti-Flag 
antibody and the immunoprecipitates were 
probed with an antibody to phosphotyrosine 
(4G10). 
C. 293T cells were transfected with 
TRANCE-R or its tyrosine mutants as 
indicated, Cbl-b, and c-Src. MG-132 (10 nM) 
was added 4 h prior to cell lysis. TRANCE-R 
(WT or tyrosine mutants) was 
immunoprecipitated and the 
immunoprecipitates were probed with 
antibodies to Cbl-b or Flag as indicated. The 
whole cell extracts were probed with Cbl-b or 
c-Src as indicated. 
D. As in (C), but with c-Cbl substituted for 
Cbl-b. 
3.1.4.4 Cbl Proteins Regulate T R A N C E - and CD40-Mediated Akt Activation 
Gene-targeted mice with deletions in c-Cbl (24) and Cbl-b (25,26) have been described 
recently. In order to determine the role of Cbl proteins in TRANCE and CD40L-mediated 
activation of Akt, w e used B lymphocytes, osteoclasts, and D C derived from mice 
deficient in c-Cbl or Cbl-b. In cells derived from Cbl-b-deficient mice, we observed that 
neither TRANCE (Figure 3.1.4A) nor CD40L (Figure 3.1.4B) was able to strongly 
activate Akt in DC within 20 minutes of stimulation, as opposed to what we observed in 
wild-type cells. In all cases, NF-kB activation as measured by IkB-o: degradation was 
identical in wild-type and knockout cells. Interestingly, at later time points (>3h), 
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TRANCE and CD40L treatment did result in Akt activation in DC, which was similar to 
a second wave of Akt activation observed in wild-type cells, suggesting that other gene 
products that activate Akt via a Cbl-b-independent mechanism are upregulated over this 
time period. Since Akt has been widely characterized as a survival factor, we investigated 
whether there was a defect in TRANCE- or CD40L-mediated survival in Cbl-b -/- DC. 
Perhaps due to the intact secondary wave of Akt activation, there was no difference 
observed in TRANCE or CD40L-mediated survival in DC derived from Cbl-b-/- mice 
over a 72h period (data not shown). In DC derived from c-Cbl-/- mice, we did not 
observe any differences in TRANCE or CD40L-induced Akt activation or survival (data 
not shown). 
In contrast to the results obtained in DC, in B lymphocytes from c-Cbl-/- mice, there was 
a marked deficiency in CD40L-induced Akt activation but Akt activation was intact in 
Cbl-b-/- B lymphocytes (Figure 3.1.4C). In osteoclasts derived from c-Cbl-/- and Cbl-b-/-
mice, we did not observe any defects in TRANCE-induced Akt activation (Figure 
3.1.4D). Consistent with intact TRANCE-mediated Akt activation in c-Cbl-/- and Cbl-b-
/- osteoclasts, we did not observe any defects in the differentiation or survival of 
osteoclasts derived from these mice as determined by TRAP assay (data not shown). 
Taken together, these results suggest that Cbl-b and c-Cbl may have cell type-dependent, 
overlapping roles in Akt activation. It appears that c-Cbl is required for CD40L-
dependent Akt activation in B cells while Cbl-b is required for TRANCE and CD40L-
dependent Akt activation in DC. In osteoclasts, c-Cbl and Cbl-b appear to be able to 
substitute for one another in TRANCE-dependent Akt activation. In whole cell extracts, 
protein expression levels of c-Cbl and Cbl-b in dendritic cells, B lymphocytes, and 
osteoclasts do not account for these cell type specific differences in function (data not 
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shown). It has been reported recently that, in c-Cbl-/- osteoclasts, Cbl-b is compensatorily 
overexpressed (36). However, it is possible that the availability of c-Cbl and Cbl-b to the 
various receptor signaling complexes differs in a cell type dependent manner due to 
other, as yet unidentified components of the signaling complexes. 
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Figure 3.1.4. Cbl proteins are required 
for cell type-specific T R A N C E and 
CD40L-mediated Akt activation. 
A. D C were derived from wild-type or 
Cbl-b deficient (-/-) mice, serum starved, 
and treated with T R A N C E (2 ng/ml) for 
the indicated time. Lysates (50 ng) were 
immunoblotted with a phospho-specific 
Akt antibody to indicate activation of 
Akt (Akt11). Membranes were stripped 
and reprobed with antibodies to total Akt 
to normalize for protein loading, and 
IkB-cc to demonstrate activation of the 
NF-kB signaling pathway as indicated. 
Note degradation of IkB-oc after 5 
minutes and appearance of newly 
synthesized protein by 180 minutes. 
B. As in (A), but cells were treated with 
CD40L (1:100) instead of T R A N C E . 
C. B lymphocytes were isolated from the 
spleens of wild-type, c-Cbl, or Cbl-b 
deficient (-/-) mice, serum starved, and 
treated with C D 4 0 L for the indicated 
time. Lysates were immunoblotted as in 
(A) and (B). 
D. Osteoclasts were derived from bone 
marrow of wild-type, Cbl-b, or c-Cbl 
deficient (-/-) mice, serum starved, and 
treated with T R A N C E for the indicated 
time. Lysates were immunoblotted as in 




3.1.5.1 A Positive Signaling Role for Cbl 
While Cbl family proteins have been widely held to play a negative role in tyrosine 
kinase signaling, our results suggest a positive role as well. c-Cbl and Cbl-b have been 
demonstrated to associate with the p85 subunit of PI3-K both constitutively and in 
response to ligand stimulation in a number of cell types and receptor/ligand pairs (12-
14,37). In dendritic cells, we observed constitutive association between c-Cbl and PI3-K, 
which is independent of Src-family kinase activity. Overexpression of Cbl-b has been 
shown to abrogate -Akt activation downstream of EGFR in response to ligand stimulation 
(23), and the hyperactivation and increased survival of T cells in Cbl-b -/- mice suggests 
that Cbl-b negatively regulates TCR and CD28-mediated signaling (25,26). However, 
using cells derived from gene-targeted mice, we found that in dendritic cells, Cbl-b is 
required for TRANCE and CD40L-induced Akt activation, and in B lymphocytes, c-Cbl 
is required for CD40L-induced Akt activation. In osteoclasts, c-Cbl and Cbl-b appear to 
substitute for one another in TRANCE-induced Akt activation. Cbl proteins, therefore, 
may positively regulate PI3-K activation via TNFR family proteins in a receptor- and cell 
type-specific manner by recruiting PI3-K to the receptor complex, where it is 
phosphorylated by Src family kinases. 
3.1.5.2 Potential Negative Roles for Cbl in T R A N C E Signaling 
This positive role, however, appears to be short-lived, as Akt activation by TRANCE and 
CD40L declines in dendritic cells after approximately 20 minutes of stimulation. It is 
possible that Cbl proteins are responsible for the termination of signaling by 
downregulating Src kinases, PI3-K, TRAF6, or TRANCE-R and CD40 via internalization 
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and/or ubiquitination. EGFR, a receptor tyrosine kinase, is rapidly autophosphorylated 
within several minutes of ligand binding and its major signaling events take place rapidly 
(38). Cbl-mediated ubiquitination of EGFR becomes evident on the order of 20-30 
minutes after ligand binding, and quenches the activation signal over the next 20-30 
minutes (15). Since c-Cbl binds exclusively to phosphorylated EGFR, only activated 
EGFR is ubiquitinated and targeted for destruction. For productive signaling to occur, 
there is necessarily a time lag between the activation of the kinase and its destruction. It 
is therefore likely that, by acting as a scaffold for the assembly of the PI3-K signaling 
complex and the TRANCE-R signaling complex, Cbl can make a short-lived positive 
contribution to signaling before downregulating activated proteins. Since the TRANCE-
R-c-Cbl-PI3-K complex is observed in DCs long after Akt activation is quenched (Figure 
3.1.1C), it is possible that Akt downregulation is independent of Cbl in the receptor 
complex. 
In support of the notion that Cbl indeed has a role in the negative regulation of TRANCE 
signaling, we were only able to observe Cbl-b binding to TRANCE-R in the presence of 
MG-132, a proteasome inhibitor. Additionally, we found that overexpression of full-
length Cbl-b and c-Src resulted in a marked decrease in TRANCE-R protein in cell 
lysates, while eliminating either the N-terminal domain of Cbl-b or c-Src overexpression 
did not reduce TRANCE-R protein levels. This suggests that TRANCE-R and/or other 
essential activated components of the TRANCE-R signaling complex are targeted for 
proteasome-mediated degradation by Cbl-b. Three likely candidates are TRAF6, c-Src, 
and PI3-K. Recently, Takayanagi et al. (38) demonstrated that TRAF6 is ubiquitinated 
and subsequently degraded by the proteasome in response to TRANCE stimulation in 
osteoclast precursor cells. Harris et al. (39) reported that active c-Src is ubiquitinated and 
subsequently degraded while the steady-state level of c-Src KD is consistently higher than 
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that of active c-Src. This may explain the slight increase in c-Src observed in the whole 
cell extract in the presence of MG-132 in Figure 3.1.2C. Fang et al. (41) reported that 
Cbl-b binds to and induces ubiquitination of the p85 subunit of PI3-K. 
3.1.5.3 Roles of TRAF6 and c-Src in Receptor Assembly 
We have shown that the C-terminal receptor binding domain of TRAF6 can interact with 
TRANCE-R (4) and c-Src (6). We have also found that the C-terminal half of TRAF6 
interacts with c-Cbl and Cbl-b. This interaction promotes the activation of c-Src to 
tyrosine phosphorylate c-Cbl and Cbl-b, but phosphorylation is dependent on the N-
terminal half of TRAF6 (6 and data not shown). Since catalytically active c-Src is 
necessary to promote an interaction between TRANCE-R and Cbl proteins, but 
phosphorylation of TRANCE-R on a specific tyrosine residue does not affect binding, it 
is likely that phosphorylation of Cbl proteins ultimately promotes this interaction. 
Nevertheless, the possibility remains that a component of the complex that has yet to be 
identified is the true target of c-Src that facilitates Cbl-TRANCE-R binding. Therefore, in 
addition to activating the PI3-K cascade, c-Src appears to play a vital role in the assembly 
of the signaling complex. 
3.1.5.4 Physiological Consequences of Cbl in TRANCE and CD40L Signaling 
If Cbl-b is essential for Akt activation by TRANCE and CD40L in dendritic cells, why is 
there no apparent defect in DC survival in Cbl-b-/- mice? When bone marrow-derived 
DC reach maturity after 8 days in GM-CSF culture, they begin to undergo apoptosis in 
the absence of survival stimuli (40). However, this process is observable on the order of 
many hours to days, and is most likely due to high levels of pre-existing bcl-2 protein 
(27). In Cbl-b-/- DC, we observed Akt activation after several hours of TRANCE or 
CD40L stimulation, consistent with a second wave of activation seen in wild-type DC. It 
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is possible that this Cbl-b independent Akt activation is due to the expression of new 
gene products induced by TRANCE or CD40L in DC, since other signaling pathways 
activated by these cytokines appear to be intact in Cbl-b deficient cells. NF-kB 
activation, as measured by decreasing and subequently increasing IkB levels, follows 
identical kinetics in Cbl-b-/- and wild-type DC. Furthermore, the upregulation of IkB 
observed in these cells at the 3 h time point suggests that the expression of other proteins 
that could potentially activate Akt is upregulated. Attempts to inhibit this second wave of 
Akt activation by blocking new gene transcription via the addition of cycloheximide were 
unsuccessful, as even extremely low doses of cycloheximide (<50 ng/ml) completely 
abrogated even the first wave of Akt activation (data not shown). Therefore, the 
contribution of Akt activation to TRANCE and CD40L-mediated DC survival remains to 
be determined. 
While Akt is principally known as a regulator of cell survival, it is possible that it may 
serve other roles as well. Meili et al. have shown that Akt plays an essential role in cell 
motility in chemoattractant responses in Dictyostelium (41). In particular, Akt has effects 
on actin-mediated cytoskeletal rearrangements. Since dendritic cells, when activated, are 
quickly mobilized to migrate from outer tissues to draining lymph nodes, it is possible 
that Akt activation by TNF family proteins or other inflammatory mediators such as IL-1 
and LPS (6) plays a role in DC migration. Indeed, CD40L-CD40 (42) and LPS-Toll-like 
Receptor (43) interactions appear to be required for dendritic cell migration in vivo. We 
did not observe significant differences in DC migration in Cbl-b deficient mice (data not 
shown), but again, the later wave of Akt activation in Cbl-b -/- DC could be sufficient to 
allow DC migration within the experimental time frame. Given the importance of Akt in 







of signaling complex components 
Figure 3.1.5. M o d e l of the proposed mechanism of Akt activation by T R A N C E . 
A. Soluble T R A N C E binds to membrane-bound T R A N C E - R , leading to its aggregation. T R A F 6 and c-Src 
are recruited to the T R A N C E - R complex. 
B. Cbl recruits PI3-K to the T R A N C E - R complex. 
C. c-Src, activated by its association with T R A F 6 , phosphorylates PI3-K, activating it to phosphorylate 
membrane phosphatidyl inositides. Akt is recruited to these phosphatidyl inositides via its pleckstrin 
homology domain and is activated. 
D. Cbl acts as an E 3 ubiqutin ligase, leading to the ubiquitination and subsequent degradation of one or 
more components of the T R A N C E - R signaling complex, quenching the activating signal. 
3.1.5.5 Conclusion 
TRANCE and CD40L activate Akt in a variety of cell types. In dendritic cells, the 
TRANCE-R and CD40 signaling complexes recruit TRAF6, Src family kinases, PI3-K, 
and Cbl in a ligand-dependent manner. The association of TRANCE-R and c-Cbl and 
Cbl-b is dependent on Src kinase activity, and TRAF6 can enhance Src-mediated Cbl 
phosphorylation. Cbl-b appears to downregulate T R A N C E - R expression in a Src-
dependent manner. In c-Cbl and Cbl-b deficient mice, there are cell type-specific defects 
in Akt activation downstream of TRANCE-R and CD40, indicating that Cbl proteins may 
be required for T R A N C E and CD40L-dependent PI3-K activation. In Figure 3.1.5, we 
propose a model in which Cbl brings PI3-K to the receptor complex, where it is activated 
by c-Src with rapid kinetics. Concurrently, but with slightly slower kinetics, Cbl acts as a 
ubiquitin ligase, leading to the degradation of one or more of the essential components of 
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the signaling complex, quenching the activating signal. Cbl proteins thereby may act as 
both positive and negative regulators of TRANCE and CD40L signaling in a kinetically 
controlled manner. 
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3.2.1 Summary 
We determined crystal structures of TRAF6, alone and in complex with TRAF6-binding 
sites from CD40 and TRANCE-R/RANK at 2.5, 1.8 and 2.0A resolution. The structures 
reveal a distinct receptor-binding groove of TRAF6, the key structural determinant of the 
interaction. The structural information allows the identification and further confirmation 
of TRAF6-binding sequences in the IRAK proteins using quantitative affinity 
determinations. This leads to a proposed TRAF6-binding motif, whose structural 
requirement was further investigated using site-directed mutagenesis. The mutual 
recognition of TRAF6 with CD40, TRANCE-R, and the IL-1 receptor (via IRAK) was 
further demonstrated in vivo by correlating the mutational effects of receptors and of a 
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dominant negative form of TRAF6 on downstream NF-kB, JNK, and p38 signaling. The 
structures of the TRAF6 complexes also provide a physical model for the connection to 
Src signaling through cooperative ternary complex formation. These studies jointly 
establish the structural basis of TRAF6 as the direct convergence point for the TNF 
receptor and the IL-1 receptor superfamilies. 
3.2.2 Introduction 
Tumor necrosis factor receptor (TNFR) family proteins are important regulators of 
immune and inflammatory responses. TNFR family proteins lack intrinsic signaling 
activity, but they are coupled to downstream signaling molecules through TRAF (TNFR 
Associated Factor) proteins, of which six have been identified (1). Of the known TRAF 
proteins, TRAF6 is of particular interest because, while it functions similarly to other 
TRAFs in mediating signaling by TNFR family proteins, it is also the only TRAF known 
to mediate signaling from receptors other than TNFR family members. Specifically, 
TRAF6 has been implicated as a key mediator of signals originating from the interleukin 
(IL)-l receptor (IL-1R) (2) and Toll-like receptors (TLR), which bind to the bacterial 
product lipopolysaccharide (LPS) (3). Thus, TRAF6 represents a central point of 
convergence for signaling by TNFR and IL-1R/TLR family proteins, and it plays a 
critical role in bone homeostasis and both adaptive and innate immunity. 
Two TNFR family proteins that bind directly to TRAF6 are CD40 and TRANCE-R. 
CD40 is a key regulator of B cell proliferation, survival, and isotype switching, as well as 
a mediator of dendritic cell (DC) maturation, survival, and costimulatory ability (4). 
TRANCE-R is also important for DC survival and costimulation, and it is essential for 
osteoclast differentiation, maturation, and survival (5). Additionally, TRANCE has been 
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shown to be a critical regulator of mammary gland development and lactation (6). 
TRAF6 does not directly interact with IL-1R or TLR proteins. IL-1R and TLRs bind to 
the cytoplasmic protein MyD88 (7-9), which interacts with the N-terminal portion of IL-
1R associated kinase (IRAK). TRAF6 binds to the C-terminal domain of activated IRAK 
in a similar fashion to its interaction with TRANCE-R and CD40 (10). 
Studies from knockout mice have shown that TRAF6 is necessary for normal bone 
metabolism, as mice deficient in TRAF6 have severe osteopetrosis due to defects in 
osteoclast differentiation and maturation (11,12). This phenotype is remarkably similar to 
that found in mice deficient for TRANCE (13,14), TRANCE-R (15), and c-Src (16), 
which has suggested that TRAF6 may serve to link TNF signaling pathways to Src-
family tyrosine kinase pathways (17). Additionally, TRAF6-deficient mice have defects 
in signaling by IL-1, CD40L, and LPS, which results in deficiencies in nitric oxide 
production by macrophages as well as in B lymphocyte proliferation and isotype 
switching (11). Furthermore, TRAF6-/- mice display defects in lymph node 
organogenesis (12), which has also been observed in TRANCE-deficient mice (13,14). 
TRAF6 has the characteristic domain structure of TRAF proteins, with an N-terminal half 
containing a RING finger and several zinc finger domains, which have been shown to be 
essential for the activation of downstream signaling pathways, including NF-kB, MAPK, 
and Src-family kinases (2,17,18). The C-terminal half of TRAF6 consists of the highly 
conserved TRAF domain (19), with a coiled-coil domain required for TRAF 
oligomerization and a receptor-binding domain. The C-terminal half of TRAF6 acts as a 
dominant negative inhibitor of signaling by binding to the receptor but preventing the 
activation of downstream kinases (2). 
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Of the six TRAF proteins, TRAFs 2, 5, and 6 can activate the NF-kB and MAPK 
signaling pathways including ERK, p38, and JNK (1). Although TRANCE-R and CD40 
have been shown to activate NF-kB and MAPK via TRAF2 and TRAF5 in 
overexpression experiments (20,21), there is evidence that in primary cells, TRAF6 may 
be the key physiological mediator of signaling by these receptors. In TRAF6-/- osteoclast 
precursor cells, TRANCE stimulation fails to activate NF-kB, p38, or JNK (22). In the 
cytoplasmic tails of both TRANCE-R and CD40, the binding site for TRAF6 is proximal 
to the membrane and is distinct from the binding site for TRAFs 1, 2, 3, and and 5, which 
bind to more C-terminal sites on each receptor. Furthermore, the sequence of the 
receptor-binding TRAF domain of TRAF6 is the least conserved of all the TRAFs (2), 
suggesting that TRAF6 may have a distinct mode of receptor binding from the other 
TRAF proteins. 
Although the RING and zinc fingers in the N-terminal half of TRAF6 are necessary for 
the activation of downstream kinases, the receptor-binding domain is important 
structurally because oligomerization of TRAF6 at the receptor in response to ligand 
stimulation is a physiological prerequisite for signaling (23). A detailed structural 
understanding of the receptor binding mode of TRAF6 will help to elucidate the 
mechanism of TRAF6 signaling and will provide a framework for the rational design of 
immunomodulatory and anti-osteoporotic therapeutics. 
3.2.3 Results and Discussion 
3.2.3.1 Identification of the core receptor binding site for TRAF6 
As a first step toward understanding the molecular basis of the signaling specificity of 
TRAF6, we used CD40 as a prototype since it contains a rather short cytoplasmic domain 
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(residues 216-277). The C-terminal region of this domain (residues 246-277) contains the 
known TRAF2-binding site, while the N-terminal region (residues 216-245) has been 
implicated in TRAF6 binding (24,25). To pinpoint the TRAF6-binding site of CD40, we 
generated a series of deletions within this region and measured the binding affinity of 
these peptides to the TRAF domain of TRAF6 (residue 333-508), using isothermal 
titration calorimetry (ITC) (Figure 3.2.1 A) (26). The interaction of TRAF6 with the entire 
N-terminal region of the CD40 intracellular domain exhibited a dissociation constant of 
"60 U.M. A short peptide of CD40 (residues 230-238) conferred close to 90% of the 
binding energy to TRAF6, while further deletion abolished the interaction. This short 
region of CD40 formed the biochemical basis for the structural studies on TRAF6 
interactions. 
3.2.3.2 Crystal structures of TRAF6 
We determined three crystal structures of the TRAF-C domain of TRAF6 (residues 346-
504), in its free form and in complex with the minimal TRAF6-binding site from human 
CD40 (230-KQEPQEIDF-238) and the homologous sequence of human TRANCE-R 
(342-QMPTEDEY-349), at 2.5A, 1.8A and 2.0A respectively. To facilitate 
crystallization, the CD40 sequence in the complex contains a mutation (N237D) that has 
been shown previously to enhance affinity to TRAF6 (Figure 3.2.1 A) (21). The overall 
architectures of the three TRAF6 structures are rather similar, with rms distances of 0.4A 
among the peptide-bound and 0.6A between the free and bound forms. Previous 
structural and biochemical studies have established that TRAF proteins are able to form 
trimers (23,27-29), as a way to sense receptor trimerization and oligomerization by 
trimeric extracellular ligands (30). Even though the current TRAF6 structures are 
monomeric due to the deletion of their coiled-coil regions, the putative 3-fold axis of the 
structures can be located. When this is aligned in the vertical orientation, the receptor 
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peptides lie along a surface ridge from the top (near the cellular membrane) to the bottom 
(towards the cytoplasm) ends of the molecule (Figure 3.2.IB). This directionality of the 
peptides makes possible the direct docking of the receptors onto TRAF6 after exiting 
from their transmembrane regions. The peptides extend the total length of 25A along this 
side of TRAF6 and bury ~580A2 surface area. 
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Figure 3.2.1. Overview of the 
structures. 
A. M a p p i n g of TRAF6-binding 
site on CD40, showing a 
representative isothermal 
titration curve (left) and the AG 
and KD of the interaction of 
TRAF6 with CD40 deletion 
series (right). 
B. Ribbon drawings of the 
structure of TRAF6 in complex 
with CD40, viewing down the 
putative three-fold axis of the 
TRAF6 molecule (left) and with 
the three-fold axis in a vertical 
orientation (right). 
C. Structural superposition of 
the TRAF6/CD40 complex with 
a TRAF2/CD40 complex, 
showing the distinct peptide 
directions in the two 
complexes. Same orientations 
as in (B). 
loop v 
Substantial structural differences between T R A F 6 and T R A F 2 (27-29) result in dramatic 
differences in the bound peptides, yielding a 40° cross in the peptide directions in their 
respective complexes (Figure 3.2.IC). The most prominent conformational difference 
resides at the (33-(34 loop of TRAF6, which exhibits up to 11.5A in Ca distances relative 
to TRAF2. This loop is displaced away from the receptor-binding site so that it no longer 
74-
3. Results 
interacts with the peptides in the TRAF6 complexes. The conformational change of the 
^3- (341oop is most likely brought about by the replacement of a 398-GxGxGxG-404 
sequence in TRAF2 and other TRAFs with non-glycine residues in TRAF6. In TRAF2, 
the (33- (34 loop is highly twisted. The glycine residues are crucial for maintaining two 
successive tight (3-turns of type II' (residues 399-DGTG-402) and type II (residues 402-
GAGT-405) respectively, which require glycines at specific positions. These two turns 
are further proceeded by a type I turn (395-YLNG-398) within the same loop. In TRAF6, 
the analogous residues continue further along the p3 strand, followed by a sharp type I 
turn at P398 (i+1 residue) to create a 90° bend in the loop. Most other connections 
between (3 strands show modest but significant differences in C„ positions (2-5A). A 
superposition of the TRAF6 structure in complex with CD40 with a TRAF2 structure in 
complex with CD40 shows an rms distance of 1.2A for 127 aligned Ca positions within 
3.0A. 
Both main chain and side chain hydrogen bonding interactions appear to play key 
anchoring roles in receptor recognition by TRAF6. A large portion of the receptor 
peptides (Q234-F238 for CD40 and T345-Y349 for TRANCE-R) assumes a typical anti-
parallel (3 conformation and makes main chain hydrogen bonds with residues P468-G472 
in the (37 strand of TRAF6 (Figure 3.2.2A and 3.2.2B). The side chains of E235 of CD40 
and E346 of TRANCE-R fit snugly into a surface groove and form hydrogen bonds to the 
main chain amide nitrogens of L457 and A458. In CD40, the carboxylate of D237 m.akes 
a hydrogen bond and a salt bridge to K469 of TRAF6. This salt bridge may explain the 
higher affinity of the N237D mutant of CD40 to TRAF6. In TRANCE-R, the carboxylate 
of D347 forms hydrogen bonds and a salt bridge to the guanidinium group of R392. The 
TRAF6 surface is in general rather basic, formed, among others, by the side chains of 
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R392 and K469, and is complementary to these acidic residues in the CD40 and 
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Figure 3.2.2. Structural details of the 
interaction of TRAF6 with CD40 and 
TRANCE-R. 
A. Details of the TRAF6/CD40 interaction. 
B. Details of the TRAF6/TRANCE-R 
interaction. 
C. Electrostatic characteristics of TRAF6 
interactions, shown here for the TRAF6/CD40 
interaction. 
D. Stereo view of the superposition of CD40 
with TRANCE-R peptides. 
/ a > 
* T y Pro (P2) 






A m o n g the eight residues that directly contact T R A F 6 (Q231-F238 of C D 4 0 and Q342-
Y349 of TRANCE-R), there are other important hydrophobic and hydrophilic 
interactions. Residue K230 of CD40 does not make any van der Waals contacts to 
TRAF6, in contrast with the previous notion that K230 is important for TRAF6 
interaction (21). Residues Q231-P233 of CD40 and Q342-P344 of TRANCE-R interact 
with hydrophobic TRAF6 residues F471 and Y473 to close the partially exposed 
hydrophobic core. In particular, the proline residue in both structures is completely 
buried. The side chains of Q231 of CD40 and Q342 of TRANCE-R are relatively less 
well defined and highly exposed to solvent, even though they appear to form several 
potential hydrogen bonds (Table 3.2.2). A dramatic difference exists between the 
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conformation of residue F238 of CD40 and the corresponding residue Y349 of 
TRANCE-R. While F238 inserts in between a series of aromatic and positively charged 
side chains including F410, R392, H394 and H412 of TRAF6, Y349 binds at the surface 
of this highly basic and aromatic region of TRAF6. A model building excise shows that 
the extra hydroxyl in Y349 appears to expel its insertion into the same pocket. 
Comparison of the CD40 and the TRANCE-R conformations by aligning the 
corresponding TRAF6 structures reveals the structural conservation and variation 
between the two sequences (Figure 3.2.2D). As residues E235 of CD40 and E346 of 
TRANCE-R superimpose extremely well and form crucial hydrogen bonding interactions 
with TRAF6, we denote this residue as the P0 position of the TRAF6-binding sequence. 
Residues P233 of CD40 and P344 of TRANCE-R are therefore at the P.2 position, while 
residues F238 of CD40 and Y349 of TRANCE-R reside at the P3 position. Main chain 
conformations are identical between the P^ to the P0 positions and slight deviations occur 
at the P,-P3 positions. Asp residues at both P, and P2 are able to form hydrogen bonds 
(Figure 3.2.2A and 3.2.2B), while a Glu at P2 is no longer able to preserve the same 
interaction. There are significant conformational adjustments in the side chains of the 
hydrogen bonding partners in TRAF6 (R392 and K469) in the presence and absence of 
these specific interactions. The difference in the side chain positions of the P3 residues is 
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3.2.3.3 Affinities of various TRAF6-binding sequences for T R A F 6 and identification 
of a consensus binding site 
To determine whether the observed interaction of TRAF6 with CD40 and TRANCE-R 
can be applied to the signal transduction of the IL-1R/TLR superfamily, we utilized the 
structural information to identify and align putative TRAF6-binding sequences from 
IRAK and its homologues IRAK2 and IRAKm (Figure 3.2.3). We used isothermal 
titration calorimetry to measure the affinities of these sequences for TRAF6. These ITC 
experiments showed that all the identified sequences in IRAK proteins produced binding 
affinities similar to that of the CD40 peptide (Figure 3.2.3), clearly demonstrating the 
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generality of the TRAF6 interaction and the mechanism of convergence of TRAF6 
signaling by the two superfamilies of receptors. In contrast, two sequences from NGFR 
and TACI, which were previously implicated in TRAF6 binding (31,32) but do not bear 
any recognizable structure-based sequence homology, failed to interact with our TRAF6 
construct. It is possible that these sequences bind to a different region of TRAF6. 
K D ( M M ) KA(103M-1) 
h C D 4 0 2 3 0 - K Q E P Q E I N F - 2 3 8 237 4.2±0.9 
hCD 4 0 (N237D) 2 3 0 - K Q E P Q E I D F - 2 3 8 84 11.912.2 
m C D 4 0 234-RQDPQEMED-242 
h T R A N C E - R 341-RQMPTEDEY-349 78 12.814.1 
m T R A N C E - R 337-RKIPTEDEY-345 
hIRAK 701-RQGPEESDE-709 56 17.912.3 
m I R A K 666-SQGPEESDE-674 
hIRAK-2 523-SNTPEETDD-531 64 15.713.0 
h I R A K - M 475-PSIPVEDDE-483 143 7.011.3 
Motif xxPxEdd(FXIXE) 
P o s i t i o n P j ^ P Q ^ P 3 
Other sequences 
hTACI SP E P V E T C S F C F P E C b e l o w d e t e c t i o n 
hNGF receptor E G E K L H S D S G I S V D S b e l o w detection 
Figure 3.2.3. Structure-based identification and alignment of TRAF6-binding sequences, showing the 
proposed TRAF6-binding motif and the measured KD of the interactions. 
The structural and sequence information led to a putative TRAF6-binding motif of 
xxPxEdd(F/Y/D/E) (positions P_4 to P3) (Figure 3.2.3), which is distinct from what was 
proposed earlier (21,24). The inclusion of the P.4and P3 residues in the motif is based on 
the role of their main chain atoms in closing the hydrophobic core of TRAF6. The Asp 
residues at positions P, and P2 are shown in lower case, as these may be the most 
favorable residues due to the specific hydrogen bonds, but other residues, especially 
acidic residues are tolerated at these positions due to the general charge complementarity 
with TRAF6. Based on the current structural information, we suspect that the Asp and 
Glu residues at the P3 position may adopt the Y349 conformation in TRANCE-R, rather 
than the inserted F238 conformation, due to a potential unfavorable charge burial. 
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To establish the importance of the peptide sequence in the context of full-length CD40 
intracellular domain, we used native gel shift and size exclusion chromatography to 
determine the mutational effects of CD40 and TRAF6 on this mutual recognition in vitro 
(Table 3.2.2). We performed mutagenesis for five out of the eight CD40 residues in 
contact with TRAF6. These residues exhibit either substantial surface area burials and/or 
potential hydrogen bonding interactions. Mutations E235A (P0) and F238A (P3) resulted 
in complete abrogation of binding, demonstrating the importance of these residues in 
TRAF6 recognition. While P233A (P.2) did not show qualitative difference in TRAF6 
binding, a P233Q mutation abolished the interaction, confirming that the buried binding 
pocket for P233 could not accommodate large side chains. On the TRAF6 side, we 
individually mutated all contacting residues involved in CD40 interaction to alanines to 
determine the energetic contributions of their side chains. Two residues, F471 and Y473, 
were singled out as the most crucial, as they produced drastic effects in the qualitative 
gel-shift and size exclusion assays. Other individual mutations did not produce qualitative 
differences in CD40 binding, suggesting that these residues contribute collectively, rather 
than singly, to the interaction. In addition, it is possible that the relative importance of 
TRAF6 residues may be somewhat different for different interacting sequences. 
Our structural observation raises the question whether the conserved Glu at the P0 
position of the TRAF6-binding motif is analogous to the P0 position (a Glu or a Gin) of 
the TRAF2-binding motif (29). Interestingly, even though the binding peptides for 
TRAF6 and TRAF2 take their own courses on the surface of the TRAF proteins, they 
intercept near the P0 residues (Figure 3.2.IC). In TRAF2 complexes, three Ser residues 
(S453-S455) appear to form a tight grip at the side chain of the P0 Glu or Gin. In TRAF6, 
these three residues are replaced by L456-L457-A458. Reciprocal movements in both 
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TRAF6 and the peptides are apparent to accommodate the P0 Glu at this position. The 
side chains of L456 and L457 move away from E235 to create an optimal cavity for E235 
to approach in the main chain amides of L457 and A458 for hydrogen bonding 
interactions. In addition, an E235Q mutation of CD40 did not produce qualitative 
difference in TRAF6 binding (Table 3.2.2). These observations led us to propose a model 
of co-evolution between TRAF proteins and their binding sequences, in which the P0 
residue serves as a primary conserved feature or anchoring point in this process. 
Table 3.2.2. Structural characteristics and mutational effects of the T R A F 6 / C D 4 0 
interaction as assessed by native gel shift and size exclusion chromatography. 






























































+: binding preserved, no or minor effects; -: binding disrupted, major effects 
*shown in parentheses are corresponding residues in mouse TR,AF6 used in the 
dominant negative experiments (see below) 
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3.2.3.4 Mapping of potential TRAF6-binding sites in CD40, TRANCE-R, and IRAK 
Previous studies have localized a single TRAF6 binding site in CD40 to a membrane 
proximal region (21). In TRANCE-R, we (20) and others (24) have identified at least two 
regions of potential TRAF6 interaction: one in what we have defined as the membrane 
proximal "N domain" of the cytoplasmic tail of TRANCE-R, and another in the "M 
domain," which is C-terminal to the N domain. The binding site(s) for TRAFs 1, 2, 3, and 
5 is in the extreme C-terminal portion of TRANCE-R, the "C domain," and this domain 
does not appear to interact with TRAF6 (20). In IRAK, similar to TRANCE-R, two 
potential TRAF6-interacting regions have been identified in the C-terminal portion of the 
molecule, defined as "Cl" and " C 2 " (10). With our structural information about the 
consensus binding sequence for TRAF6 (xxPxEdd[F/Y/E/D], Figure 3.2.3), we identified 
one T R A F 6 binding site in C D 4 0 and three potential T R A F 6 binding sites each in 
T R A N C E - R and I R A K (Figure 3.2.4A). T w o of the predicted binding sites in T R A N C E -
R are located in the "M" region and two of the predicted binding sites in IRAK are 
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TRAF6-binding sequences in mCD40, 
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A. Alignment of consensus TRAF6-binding 
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and C in TRANCE-R follow convention in 
(20). D D denotes death domain, U D 
unknown domain, and K D kinase domain 
(IRAK). TRAF6-binding sites are marked 




3.2.3.5 Functional mapping of predicted TRAF6-binding residues on CD40, 
TRANCE-R, and IRAK 
In order to determine the relative in vivo contributions of each residue in the predicted 
TRAF6-binding consensus sequences of mCD40, mTRANCE-R (site 1), and hIRAK (site 
3), we changed potential TRAF6-interacting residues by site-directed mutagenesis and 
analyzed the ability of these mutants to activate NF-kB in a luciferase reporter assay. 
Mutation of positions P.4, P.2, P0, P2, and P3 revealed that each of the residues from P_2 to 
P3 contributed to TRAF6-mediated NF-kB activation, while the side chain of postion P.4 
was unimportant for TRAF6-mediated NF-kB activation, in agreement with the structural 
observation that the contribution of the P.4 position to TRAF6 binding is from the main-
chain Ca. In CD40, there was a variable degree of inhibition in each of the mutants, with 
E239A mutation, predicted by our structural observations to be at the center of the 
TRAF6 binding groove (postion P0), producing the most significant block in NF-kB 
activation (Figure 3.2.5A). The residual NF-kB activity in the CD40 mutants is due to an 
incomplete block of TRAF6 binding and/or normal binding to other TRAFs including 
TRAF2 and TRAF5 through CD40's C-terminal TRAF-binding site, shown to interact 
with TRAFs 1, 2, 3, and 5 but not TRAF6 (21). In order to map similar sites on 
TRANCE-R and IRAK and rule out the possibility of other TRAFs contributing to NF-
kB activation, we examined deletion constructs of TRANCE-R and IRAK predicted to 
have only a single TRAF6 binding site (TR-N and IRAK-AC 1, Figure 3.2.4B). Without 
the potential for residual activity mediated by other TRAFs, it is clear that single 
mutations of P 2, P0, P2, and P3 are all capable of substantial inhbition of TRAF6-mediated 
NF-kB activation by TR-N and IRAK-AC1 (Figure 3.2.5, B and C). To examine whether 
other TRAF6-mediated signaling pathways are blocked by these mutations, we 
performed an in vitro JNK assay on overexpressed TR-N and its mutants, obtaining 
similar results (Figure 3.2.5D). Taken together, these data suggest that mutation of any of 
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the predicted TRAF6-interacting residues of the consensus binding site is sufficient to 
block TRAF6-mediated signaling by CD40, TRANCE-R, or IRAK. 
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Figure 3.2.5. Functional importance of predicted TRAF6-binding residues in C D 4 0 , T R A N C E - R , 
and IRAK. 
A. Site-directed mutagenesis was employed to generate point mutations in residues predicted to bind to 
TRAF6 in mCD40. CD40 (wild-type and mutants, 100 ng) were transfected in 293T cells with an NF-kB-
responsive luciferase reporter plasmid (75 ng) and 3-galactosidase (25 ng). Relative luciferase activity was 
normalized for 3-galactosidases activity. Representative results of at lest 3 separate transfections are 
shown. 
B. Mouse TRANCE-R consisting of the extracellular domain and residues 235-368 of the cytoplasmic tail 
(TR-N, wild-type and mutants, 50 ng) was transfected as in A. 
C. Human IRAK (full-length, FL; and with a deletion of residues 522-618, AC1; wild-type and mutants, 
100 ng) was transfected as in A. 
D. As in B, but TR-N constructs were transfected with JNK1 and the lysates were subjected to an in vitro c-
Jun N-terminal kinase assay. MEKK1 was included as a positive control. 
3.2.3.6 Functional mapping of predicted receptor-binding residues on T R A F 6 
We next determined the importance of the observed TRAF6 interface for signaling by 
C D 4 0 , T R A N C E - R , and I R A K using a dominant negative assay. The receptor-binding 
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TRAF domain of TRAF6 has been shown to exert a strong dominant negative phenotype 
on endogenous signaling by these receptors, presumably due its ability to bind to 
receptors and its lack of the N-terminal domains necessary for downstream signaling 
(2,33,34). Mutant TRAF domain constructs of TRAF6 that are defective in receptor or 
IRAK binding, on the other hand, should then be incapable of or exhibit reduced ability 
for dominant negative interference. 
We created the following point mutants of dominant negative mouse TRAF6 (T6.DN, 
residues 289-530) by site-directed mutagenesis: R400A, F418A, K477A, F479A, and 
Y481A (see Table 3.2.2 for the corresponding human TRAF6 residues). When co-
expressed with CD40, R400A, F479A and Y481A exhibited significantly reduced ability 
to inhibit NF-kB activation, while the F418A and K477A mutants retained the ability to 
reduce NF-kB activation nearly as well as wild-type TRAF6.DN (Figure 3.2.6A). When 
co-expressed with TR-N, all of the TRAF6.DN mutants could inhibit NF-kB activation 
to varying degrees, but none of the mutants could block activation as strongly as wild-
type TRAF6.DN (Figure 3.2.6B). Taken together, these functional data are consistent 
with the TRAF6 interface defined by structural studies. 
To test the effect of the TRAF6.DN mutants on IL-1 mediated NF-kB activation, we 
transfected 293T cells with the various TRAF6.DN constructs and NF-kB responsive 
reporter elements, and treated them for 6 hours with IL-1. The F418A and K477A 
mutants could block NF-kB induction as effectively as wild-type TRAF6.DN, while the 
others demonstrated virtually no blockade (Figure 3.2.6C), confirming the functional 
significance of the observed structural information on IL-1 signaling as well. As there are 
several known IRAK isoforms, the complete inability of some of the TRAF6 mutants to 
exert dominant negative interference on NF-kB activation confirmed our structural 
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observation on the conserved recognition of TRAF6 for all three IRAKs including IRAK, 
IRAK2 and IRAKm. 
Figure 3.2.6. Functional importance of 
predicted receptor and IRAK-binding sites on 
TRAF6. 
A. Residues 289-530 of mouse TRAF6 (T6DN, 
wild-type and mutants as indicated, 800 ng) was 
cotransfected with wild-type mouse CD40 (100 
ng). NF-kB activity was determined as in A. 
B. As in A, but with wild-type TR-N (50 ng) 
instead of CD40. 
C. T6.DN (wild-type and mutants as indicated, 
800 ng) was transfected as in A and B. Cells 
were treated with 1 ng/ml recombinant hIL-la 6 
hours prior to h.arvesting. 
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3.2.3.7 Relative contributions of each TRAF6-binding site in TRANCE-R and IRAK 
Since there are multiple predicted TRAF6-binding sites in both TRANCE-R and IRAK, 
we assayed the relative contribution of each of these binding sites to signaling by full-
length TRANCE-R and IRAK. As mutation of the P0 glutamate residue was sufficient to 
substantially reduce TRAF6-mediated signaling by all of the consensus sites examined in 
Figure 3.2.5, we employed only P0 E-A mutations to examine each predicted site in full-
length TRANCE-R and IRAK individually and in combination. Single mutations of 
E342A, E375A, and E449A resulted in minimal effects on the ability of overexpressed 
TRANCE-R to activate NF-kB. Double mutations, particularly 342/375 and 342/449, and 
to a lesser extent 375/449, slightly reduced NF-kB activation by TRANCE-R, but not 
substantially. Triple mutation of E342A, E375A, and E449A (E3A) markedly reduced 
TRANCE-R-mediated NF-kB activation (Figure 3.2.7A). It is somewhat surprising that 
any single TRAF6-binding site was sufficient to mediate TRANCE-R-induced NF-kB 
activation almost to the level of the wild-type sequence. The functional NF-kB activating 
potential by these mutants was confirmed structurally by their ability to bind to and 
immunoprecipitate TRAF6. The relative amount of TRAF6 immunoprecipitated by 
TRANCE-R mutants correlated with the relative ability of these mutants to activate NF-
kB. In particular, double mutants with the site 1 E342A mutation (342/375 and 342/449) 
co-precipitated less TRAF6 than did the 375/449 mutant, and the E3A mutant co-
precipitated a negligible amount of TRAF6 (Figure 3.2.7B). 
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Figure 3.2.7. Relative contributions of each TRAF6-binding site to TRANCE-R and IRAK signaling. 
A. Full-length TRANCE-R (wild-type and mutants as indicated, 50 ng) was transfected and NF-kB 
activity was determined as in Figure 3.2.5. 
B. TRANCE-R (wild-type and mutants as indicated, 500 ng) was co-transfected with wild-type TRAF6 
(500 ng). Cell lysates were immunoprecipitated with an antibody to TRANCE-R (1E6.66) and 
immunoprecipitates (IP) and whole cell lysates (WCE) were probed with anti-Flag M 2 antibody. 
C. TRANCE-R constructs consisting of the ectodomain/transmembrane region and residues 354-536 of 
the cytoplasmic tail (TR-M, see Figure 3.2.4B for diagram, wild-type and mutants as indicated, 50 ng) 
were transfected as in A. 
D. Full-length IRAK (wild-type and mutants as indicated, 100 ng) was transfected as in A. 
In the double mutants, mutation of the two " M " region glutamates (375/449) consistently 
produced less inhibition of NF-kB activation than did either double mutant involving the 
"N" region glutamate (342/375 and 342/449), so we examined the relative contribution of 
sites 2 and 3 in the context of the "M" region alone. Unexpectedly, the E375A mutation 
almost completely abolished TR-M-mediated NF-kB activation, while the E449A 
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mutation had minimal effect (Figure 3.2.7C). Similar results were obtained with 342/375 
and 342/449 mutants of the "N+M" regions, omitting the "C" region (data not shown). 
This discrepancy between the "M" region or "N+M" region alone and the full 
cytoplasmic tail of TRANCE-R suggests a potential cooperativity between the C-terminal 
portion of TRANCE-R and the third TRAF6 binding site. Whether this is due to binding 
of other TRAFs to the "C" region or differential protein folding leading to masking of 
site 3 in the absence of the "C" region is unclear at this point. 
Mutation of the three predicted TRAF6-binding sites in IRAK revealed, unexpectedly, a 
slight gain of NF-kB-activating potential by mutation of site 1 (E544A), as full-length 
IRAK with a single E544A mutation activated NF-kB slightly more strongly than wild-
type full-length IRAK. Single mutation of E587A and E706A both reduced NF-kB 
activation by IRAK, while double mutation of E544A with either E587A or E706A 
slightly increased NF-kB activation over single mutants of either E587A or E706A. 
Triple mutation of E544A, E587A, and E706A almost completely reduced NF-kB 
activation by IRAK to background levels (Figure 3.2.7D). The increased activity 
observed in single and double mutants containing E544A suggests that site 1 in IRAK 
may somehow negatively regulate IRAK signaling by sequestering TRAF6 away from 
the other two sites while not allowing it to activate downstream signals or through some 
other, unknown mechanism. Given that the mode of TRAF6 interaction with TNFR 
family receptors is trimeric, it is likely that the mode of TRAF6 interaction with IRAK is 
similarly trimeric. There may be structural constraints of trimeric IRAK that prevent 
trimeric TRAF6 from interacting properly with site 1, thus sequestering monomeric 
TRAF6 at that site, preventing it from trimerizing and activating downstream signals. 
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3.2.3.8 The role of TRAF6 in ligand-dependent signaling by TR-N 
In order to confirm the functional role of TRAF6 in TRANCE-mediated signaling, we 
generated stable HEK 293 cell lines expressing TR-N and TR-N-E342A. Stable clones 
were selected that expressed similar levels of surface TR-N as determined by FACS 
analysis (data not shown). In response to TRANCE stimulation, 293/TR-N cells 
demonstrated strong activation of JNK as measured by an in vitro kinase assay, while 
293/TR-N-E342A cells did not activate JNK in response to TRANCE (Figure 3.2.8A, 
top). Similarly, TRANCE stimulation of 293/TR-N cells resulted in p38 activation as 
measured with phospho-p38 specific antibodies, while TRANCE did not activate p38 in 
293/TR-N-E342A cells (Figure 3.2.8A, bottom). In order to measure TRANCE-
dependent NF-kB activation, we transfected 293/TR-N and 293/TR-N-E342A cells with 
an NF-kB reporter plasmid, stimulated the cells for 24h with soluble TRANCE, and 
measured reporter activity. While 293/TR-N cells showed a robust activation of NF-kB 
in response to TRANCE, 293/TR-N-E342A cells had no measurable NF-kB induction in 
response to TRANCE (Figure 3.2.8B). Thus, the observed effects achieved by transient 
overexpression of TR-N constructs elsewhere in this report are similar to those found in a 
ligand-dependent situation with stable expression of TR-N. Furthermore, TR-N is 
functional for surface expression and ligand-dependent signaling through TRAF6 and 
will be a useful tool to isolate TRAF6-specific signals emanating from TRANCE-R. 
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Figure 3.2.8. Ligand-dependent T R A F 6 
signaling by TR-N. 
A. Stably transfected 293 cells expressing TR-N 
(wild-type and E342A as indicated) were 
stimulated with T R A N C E (2 ng/ml) for the 
indicated time, lysed, and subjected to an in 
vitro J N K assay. Whole cell extracts ( W C E ) 
were probed with phospho-specific and total 
ap38 antibodies as indicated. 
B. Stably transfected 293 cells expressing TR-N 
(wild-type and E342A as indicated) were 
transfected with an NF-kB luciferase reporter 
plasmid and stimulated for 24h with the 
indicated amount of soluble T R A N C E . 
Luciferase activity was measured as in Figure 
3.2.5. 
3.2.3.9 Relative contributions of T R A F 6 - b i n d i n g sites a n d T R A F 1 / 2 / 3 / 5 binding 
sites to CD40 and T R A N C E - R signaling 
To account for residual, non-TRAF6-mediated NF-kB activation by TRANCE-R and 
CD40, we overexpressed an excess of TRAF2 or TRAF6 constructs lacking the N-
terminal zinc-binding domains as dominant negatives (T2.DN and T6.DN). With wild-
type full-length CD40, T6.DN inhibited NF-kB activation slightly more than did T2.DN. 
CD40-E239A activated NF-kB as strongly as CD40-WT + T6.DN, while CD40-E239A + 
T2.DN showed no NF-kB activation, suggesting that the defined TRAF6-binding site in 
CD40 is the only TRAF6-binding site in CD40 capable of signaling (Figure 3.2.9A). A 
similar set of transfections with TR-N and TR-N-E342A shows that TR-N activates NF-
kB exclusively through TRAF6, as T2.DN had no effect on the ability of TR-N to 
activate NF-kB (Figure 3.2.9B). To determine if the C-terminal TRAF1/2/3/5 binding 
site(s) contribute to the residual non-TRAF6-dependent NF-kB activation in full-length 
TRANCE-R, we transfected the TR-FL-E3A construct with T6.DN and T2.DN. T6.DN 
had minimal effect on the residual activity of TR-FL-E3A to activate NF-kB, while 
T2.DN abolished the residual NF-kB activity (Figure 3.2.9C). Since TRANCE-R has 
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three TRAF6-binding sites, in order to more directly compare it to C D 4 0 , we deleted the 
"M" region, which contains two TRAF6-binding sites, leaving only site 1 (TR-AM, 
Figure 3.2.4B). The relative inhibition of TR-AM and TR-AM-E342A signaling by 
T6.DN and T2.DN (Figure 3.2.9D) was comparable to that observed in C D 4 0 - W T and 
CD40-E239A (Figure 3.2.9A). Thus, the presence of three TRAF6-binding sites in 
T R A N C E - R as opposed to a single TRAF6-binding site in C D 4 0 suggests that T R A F 6 
may play a more dominant role in T R A N C E - R signaling. This may explain the observed 
absence of NF-kB, JNK, and p38 activation in TRAF6-/- cells upon T R A N C E treatment 
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Figure 3.2.9. Relative contributions of TRAF6- and TRAFl/2/3/5-binding sites to CD40 and 
TRANCE-R signaling. 
A. CD40 constructs (wild-type and E239A as indicated, 100 ng) were cotransfected with empty vector, 
TRAF6 residues 289-530 (T6.DN, 800 ng) or TRAF2 residues 241-501 (T2.DN, 800 ng) and subjected 
to an NF-kB reporter assay as in Figure 3.2.5. 
B. As in A, but with TR-N (50 ng) instead of CD40. 
C. As in A, but with full-length TRANCE-R (TR-FL, W T and triple E-A mutant, E3A, as indicated, 50 
ng). 
D. As in A, but with full-length TRANCE-R or TRANCE-R with a deletion of residues 254-536 (TR-AM, 
W T and E342A as indicated). 
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3.2.10 Formation of a ternary complex consisting of TRAF6, CD40, and c-Src 
A specific role of TRAF6 in anti-apoptotic signaling (17,35) has recently been 
demonstrated by its activation of the Ser/Thr kinase Akt, which specifically 
phosphorylates and inactivates pro-apoptotic molecules such as B A D and pro-caspase-9 
(36-38). For TRANCE-R, this Akt activation appears to be mediated by c-Src, a member 
of the Src tyrosine kinase family, with TRAF6 acting upstream of c-Src activation. Mice 
deficient in either TRAF6 (11,12) or c-Src (18) share similar phenotypes in TRANCE-R -
mediated osteoclast function. A universal role of TRAF6 as an upstream event for Akt 
activation through the Src kinases has also been implicated for CD40 (39-41) and IL-





Figure 3.2.10. Ternary complex formation 
of T R A F 6 , CD40, and c-Src. 
A. Mapping of the potential Src-binding site 
on the surface of the T R A F 6 / C D 4 0 
complex. C D 4 0 peptide: ball and stick 
model; TRAF6: green; proline-rich sequence 
of TRAF6: orange. 
B. Native gel electrophoresis, showing the 
ternary complex formation of TRjAF6, GST-
CD40cyt, and c-Src. 
proposed Src-binding 
site on a receptor 
B 
C D 4 0 T R A F 6 c-Src complex 
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The structures of TRAF6 in complex with CD40 and TRANCE-R suggest a model for a 
ternary complex formation among TRAF6, a receptor and a Src kinase (Figure 3.2.10A). 
TRAF6 is the only TRAF family member that contains a putative SH3 domain binding 
sequence (462-PxxPxxP-468) as an insertion between the strands (36 and [57. 
Interestingly, residues 465-468 within this proline-rich sequence are disordered in the 
free TRAF6 structure and become ordered in the CD40 and TRANCE-R-bound 
structures. Previous binding studies using in vitro translated proteins suggested that c-Src 
interacts with TRAF6 via these proline-rich sequences and with TRANCE-R via a region 
immediately after its TR.^VF6-binding site. In the TRAF6 complexes, these proline-rich 
residues are situated adjacent to the bound CD40 and TRANCE-R receptor peptides, 
suggesting that a Src kinase may interact with an integrated surface formed by both 
TRAF6 and the receptors. 
To determine whether such a ternary complex can be assembled in vitro, we assessed the 
pattern of native gel shift using purified TRAF6, GST-CD40 intracellular domain and c-
Src (Figure 3.2.10B). The native gel clearly shows that a ternary complex is formed upon 
addition of the three proteins, as shown by the disappearance of protein bands 
corresponding to the individual components. Therefore, the biochemical evidence further 
suggests a cooperative (rather than a competitive) assembly of the ternary complex, 
providing an explanation for the interdependence of TRAF6 and Src kinases in the signal 
transduction of these receptors. The experiment also demonstrates a direct linkage of a 
TRAF protein to a downstream molecule among the many that have been implicated but 




Our studies of the TRAF domain of TRAF6 reveal the structural underpinnings of its 
interaction with TNFR family proteins and components of the IL-lR/Toll-like receptor 
family signaling complex. Previous studies have demonstrated that TRAF6 is divergent 
from other TRAF proteins in that it binds to unique receptor sites and participates in 
signal transduction downstream of non-TNFR family proteins through its association 
with IRAK. While the overall structure of TRAF6 is similar to that of TRAF2, its mode 
of binding to receptor sequences is quite divergent, although it centers around a critical 
binding residue on the receptor (Glu) similar to TRAF2's binding to a central receptor 
residue (Gin). This suggests an evolutionary point of divergence between TRAF6 and 
TRAFs 1, 2, 3, and 5. Identification of a consensus binding sequence for TRAF6 revealed 
that there are numerous TRAF6 binding sites in TRANCE-R and IRAK, which we have 
confirmed functionally. Finally, we propose a potential mechanism by which TRAF6 
links TNFR family proteins and the c-Src tyrosine kinase, in a cooperative ternary 
complex assembly. Given the importance of TRAF6 in bone remodeling and adaptive 
and innate immunity, structural information about its mode of signaling is an important 
starting point for the rational design of anti-osteoporotic and anti-inflammatory 
molecules. 
3.2.5 Experimental Procedures 
3.2.5.1 Isothermal titration calorimetry 
Peptides containing putative TRAF6-binding sequences were chemically synthesized 
with amino-terminal acetylation and carboxy-terminal amidation. The molecular mass of 
each peptide was verified by MALDI-TOF mass spectrometry. A different TRAF6 
construct (residues 333-508), which was expressed and purified similarly as described for 
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the TRAF6 construct used for crystallization, was used for ITC experiments due to its 
higher expression yield. Both protein and peptides were dialyzed extensively against 
50mM sodium phosphate at pH 7.5 for at least two days at 4°C to ensure buffer 
equilibration. Accurate concentrations of the protein and peptide samples after dialysis 
were determined by quantitative amino acid analysis. ITC experiments were performed at 
20°C for determination of binding enthalpy and affinity using a microcalorimetry system 
(MicroCal Inc.). Approximately 20 to 45 injections were titrated for each measurement. 
The data were analyzed by the ORIGIN data analysis software (MicroCal Inc.) (26). The 
heat of dilution obtained from injecting a ligand into the buffer was subtracted before the 
fitting process. 
3.2.5.2 Protein expression, purification and crystallization 
The TRAF proteins contain an N-terminal effector domain of RING and zinc-fingers and 
a C-terminal TRAF domain that can be further divided into a coiled-coil region and a 
homologous TRAF-C domain for receptor interaction (1,19). A combination of genetic, 
biochemical and crystallographic methods was used in identifying a crystallizable TRAF 
domain construct of TRAF6 and a detailed description will be presented elsewhere. In 
summary, the TRAF6 construct (residues 346-504) containing a carboxy-terminal His-tag 
was expressed in E. coli with overnight IPTG induction at 20°C. The protein was purified 
by Ni-affinity chromatography and gel filtration. The protein was concentrated to around 
3 mg/ml and crystallized under 5-25% PEG8K and lOOmM Tris at pH 7.5. For complex 
formation with TRAF6-binding peptides, a 10-fold molar excess of a mutant human 
CD40 peptide (230-KQEPQEIDF-238) or a human TRANCE-R peptide (342-
QMPTEDEY-349) was included in the crystallization drops. Crystals grew as thin plates 
and chunky prisms respectively in the absence and presence of the peptides. 
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3.2.5.3 Data collection and structure determination 
Preliminary crystal characterization and screening were conducted on an Raxis-IV 
imaging plate detector mounted on a Rigaku RU300 X-ray generator. Diffraction data 
were collected at the X4A beamline of NSLS and the Al beamline of CHESS. The 
structures were determined by molecular replacement using the program Replace . The 
atomic model of the TRAF domain of TRAF2 was modified by removing the side chains 
of residues that are not conserved in TRAF6. Structural refinement was performed by the 
simulated annealing protocol in CNS (42). Ribbon and stick models were created using 
Setor (43) and the molecular surface representation was calculated and presented by 
Grasp (44). 
3.2.5.4 Native gel shift and size exclusion chromatography 
Native gel shift experiments were performed using the PhastGel system (Pharmacia) and 
8-25% gradient polyacrylamide gel. Size exclusion chromatography was carried out 
using a Superdex 200 (10/30) column (Pharmacia). 
3.2.5.5 Transfection and Reporter Assays 
Mouse CD40 was cloned by RT-PCR from whole spleen mRNA and inserted into the 
pFLAG-CMVl cloning vector (Sigma). Flag-tagged mouse TRANCE-R consisting of the 
extracellular domain and residues 235-368 or 354-536 of the cytoplasmic tail (TR-N and 
TR-M), mouse TRAF6 consisting of residues 289-530 (T6.DN), and TRAF2 consisting 
of residues 241-501 (T2.DN) have been described (20). Site-directed mutagenesis of 
CD40, TRANCE-R, IRAK, and TRAF6.DN was performed on the indicated residues by 
the Quick-change method (Stratagene). All constructs were confirmed by sequencing. 
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293T HEK cells were transfected in 6-well plates with the indicated amounts of CD40, 
TR-N, and TRAF6.DN and mutants along with 75 ng of an NF-KB-luciferase reporter 
plasmid and 25 ng of a (3-galactosidase plasmid to control for transfection efficiency. 
Transfection amounts were kept constant at 1 (ig by addition of empty pFLAG-CMV 1 
vector. Cells were harvested 24-30 h after transfection and reporter activity was assayed 
as described (20). Where indicated, cells were treated with 1 ng/ml recombinant human 
IL-1 (R & D) 6 hour prior to harvesting. 
For the in vitro JNK kinase assay, full length TRANCE-R, TR-N, TR-N mutants, and 
MEKK1 were transfected along with JNK1 (100 ng) as indicated. JNK1 was 
immunoprecipitated with an a-JNKl antibody (E-17, Santa Cruz Biotechnology), and 
the immunoprecipitates were subjected to an in vitro kinase assay using recombinant 
GST-c-jun (1-79, Calbiochem) as a substrate as described previously (45). Transfection 
efficiency was confirmed by western blotting the immunoprecipitates with a-JNKl. 
Stable cell lines expressing TR-N and TR-N-E342A were generated by co-transfection of 
HEK 293 cells with the indicated expression vectors with a vector carrying a neomycin 
resistance plasmid (pcDNA3.1). Cells were selected for resistance to G418 and cloned by 
limiting dilution. Clones with similar levels of surface expression of TR-N were 
identified by FACS analysis. 
3.2.6 Acknowledgements 
We thank Nikola Pavletich for access to the calorimetry instrument, Yangchao Ma for 
purified c-Src protein, Liang Tong, Reza Khayat, Zhiru Yang and Chris Lima for help 
with diffraction data collection, Craig Ogata and MacCHESS staff for beamline access 
and support, Temple Burling for maintaining the home X-ray source and Moses Chao for 
98-
3. Results 
a dominant negative TRAF6 cDNA. This work was supported by the Speaker's Fund for 
Biomedical Research (H. W.), the departmental startup fund (H. W.) and MSTP grant 
GM-07739 (J. R. A.). H. Y. is a postdoctoral fellow from the Revson Foundation. Y. C. is 
an associate investigator of the Howard Hughes Medical Institute. H. W. is a Pew scholar 
of biomedical sciences. 
3.2.7 References 
1. Arch, R. H., Gedrich, R. W., and Thompson, C. B. (1998) Tumor necrosis factor 
receptor-associated factors (TRAFs)—a family of adapter proteins that regulates 
life and death. Genes Dev 12(18), 2821-30. 
2. Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D. V. (1996) TRAF6 
is a signal transducer for interleukin-1. Nature 383(6599), 443-6. 
3. Medzhitov, R., and Janeway, C. A., Jr. (1998) Innate immune recognition and 
control of adaptive immune responses. Semin Immunol 10(5), 351-3. 
4. van Kooten, C , and Banchereau, J. (2000) CD40-CD40 ligand. J Leukoc Biol 
67(1), 2-17. 
5. Wong, B. R., Josien, R., and Choi, Y. (1999) T R A N C E is a TNF family member 
that regulates dendritic cell and osteoclast function. J Leukoc Biol 65(6), 715-24. 
6. Fata, J. E., Kong, Y. Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., 
Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., Boyle, W . J., Khokha, R., and 
Penninger, J. M. (2000) The osteoclast differentiation factor osteoprotegerin-
ligand is essential for mammary gland development. Cell 103(1), 41-50. 
7. Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C , Ghosh, S., 
and Janeway, C. A., Jr. (1998) MyD88 is an adaptor protein in the hToll/IL-1 
receptor family signaling pathways. Mol Cell 2(2), 253-8. 
8. Kawai, T., Adachi, O., Ogawa, T., Takeda, K., and Akira, S. (1999) 
Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11(1), 115-
22. 
9. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., 
Nakanishi, K., and Akira, S. (1998) Targeted disruption of the M y D 8 8 gene 
results in loss of IL-1- and IL- 18-mediated function. Immunity 9(1), 143-50. 
10. Li, X., Commane, M., Jiang, Z., and Stark, G. R. (2001) IL-1-induced NFkappa B 
and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated 
kinase (IRAK). ProcNatlAcadSciUSA 98(8), 4461-5. 
-99 
3. Results 
11. Lomaga, M. A., Yeh, W. C, Sarosi, I., Duncan, G. S., Furlonger, C, Ho, A., 
Morony, S., Capparelli, C , Van, G., Kaufman, S., van der Heiden, A., Itie, A., 
Wakeham, A., Khoo, W., Sasaki, T., Cao, Z., Penninger, J. M., Paige, C. J., 
Lacey, D. L., Dunstan, C. R., Boyle, W . J., Goeddel, D. V., and Mak, T. W . 
(1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, 
CD40, and LPS signaling. Genes Dev 13(8), 1015-24. 
12. Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, 
K., Nakamura, K., Katsuki, M., Yamamoto, T., and Inoue, J. (1999) Severe 
osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in 
TRAF6-deficient mice. Genes Cells 4(6), 353-62. 
13. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C , 
Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, 
A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W . J., and Penninger, J. M. 
(1999) O P G L is a key regulator of osteoclastogenesis, lymphocyte development 
and lymph-node organogenesis. Nature 397(6717), 315-23. 
14. Kim, D., Mebius, R. E., MacMicking, J. D., Jung, S., Cupedo, T., Castellanos, Y., 
Rho, J., Wong, B. R., Josien, R., Kim, N., Rennert, P. D., and Choi, Y. (2000) 
Regulation of peripheral lymph node genesis by the tumor necrosis factor family 
member TRANCE. J Exp Med 192(10), 1467-78. 
15. Dougall, W . C , Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, 
T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., Armstrong, A., 
Shen, V., Bain, S., Cosman, D., Anderson, D., Morrissey, P. J., Peschon, J. J., and 
Schuh, J. (1999) R A N K is essential for osteoclast and lymph node development. 
Genes Dev 13(18), 2412-24. 
16. Soriano, P., Montgomery, C , Geske, R., and Bradley, A. (1991) Targeted 
disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64(4), 
693-702. 
17. Wong, B. R., Besser, D., Kim, N., Arron, J. R., Vologodskaia, M., Hanafusa, H., 
and Choi, Y. (1999) T R A N C E , a T N F family member, activates Akt/PKB 
through a signaling complex involving TRAF6 and c-Src. Mol Cell 4(6), 1041-9. 
18. Xing, L., Venegas, A. M., Chen, A., Garrett-Beal, L., Boyce, B. F., Varmus, H. 
E., and Schwartzberg, P. L. (2001) Genetic evidence for a role for Src family 
kinases in T N F family receptor signaling and cell survival. Genes Dev 15(2), 241-
53. 
19. Rothe, M., Wong, S. C , Henzel, W . J., and Goeddel, D. V. (1994) A novel family 
of putative signal transducers associated with the cytoplasmic domain of the 75 
kDa tumor necrosis factor receptor. Cell 78(4), 681-92. 
100-
3. Results 
20. Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M., and 
Choi, Y. (1998) The T R A F family of signal transducers mediates NF-kappaB 
activation by the T R A N C E receptor. J Biol Chem 273(43), 28355-9. 
21. Pullen, S. S., Dang, T. T., Crate, J. J., and Kehry, M. R. (1999) CD40 signaling 
through tumor necrosis factor receptor-associated factors (TRAFs). Binding site 
specificity and activation of downstream pathways by distinct TRAFs. J Biol 
Chem 274(20), 14246-54. 
22. Kobayashi, N., Kadono, Y., Naito, A., Matsumoto, K., Yamamoto, T., Tanaka, S., 
and Inoue, J. (2001) Segregation of TRAF6-mediated signaling pathways clarifies 
its role in osteoclastogenesis. Embo J 20(6), 1271-80. 
23. Pullen, S. S., Labadia, M. E., Ingraham, R. H., McWhirter, S. M., Everdeen, D. 
S., Alber, T., Crate, J. J., and Kehry, M. R. (1999) High-affinity interactions of 
tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require 
T R A F trimerization and CD40 multimerization. Biochemistry 38(31), 10168-77. 
24. Darnay, B. G., Ni, J., Moore, P A., and Aggarwal, B. B. (1999) Activation of NF-
kappaB by R A N K requires tumor necrosis factor receptor- associated factor 
(TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 
interaction motif. J Biol Chem 274(12), 7724-31. 
25. Pullen, S. S., Miller, H. G., Everdeen, D. S., Dang, T. T., Crate, J. J., and Kehry, 
M. R. (1998) CD40-tumor necrosis factor receptor-associated factor (TRAF) 
interactions: regulation of CD40 signaling through multiple T R A F binding sites 
and TRAF hetero-oligomerization. Biochemistry 37(34), 11836-45. 
26. Ye, H., and W u , H. (2000) Thermodynamic characterization of the interaction 
between TRAF2 and tumor necrosis factor receptor peptides by isothermal 
titration calorimetry. Proc Natl Acad Sci U S A 97(16), 8961-6. 
27. McWhirter, S. M., Pullen, S. S., Holton, J. M., Crate, J. J., Kehry, M. R., and 
Alber, T. (1999) Crystallographic analysis of CD40 recognition and signaling by 
human TRAF2. Proc Natl Acad Sci USA96(\ 5), 8408-13. 
28. Park, Y. C , Burkitt, V., Villa, A. R., Tong, L., and W u , H. (1999) Structural basis 
for self-association and receptor recognition of human TRAF2. Nature 398(6727), 
533-8. 
29. Ye, H., Park, Y. C , Kreishman, M., Kieff, E., and W u , H. (1999) The structural 
basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell 4(3), 
321-30. 
30. Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H. J., Broger, C , 
Loetscher, H., and Lesslauer, W . (1993) Crystal structure of the soluble human 55 
kd T N F receptor-human T N F beta complex: implications for T N F receptor 
activation. Cell 73(3), 431-45. 
101 
3. Results 
31. Khursigara, G., Orlinick, J. R., and Chao, M. V. (1999) Association of the p75 
neurotrophin receptor with TRAF6. J Biol Chem 274(5), 2597-600. 
32. Xia, X. Z., Treanor, J., Senaldi, G., Khare, S. D., Boone, T., Kelley, M., Theill, L. 
E., Colombero, A., Solovyev, I., Lee, F., McCabe, S., Elliott, R., Miner, K., 
Hawkins, N., Guo, J., Stolina, M., Yu, G., Wang, J., Delaney, J., Meng, S. Y., 
Boyle, W . J., and Hsu, H. (2000) TACI is a TRAF-interacting receptor for TALL-
1, a tumor necrosis factor family member involved in B cell regulation. J Exp 
Med 192(1), 137-43. 
33. Takeuchi, M., Rothe, M., and Goeddel, D. V. (1996) Anatomy of TRAF2. 
Distinct domains for nuclear factor-kappaB activation and association with tumor 
necrosis factor signaling proteins. J Biol Chem 271(33), 19935-42. 
34. Song, H. Y., Regnier, C. H., Kirschning, C. J., Goeddel, D. V., and Rothe, M. 
(1997) Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of 
nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at 
TNF receptor-associated factor 2. Proc Natl Acad Sci U S A 94(18), 9792-6. 
35. Arron, J. R., Vologodskaia, M., Wong, B. R., Naramura, M., Kim, N., Gu, H., and 
Choi, Y. (2001) A positive regulatory role for Cbl family proteins in tumor 
necrosis factor-related activation-induced cytokine (trance) and CD40L-mediated 
Akt activation. J Biol Chem 276(32), 30011-7. 
36. Yano, S., Tokumitsu, H., and Soderling, T. R. (1998) Calcium promotes cell 
survival through CaM-K kinase activation of the protein-kinase-B pathway. 
Nature 396(6711), 584-7. 
37. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., 
Stanbridge, E., Frisch, S., and Reed, J. C. (1998) Regulation of cell death protease 
caspase-9 by phosphorylation. Science 282(5392), 1318-21. 
38. Coffer, P. J., Jin, J., and Woodgett, J. R. (1998) Protein kinase B (c-Akt): a 
multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 
335(Pt 1), 1-13. 
39. Ren, C. L., Morio, T., Fu, S. M., and Geha, R. S. (1994) Signal transduction via 
CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and 
phosphorylation of phospholipase C gamma 2. J Exp Med 179(2), 673-80. 
40. Vidalain, P. O., Azocar, O., Servet-Delprat, C , Rabourdin-Combe, C , Gerlier, 
D., and Manie, S. (2000) CD40 signaling in human dendritic cells is initiated 
within membrane rafts. Embo J 19(13), 3304-13. 
41. Hostager, B. S., Catlett, I. M., and Bishop, G. A. (2000) Recruitment of CD40 and 
tumor necrosis factor receptor-associated factors 2 and 3 to membrane 
microdomains during CD40 signaling. J Biol Chem 275(20), 15392-8. 
42. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W . L., Gros, P., Grosse-
Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. 
102 
3. Results 
J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR 
system: A new software suite for macromolecular structure determination. Acta 
Crystallogr D Biol Crystallogr 54(Pt 5), 905-21. 
43. Evans, S. V. (1993) SETOR: hardware-lighted three-dimensional solid model 
representations of macromolecules. J Mol Graph 11(2), 134-8, 127-8. 
44. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Protein folding and association: 
insights from the interfacial and thermodynamic properties of hydrocarbons. 
Proteins 11(4), 281-96 
45. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, 
S., Cayani, E., Bartlett, F. S., 3rd, Frankel, W . N., Lee, S. Y., and Choi, Y. (1997) 
T R A N C E is a novel ligand of the tumor necrosis factor receptor family that 
activates c-Jun N-terminal kinase in T cells. J Biol Chem 272(40), 25190-4. 
103 
3. Results 
3.3 REGULATION OF THE SUBCELLULAR LOCALIZATION OF TRAF2 BY 
T R A F 1 R E V E A L S M E C H A N I S M S O F T R A F 2 SIGNALING 
Joseph R. Arron1 A Yael Pewzner-Jung2, Matthew C. Walsh3, Takashi Kobayashi3, and 
Yongwon Choi3* 
'Tri-Institutional MD-PhD Program, and laboratory of Immunology, The Rockefeller 
University, New York, New York 10021, USA. 
3Abramson Family Cancer Research Institute, Department of Pathology and Laboratory 




TRAF2 is a critical adaptor molecule for TNF receptors in inflammatory and immune 
signaling. In response to ligand engagement, TRAF2 is recruited to CD40 and 
translocates to lipid rafts in a RING finger-dependent process, which is required for its 
ability to activate downstream kinases. TRAF1 can displace TRAF2 and CD40 from raft 
fractions, and it promotes the ability of TRAF2 to sustain activation of signal cascades. 
Replacement of the RING finger of TRAF2 with a raft-targeting dual acylation signal 
restores JNK activation and association with the cytoskeletal protein Filamin, but not NF-
kB activation. TRAF1-/- dendritic cells show attenuated responses to secondary 
stimulation by TRAF2-dependent factors. These findings offer insights into the 
mechanism of TRAF2 signaling and identify a physiological role for TRAF1 as a positive 




Tumor necrosis factor (TNF) family proteins are essential regulators of the life and death 
of hematopoietic cells, bone and mammary gland homeostasis, and embryonic 
development (1). Signaling through TNF receptor (TNFR) proteins is mediated in part by 
TNFR associated factor (TRAF) adaptor proteins, which have been shown to activate the 
transcription factor NF-kB, MAP kinases, and Src-family kinases (2). Of the six 
mammalian TRAFs, sequence conservation analysis has shown that TRAFs 1, 2, 3, and 5 
are closely related, while TRAFs 4 and 6 are more evolutionarily divergent. Of these 
evolutionary relations, TRAF1 and TRAF2 appear to have arisen after duplication of a 
common precursor, while TRAF3 and TRAF5 have arisen from a different common 
precursor (3). 
The general domain organization of TRAF proteins, of which TRAF2 is the archetype, 
comprises an N-terminal zinc-binding domain, specifically a RING finger followed by 
several Zn fingers, and a C-terminal TRAF domain, consisting of a coiled-coil which 
permits TRAF oligomerization (TRAF-N) and a receptor binding domain (TRAF-C) 
(4,5). There are some exceptions to this scheme, most notably in TRAF1, which has a C-
terminal TRAF domain that is highly homologous to TRAF2, but lacks the RING and all 
but one of the Zn fingers. The specificity conferred by a particular TRAF-binding 
receptor is conferred by its relative affinity for the different TRAF proteins, the cell type-
specific expression of TRAFs, and the stoichiometry of TRAFs in a given receptor 
complex. Trimeric TNF family ligands bind to trimerized TNFR family proteins, 
dictating a trimeric mode of binding of TRAFs in which the affinity and avidity of TRAF 
proteins for receptor complexes is greatly enhanced (6-9) 
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Although TRAFs are essential adaptors for signaling through TNFR family proteins, they 
do not appear to possess intrinsic enzymatic activity and the precise mechanism of their 
action is as yet unknown. It is clear that the TRAF domain of TRAF2 is necessary for its 
direct interactions with TNFR proteins such as TNFR2, CD40, TRANCE-R, CD30 and 
others, as well as interactions with cytoplasmic factors including TRADD, RIP, NIK, 
ASK1, GCK, c-IAPs, I-TRAF, TRIP, A20 and others (2,10,11). However, expression of 
the TRAF domain alone inhibits signaling by TNF family ligands, and indeed, mutants of 
TRAF2 lacking the RING finger act as dominant negative factors for NF-icB and MAPK 
activation (12,13). The N-terminal RING and Zn fingers are therefore required for the 
activation of these cascades. The RING finger has been proposed to interact with 
MEKK1, a MAP3K that is potentially involved in TNF-a induced JNK activation 
(14,15), and the actin-binding protein Filamin (16), but physical association of the RING 
finger of TRAF2 and these proteins has not been rigorously demonstrated. TRAF2A, a 
splice variant of TRAF2 identified only in the murine traf2 locus which carries a 7-amino 
acid insert in the RING finger, cannot activate NF-kB, but is capable of JNK activation 
(3,17). It has been recently shown in vitro that the RING fingers of TRAF2 and TRAF6 
can serve as E3 ubiquitin ligases, mediating non-degradative K63 polyubiquitination of 
some interacting partners of TRAFs as well as TRAFs themselves. This 
polyubiquitination is linked to the ability to activate the IKK complex upstream of NF-
kB (18,19). Ubiquitination of TRAFs may also lead to signal-dependent degradation, thus 
serving as a means of downregulating TRAF-dependent signals (20). 
While most TRAFs are constitutively present in the cell types in which they are 
expressed, TRAF1 is absent in most resting cells (21). Expression of TRAF1 is rapidly 
upregulated in response to NF-kB and AP-1 activation by a variety of inflammatory 
mediators, including TNF-a, CD40L, LPS, and lymphocyte receptors (22-24). By itself, 
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TRAF1 does not appear to activate signaling cascades activated by TRAF2, although it 
can hetero-oligomerize with TRAF2 (4) and interact with many of the same receptors and 
cytoplasmic proteins as TRAF2 (11). While the exact physiological role of TRAF1 is 
unknown, it appears to positively regulate survival signals mediated by TRAF2 
(22,25,26). Recently, TRAF1 was found to be a target of caspases, and the resulting 
cleavage product negatively regulated the anti-apoptotic signals of TRAF2 during TNF-
induced cell death (27,28). 
An emerging theme in cell surface receptor signaling is detergent-resistant liquid-ordered 
lipid membrane microdomains, or lipid rafts (29-32). Contrary to the long-held fluid-
mosaic model of membranes as proteins floating freely in a sea of phospholipids, it 
appears that the membrane lipids may have regions of higher-order organization enriched 
in cholesterol and sphingolipids that coalesce around activated transmembrane receptor 
protein complexes. These complexes are resistant to solubilization at low temperatures in 
non-ionic detergents such as Triton X-100 and thus may serve to assemble or exclude 
various signaling complex components, which may enhance signaling specificity. 
Recently, several reports have demonstrated that CD40 engagement or Epstein-Barr virus 
LMP1 expression results in recruitment of CD40 or LMP1, TRAF2, TRAF3, and several 
other proteins to lipid rafts, which are thought to be intrinsic to some of the signaling 
functions of CD40 and LMP1 (33-37). 
In this report, we examine the role of the translocation of TRAF2 into detergent-insoluble 
complexes in the TRAF2-dependent activation of NF-kB and JNK. In response to CD40 
stimulation, TRAF2 translocates into lipid rafts in a RING finger-dependent process, 
which is required for kinase activation. TRAF1, which is upregulated in response to 
TRAF2-mediated signals, regulates the removal of CD40 and TRAF2 from insoluble 
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complexes, but increases the ability of TRAF2 to mediate sustained activation of NF-icB 
and JNK. Substitution of the RING finger of TRAF2 with a lipid raft-targeting dual 
acylation signal rescues JNK activation, but not NF-kB activation by TRAF2, suggesting 
that raft translocation is necessary and sufficient for JNK activation, but insufficient for 
NF-kB activation. Finally, in TRAF1-/- dendritic cells, we show that maturation by 
CD40L leads to a loss of soluble TRAF2 and a concomitant reduction in TNF, TRANCE, 
and CD40L-mediated survival, revealing a positive physiological role for TRAF1 in the 
regulation of TRAF2-dependent signaling. 
3.3.3 Results 
3.3.3.1 TRAF1 increases the detergent solubility of TRAF2 
Recently, it has been shown by several groups that CD40 engagement results in 
translocation of TRAF2 to detergent resistant lipid-ordered membrane microdomains, or 
lipid rafts (33-37). Since TRAF1 can hetero-oligomerize with TRAF2 and interact with 
the TRAF2 binding site of CD40, we investigated the effect of TRAF1 on the solubility 
of TRAF2 in non-ionic detergent (0.75% Triton X-100). Transient overexpression of 
TNFR or TRAF proteins leads to self-aggregation and signaling, mimicking ligand 
engagement, so we co-transfected HEK 293T cells with constant amounts of plasmids 
driving the expression CD40 and TRAF2, while titrating the amount of TRAFl. In the 
absence of TRAFl, a majority of TRAF2 was found in the insoluble fraction, while the 
addition of TRAFl resulted in a dose-dependent redistribution of TRAF2 to the soluble 
fraction (Fig. 3.3.1 A). The N-terminal zinc-binding RING finger of TRAF2 has been 
shown to be essential for NF-kB (12) and JNK (13) activation. It has also been suggested 
that the zinc binding capacity of TRAF2 is required for its translocation into lipid rafts 
(33). To determine if the RING finger of TRAF2 mediates translocation into the insoluble 
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fraction, we cotransfected CD40 and wild-type TRAF2 or TRAF2 with a deletion of the 
first 87 amino acids (T2A87), which comprise the RING finger, with or without TRAFl. 
T2A87 was found completely in the soluble fraction, regardless of TRAFl expression 
(Fig. 3.3.IB). Like TRAFl, TRAF5 has been shown to hetero-oligomerize with TRAF2 
(38). In order to determine if TRAF5 can mediate solubilization of TRAF2, we 
cotransfected CD40, TRAF2, and TRAFl or TRAF5. While TRAFl can mediate 
solubilization of TRAF2, TRAF5 cannot (Fig. 3.3.IC), suggesting a unique role for 
TRAFl. 
To determine if TRAFl could indeed mediate translocation of TRAF2 out of lipid rafts 
under sustained signaling conditions, we performed sucrose density gradient 
centrifugation on extracts of cells transfected with CD40, TRAF2 or T2A87, with or 
without TRAFl, treated for the last 6 h prior to lysis with soluble CD40L. In cells 
transfected with CD40 and TRAF2, both CD40 and TRAF2 could be found in the low-
density raft fractions, co-migrating with the known raft-associated tyrosine kinase Lyn 
(Fig. 3.3.ID, upper left). However, addition of TRAFl resulted in redistribution of both 
CD40 and TRAF2 out of the raft fractions (Fig. 3.3.ID, upper right). T2A87 was not 
found in significant amounts in the raft fractions with or without TRAFl, and even in the 
absence of overexpressed TRAFl, T2A87 coexpression resulted in a steady-state 
reduction of CD40 in the raft fractions as compared to coexpression with wild-type 
TRAF2 (Fig. 3.3.1D, bottom). Although TRAFl resulted in a complete loss of TRAF2 
from the raft fractions, there was still a considerable amount of insoluble TRAF2 in the 
crude cell extract, which may represent cytoskeleton-associated TRAF2 ((35) and further 
discussion below). To visually examine the distribution of TRAF2 in the cell, we co-
transfected TRAF2 fused at its C terminus to EGFP (TRAF2-GFP) with or without CD40 
and TRAFl. Fluorescence microscopy 24 hours after transfection revealed that TRAF2-
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GFP by itself was distributed throughout the cytoplasm with several aggregates in the 
cell, which is consistent with the ability of overexpressed T R A F 2 to self-associate. 
Coexpression of C D 4 0 resulted in the complete redistribution of T R A F 2 - G F P to punctate 
structures distributed throughout the cell. Addition of T R A F l to T R A F 2 - G F P alone or 
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Figure 3.3.1. T R A F l regulates the 
detergent solubility of TRAF2. 
A. 293T H E K cells were transfected in 6-
well plates with the indicated amounts of 
CD40, TRAFl, and TRAF2. Total D N A 
content was maintained constant at 1 )J.g by 
the addition of empty vector. Cells were 
lysed in 0.75% Triton X-100, and soluble 
(S) and insoluble (I) fractions were 
immunoblotted as indicated. After probing 
with T R A F 2 antibodies (C-20), blots were 
stripped and reprobed with anti-Flag M 2 to 
detect TRAFl and CD40. 
B. As in (A), but with 0.1 jig of TRAF2 or an N-terminal truncation mutant removing the first 87 residues 
(comprising the RING finger) of TRAF2 (T2A87). 0.5 ,ug of TRAFl was transfected where indicated (+). 
C. As in (A), with TRAF5 where indicated. 
D. 293T cells were transfected with 1.5 jig of TRAF2 or T2A87, 2.5 ng of TRAFl, and 1.0 ng of CD40 
where indicated. Cells were treated with CD40L 6 h prior to harvesting then subjected to sucrose gradient 




E. 293T cells were transfected as in (A) with TRAF2-GFP or GFP alone (0.2 ng), CD40 (0.1 (ig). and 
TRAFl (0.3 ng) as indicated. Cells were visualized by fluorescent microscopy 24 h after transfection. 
3.3.3.2 Differential effects of T R A F 2 and T R A F 6 on CD40 localization 
While oligomerization at the receptor appears to be necessary for the translocation of 
TRAF2 and CD40 into lipid rafts (33), it is unclear whether receptor engagement per se is 
sufficient for stable translocation of the receptor. The cytoplasmic tail of CD40 has two 
defined TRAF binding sites, one that is proximal to the membrane to which TRAF6 
binds, and a more distal site which binds to TRAFs 1, 2, 3, and 5 (7). While TRAF2 and 
TRAF3 have been shown to be recruited to membrane rafts by CD40 engagement in 
primary cells (34), TRAF6 does not appear to play a prominent role in CD40-associated 
lipid rafts (33). In order to compare the contributions of TRAF2 and TRAF6 to CD40 
translocation, we generated point mutants of CD40 that are deficient in binding to 
TRAF2, TRAF6, or both. Based on structural studies, we (section 3.2) and others (7) 
have identified E239 of mouse CD40 (corresponding to E235 of human CD40) as a 
critical binding residue for TRAF6 and Q253 (corresponding to Q252 of human CD40) 
as a critical binding residue for TRAF2. Cotransfection of CD40 and alanine mutations of 
E239, Q253, or both with TRAF2 followed by immunoprecipitation of CD40 
demonstrated that TRAF2 binding to CD40-Q253A is greatly attenuated (Fig. 3.3.2A, 
top). A similar cotransfection of CD40 constructs with TRAF6 and immunoprecipitation 
of TRAF6 demonstrated that TRAF6 binding to CD40-E239A is greatly attenuated (Fig. 
3.3.2A, bottom). Sucrose density gradient fractionation revealed that wild-type CD40 and 
CD40-E239A translocated to raft fractions, but to a greater extent in the presence of 
overexpressed TRAF2 than in the presence of overexpressed TRAF6. However, CD40-
Q253A and the double E239A/Q253A mutant remained in the soluble fraction in the 
presence of overexpressed TRAF2 or TRAF6 (Fig. 3.3.2B). Since CD40-WT is found in 
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the raft fraction in the presence of overexpressed TRAF6 at similar levels to those of 
CD40-E239A, raft translocation of CD40 appears to be dependent on its ability to bind to 
TRAF2, but not to TRAF6. Furthermore, a higher level of raft-associated CD40-E239A 
than CD40-WT was observed in the presence of overexpressed TRAF2, which suggests 
that TRAF6 binding may actually decrease the steady-state affinity of CD40 for the raft 
fraction. 
A m 
.̂ *r ̂  
< **• CM 
01 fo \ 
. cn y~> <n 
C N N. (O 
> HJ U IN j ^ W f l m ^ CD40/mutants 
WCE tm •»^-**«TRAF2 
ro 
< S ~ 
CT, rn ^ 
. fY> cn Oi 
C c\j cy, m 
s uj a w 
1 (*•> "" m -«CD40/mutants 
IP:aTRAF6!(«,»,. m * „TRAF6 













2 3 4 5 W n i O 
m ^ ^ m m + CD40- WT 
* 1 ^^^^BAd40-E239A 
. * mmmmm'* 
" j Z 2 8 ^ CD40-Q2 5 3 A 
" ,n-r-'7^mmmmmmmlCD40-Z39/Z53 
Figure 3.3.2. TRAF2 regulates the steady-state detergent solubility of CD40. 
A. 293T cells were transfected with Flag-tagged CD40 constructs (0.5 ng of W T or mutants as indicated) 
and TRAF2 (0.5 ng. top) or Flag-tagged TRAF6 (0.5 ng» bottom). CD40 was immunoprecipitated with 
anti-Flag M 2 antibodies and immunoprecipitates were probed for TRAF2 and CD40 as indicated. TRAF6 
was immunoprecipitated with anti-TRAF6 antibodies and immunoprecipitates were probed for CD40 and 
TRAF6 as indicated. 
B. As in Fig. ID, but cells were transfected with CD40-WT or the indicated mutants (1.0 ng) and TRAF2 
or TRAF6 (1.5 ng) and subjected to sucrose density gradient centrifugation and immunoblotting. 
3.3.3.3 T R A F l promotes sustained TRAF2-mediated signaling 
It has previously been shown that stable expression of T R A F l promotes sustained J N K 
activation by TNF-a (22). We found that, with the transfection of limiting amounts of 
TRAF2 (100 ng) and treatment with TNF-a (5 ng/ml) over the final 6 hours prior to cell 
lysis, TRAFl co-expression increased the steady-state level of JNK activation, which 
correlates with the redistribution of TRAF2 from the insoluble fraction to the soluble 
fraction (Fig. 3.3.3A). Short-term treatment by TNF-a (<30 minutes) induced high levels 
of JNK activation in untransfected cells or cells transfected with TRAF2 and varying 
amounts of TRAFl ((22) and data not shown). In an NF-tcB-luciferase reporter assay, 
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levels of luciferase activity should reflect the integrated total of NF-kB activation over 
the time between transfection and cell lysis. We found that, although increasing levels of 
TRAFl expression had little effect on the ability of limiting amounts of CD40 (50 ng) 
alone to activate NF-kB, in the presence of limiting amounts of TRAF2 (100 ng), TRAFl 
overexpression could increase sustained NF-kB reporter activity (Fig. 3.3.3B). Thus, the 
ability of TRAF2 to mediate the sustained activation of downstream signal cascades 
appears to correlate with its solubility. 
IP: JNK 1 
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Figure 3.3.3. T R A F l promotes sustained 
TRAF2-mediated J N K and NF-kB activation. 
A. 293T cells were transfected with T R A F l and 
T R A F 2 as indicated. 6 h prior to harvesting, 10 
ng/ml TNF-a was added to the culture medium. 
Cells were lysed in 0.75% Triton X-100 and 
subjected to an in vitro J N K kinase assay or 
fractionation as in Fig. 1. 
B. 293T cells were transfected with varying 
amounts of T R A F l (0, 0.1, or 0.5 ng. indicated 
by broadening line), C D 4 0 (50 ng), and T R A F 2 
(0.1 ng) as indicated and subjected to an NF-kB 
reporter assay. Values are indicated as fold 
increase over background, and are normalized 
against an internal standard (P-galactosidase). 
3.3.3.4 Raft translocation of T R A F 2 is necessary and sufficient for JNK, but not NF-
kB activation 
Since the RING finger of TRAF2 is necessary for NF-kB (12) and JNK (13) activation, 
as well as for raft translocation (Fig. 3.3.2), we investigated whether raft translocation is 
sufficient for the ability of TRAF2 to activate these signals. Many Src-family kinases are 
acylated, leading to their accumulation in membrane rafts (29). Previously, fusion of the 
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N-terminal myristoylation/palmitoylation signal sequence of Lck to Akt has been used to 
force membrane localization of Akt, leading to constitutive Akt activity (39). We 
therefore generated cDNA encoding the myristoylation-palmitoylation signal from Lck 
linked to the N-terminus of T2A87 (M/P-T2A87), thus directing redistribution of T2A87 
to the membrane raft fraction in a RING finger-independent manner. When 
overexpressed with or without CD40 and/or TRAFl, M/P-T2A87 was localized primarily 
in the insoluble fraction, although co-expression of TRAFl could redistribute a small 
amount of M/P-T2A87 to the soluble fraction (Fig. 3.3.4A). M/P-T2A87 could not 
substantially activate NF-kB (Fig. 3.3.4B). However, in a JNK assay, overexpressed 
M/P-T2A87 was able to rescue the deficiency in JNK activation by T2A87, although only 
about half as efficiently as wild-type TRAF2 (Fig. 3.3.4C). This bifurcation of the ability 
to activate JNK and NF-kB indicates that the RING finger's ability to mediate raft 
translocation is necessary and sufficient for JNK activation. However, raft translocation 
is not sufficient to activate NF-kB, suggesting that the RING finger has an essential 
function in addition to raft translocation that is required for NF-kB activation. 
Since it has been suggested that the RING finger of TRAF2 is necessary to interact with 
the MAP3K MEKK1 (14), which may be, in turn, necessary for JNK activation (15), we 
tested the ability of M/P-T2A87 to induce the translocation of MEKK1 to detergent-
resistant membranes. Co-expression of wild-type TRAF2, T2A87, and M/P-T2A87 with 
MEKK1 and lysis in 0.75% Triton X-100 showed that the ability of TRAF2 to mediate 
translocation of MEKK1 into the insoluble fraction correlated with its ability to activate 
JNK. Wild-type TRAF2 and M/P-T2A87 induced the translocation of MEKK1, but 
T2A87 did not (Fig. 3.3.4D, top). ASK1, another MAP3K known to interact with TRAF2 
and activate JNK, interacts with the TRAF domain of TRAF2. Unlike MEKK1, the 
association of ASK 1 and TRAF2 is not dependent on the RING finger of TRAF2 (40,41). 
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Accordingly, A S K 1 did not translocate to detergent-resistant membranes upon co-
expression with TRAF2 (Fig. 3.3.4D, bottom). The apparent necessity of the RING finger 
for interaction with MEKK1 actually reflects a requirement for lipid raft translocation but 
not the physical presence of the RING finger. Thus, since MEKK1 was previously shown 
to interact with a TRAF2 fusion construct with the C-terminal TRAF domain replaced by 
FKBP (14), it appears that MEKK1 interacts with the Zn fingers of TRAF2, and this 
interaction is dependent upon the ability of TRAF2 to translocate to lipid rafts. 
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Figure 3.3.4. Forced raft localization of T R A F 2 is sufficient to activate J N K , but not NF-kB. 
A. 0.1 ng °f wild-type T R A F 2 (wt), T2A87, or T2A87 with an N-terminal myristoylation-palmitoylation 
signal peptide (M/P-T2A87) was cotransfected with or without T R A F l (+, 0.5 ng). with or without C D 4 0 
(+, 0.2 ng) as indicated. Soluble and insoluble fractions were prepared as in Fig. 3.3.1. T h e relative 
proportion of soluble T R A F 2 or its mutants w a s determined by densitometry and is indicated below the 
immunoblots (Note: this is a reflection of values relative to one another, but does not provide an absolute 
measure of solubility). 
B . Cells were transfected with the indicated T R A F 2 constructs (0.4 ng) and subjected to an N F - k B reporter 
assay as in Fig. 3.3.3B. 
C. Cells were transfected as in (B) and subjected to an in vitro J N K assay as in Fig. 3.3.3A. 
D. Cells were transfected with the indicated T R A F 2 constructs (0.3 n g ) and M E K K 1 or A S K 1 (0.3 n g ) as 
indicated and soluble and insoluble fractions were prepared and immunoblotted. 
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3.3.3.5 Raft translocation is necessary for the interaction of TRAF2 with the actin-
binding protein Filamin 
Some TRAF proteins have been shown, upon activation, to localize to the actin 
cytoskeleton (35), potentially mediated through binding to Filamin (16). Furthermore, 
although nearly all of the known interactions TRAF2 has with other proteins appear to be 
mediated through the TRAF-C domain, it was proposed that TRAF2 interacts with 
Filamin through its RING finger domain (16). The presence of non-raft-associated, 
insoluble TRAF2 but not T2A87 in crude extracts (Fig. 3.3.2A) led us to investigate 
whether raft translocation was necessary for binding to cytoskeletal components. We 
cotransfected Filamin with TRAF2, T2A87, or M/P-T2A87 in the presence or absence of 
TRAFl. We then lysed the cells in 0.5% NP-40 to more efficiently dissociate M/P-T2A87 
from membrane rafts, and separately lysed a small aliquot of cells in 0.75% Triton X-100 
to show raft association. Immunoprecipitation of Filamin and western blotting revealed 
that, surprisingly, M/P-T2A87 could interact with Filamin as efficiently as wild-type 
TRAF2, while non-acylated T2A87 could not (Fig. 3.3.5, left side). Thus, it appears that, 
as in the case of MEKK1 (Fig. 3.3.4D), the RING finger is not essential for physical 
interaction of TRAF2 and Filamin, but raft translocation, ordinarily mediated by the 
RING finger, is necessary for Filamin binding. Furthermore, TRAFl was able to compete 
for binding to Filamin with TRAF2, thus in the presence of overexpressed TRAFl, 
TRAF2 did not bind to Filamin (Fig. 3.3.5, right side). This suggests that sequestration 
into the cytoskeleton by Filamin may serve to inactivate TRAF2 after it has translocated 
into membrane rafts, thus downregulating sustained or repeated TRAF2 signaling by 
internalization and possible degradation (36). By preventing TRAF2 from interacting 






























Figure 3.3.5. Interactions with T R A F 2 
a n d the actin-binding protein Filamin 
are dependent o n raft translocation of 
TRAF2. 
Cells were transfected as indicated with 
HA-tagged Filamin (a.a. 1644-2118; 0.3 
ng), TRAF2 constructs (0.3 ng). and 
TRAFl (0.3 ng) as indicated. Upon 
harvesting, 80% of the cells were lysed in 
0.5% NP-40, subjected to 
immunoprecipitation of Filamin with 
antibodies against HA, and immunoblotted 
as indicated. The remaining cells were 
lysed in 0.75% Triton X-100 and soluble 
and insoluble fractions were 
immunoblotted as indicated. 
3.3.3.6 T R A F l recycles T R A F 2 for signaling via serial receptor engagement in 
dendritic cells 
TRAFl is not ordinarily expressed at high levels in non-activated cells, but it is rapidly 
upregulated by NF-kB activation downstream of TNF family ligand stimulation (22). 
Therefore, we hypothesized that TRAFl may play a physiological role in situations 
where multiple T N F family ligands that signal through T R A F 2 engage cells over time. 
Dendritic cells (DCs) are known to respond to numerous TNF family members 
throughout their life cycle, including TNF-a, CD40L, and TRANCE. Furthermore, 
histological studies have shown that TRAFl expression is consistently elevated in DCs, 
perhaps more so than in any other cell type examined (21). Using bone marrow-derived 
DCs from wild-type mice and mice with a targeted deletion of the TRAF domain of 
TRAFl (TRAFl-/-; Y. Pewzner-Jung et al, manuscript in preparation), we found that 
CD40L or LPS maturation induces comparable levels of CD86 expression on CDllc+ 




In wild-type DCs, TRAFl expression is relatively low in the immature stage, but is 
greatly upregulated by maturation in CD40L or LPS (Fig. 3.3.6B). Treatment of 
immature or LPS-matured DCs from wild-type or TRAFl-/- mice with CD40L induced 
similar levels of NF-kB activation as measured by IkB degradation (Fig. 3.3.6B, lanes 1-
2, 5-6, 7-8, and 11-12). In DCs matured in CD40L, there was a marked deficiency in NF-
kB activation by CD40L restimulation in TRAFl-/- DCs as compared to wild-type DCs 
(Fig. 3.3.6B, lanes 3-4 and 9-10). Consistent with this deficiency in NF-kB activation, 
there was substantially less pre-existing soluble TRAF2 in CD40L-matured TRAF1-/-
DCs than in CD40L-matured wild-type DCs (Fig. 3.3.6B, lanes 1 and 3 vs. lanes 7 and 
9). Similar levels of pre-existing soluble TRAF2 were observed in immature and LPS-
matured TRAFl-/- DCs and wild-type DCs prior to CD40L restimulation (Fig. 3.3.6B, 
lanes 5 and 11). CD40L restimulation in all cases resulted in similar short-term (20 
minutes) reductions of soluble TRAF2, consistent with previous observations (34,36). 
Once mature, DCs quickly undergo apoptosis in the absence of survival stimuli provided 
by activated T cells including TNF family ligands such as TNF-a, CD40L, and TRANCE 
(42). We found that TRAFl-/- DCs matured in CD40L display severely impaired survival 
in response to TNF-a stimulation and partially impaired survival in response to CD40L, 
with a negligible defect in TRANCE-mediated survival. TRAFl-/- DCs matured in LPS, 
which does not signal through TRAF2, had comparable survival responses to wild-type 
DCs under stimulation by TNF-a, CD40L, and TRANCE (Fig. 3.3.6C). Thus, TRAFl 
appears to be dispensable for the first TRAF2-dependent signal (CD40L-induced 
maturation), but its upregulation by the maturation signal maintains high levels of soluble 
TRAF2, enabling subsequent TRAF2-dependent signals (TNF-a or CD40L-induced 
survival) to occur. While TRANCE can activate NF-icB through TRAF2 in vitro, (43), it 
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predominantly signals through T R A F 6 (43,44), which m a y explain the negligible 
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Figure 3.3.6. T R A F l - / - dendritic cells 
have deficient secondary responses to 
TRAF 2 - d e p e n d e n t signals. 
A. Wild-type and TRAFl-/- (Tl-/-) D C s 
were matured by overnight culture in 
CD40L (1:200) or LPS (100 ng/ml) and 
CD86 expression was monitored by 
FACS analysis. Immature cells are 
shown as shaded areas on the histogram 
and matured cells are shown as broad 
dark lines. 
B. DCs were matured as in (A) 
(immature, lanes 1-2 and 7-8; CD40L 
matured, lanes 3-4 and 9-10; LPS 
matured, lanes 5-6 and 11-12), starved in 
medium containing 0.5% serum for 2 h, 
and restimulated with CD40L (1:200) as 
indicated for 20 minutes (even numbered 
lanes; odd numbered lanes were not 
restimulated). Cells were lysed and the 
soluble fractions were immunoblotted as 
indicated. Normalized ratios of soluble 
TRAF2 relative to the level of soluble 
TRAF2 in unstimulated immature cells 
were determined by densitometry and 
are indicated below the P-actin blots. 
C. DCs prepared as in (A) were 
incubated in normal medium, or medium 
containing TNF-a (10 ng/ml), CD40L 
(1:200), or TRANCE (1 ng/ml) for 48 h 
as indicated. Survival was determined by 
PI exclusion FACS. Specific rescue is 
represented as [% of surviving cells 
(stimulated)-% of surviving cells 





The data presented in this report reconcile widely varying observations about TRAF2 
signaling to provide a potential mechanism of TRAF2's action. First, the mechanism of 
TRAF2 signaling centers on its ability to translocate to lipid rafts. The N-terminal RING 
finger domain of TRAF2 is necessary both for TRAF2's ability to activate signaling 
cascades and to translocate to lipid rafts. Enforced raft translocation of TRAF2 lacking its 
RING finger (T2A87) rescues T2A87's ability to activate JNK, but not NF-kB. Second, 
under conditions of sustained stimulation through TRAF2-dependent receptors, TRAF2 
becomes mostly insoluble and total cellular TRAF2 decreases. Third, TRAFl is known to 
be upregulated by activation of NF-kB and AP-1, often in TRAF2-dependent signaling. 
TRAFl can displace TRAF2 from rafts and promote sustained TRAF2-mediated 
signaling in response to a single stimulus or multiple stimuli over time. Thus, a dynamic 
model emerges of translocation of the receptor complex mediated by TRAF2, which is 
likely to be the trigger for signal activation in response to a stimulus. The physiological 
role for TRAFl is to "reset" the system by dissociating TRAF2 from insoluble complexes 
and enabling subsequent stimuli to transduce signals through TRAF2. 
Prior reports have suggested that a receptor, such as CD40, translocates to rafts upon 
ligand engagement and this leads to binding of TRAF proteins (33,34). In agreement with 
the potential requirement for zinc binding ability for TRAF2 to translocate to rafts (33), 
we have found that TRAF2 requires its N-terminal RING finger domain to translocate to 
the insoluble fraction (Fig. 3.3.1). Nevertheless, a mutant of TRAF2 lacking the RING 
finger, T2A87, is fully capable of binding to CD40 and acting as a dominant-negative for 
TRAF signaling (12.13). Furthermore, we have found that T2A87 overexpression actually 
reduces the amount of raft-associated CD40 (Fig. 3.3.ID), so the TRAF domain of 
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TRAF2 can clearly interact with CD40 in the soluble fraction. Although short-term 
stimulation of a CD40 mutant that cannot bind to TRAF2 resulted in its apparent 
translocation to lipid rafts (33), our data show that steady-state residence in lipid rafts by 
CD40 is dependent on its ability to bind to TRAF2 (Fig. 3.3.2). This suggests that the 
ability to activate downstream signals upon binding to a receptor is tied to the ability of 
TRAF2 to translocate the receptor complex to lipid rafts. It is thought that the N-terminal 
domain of TRAF2 somehow activates kinases that lead to NF-kB and MAPK signaling. 
However, with the exception of MEKK1 (14), all of the kinases known to interact with 
TRAF2 interact with the C-terminal receptor-binding domain (11). Our data suggest that 
MEKK1 does not physically associate with the RING finger of TRAF2 since enforced 
raft translocation of M/P-T2A87 induces JNK activation and translocation of MEKK1 
(Fig. 3.3.4). This apparent discrepancy may be explained by the observation that wild-
type TRAF2 did not interact with MEKK1 until TNF-a stimulation (14). TNF-a 
stimulation likely induced the translocation of TRAF2 to lipid rafts, where it may have 
had better access to MEKK1 or to intermediary proteins linking TRAF2 to MEKK1. 
Taken together with observations by the same authors that a construct with replacement 
of the TRAF-C domain of TRAF2 with an inducible multimerization signal could interact 
with and activate MEKK1, our data suggest that TRAF2 interacts with MEKK1 via its Zn 
fingers, but can only do so upon raft translocation. Regardless, the importance of 
MEKK1 in TNF-a mediated JNK activation is disputable, as genetic deletion targeting 
different regions of MEKK1 has shown opposite results with regard to its role in TNF-
mediated JNK activation (15,45). Thus, all of the known protein-protein interactions 
mediated by TRAF2 appear to be via the C-terminal receptor-binding TRAF domain or 
Zn fingers, but not the RING finger. This favors a model wherein receptor engagement 
by a ligand recruits TRAF2 and cytoplasmic factors including MAP3Ks, first in the 
soluble fraction. Subsequently, the RING finger mediates translocation of the receptor 
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complex to lipid rafts, which may simultaneously activate and release the kinases in a 
concerted mechanism, the details of which are still unclear. 
While the ability of TRAF2 to translocate to rafts appears to be tied to its ability to 
activate signal cascades, we have found that in primary cells under circumstances of 
sustained receptor engagement (~16h) in the absence of TRAFl, the steady-state level of 
TRAF2 in the soluble fraction decreases and TRAF2-dependent receptors become 
refractory to further stimulation (Fig. 3.3.6). Others have demonstrated that, under short-
term periods of signaling (<1 h), TRAF2 becomes insoluble and degrades in response to 
CD40 (36) and CD30 engagement (46). Stimulation of TNFR2 has resulted in a depletion 
of soluble TRAF2, potentiating TNFR 1-mediated cell death (47). Thus, while 
translocation into lipid rafts is essential for TRAF2 to activate signaling processes, once 
translocated, it appears that a given complex of TRAF2 is inactivated, thus supporting the 
idea that translocation and kinase activation are concerted, instantaneous processes. 
TRAFl, however, is able to displace TRAF2 away from the insoluble fraction back into 
the cytosolic fraction. The mechanism of how this happens is unclear, but it is possible 
that TRAFl hetero-oligomerizes with TRAF2, displacing it from rafts, and/or it competes 
with TRAF2 for binding sites on the receptor. In support of this, in transient transfection 
assays with prolonged TNF-a stimulation or overexpression of CD40 and TRAF2, which 
simulates prolonged stimulation, TRAFl not only increases the solubility of TRAF2, but 
it also increases JNK and NF-kB activation (Fig. 3.3.3). 
The presence of considerable amounts of TRAF2 in insoluble complexes that are not raft-
associated (Fig. 3.3.ID) indicates that there may be another subcellular location of 
insoluble TRAF2 complexes. TRAF2 has been shown to interact with Caveolin-1 (48) 
and the actin-binding protein Filamin (Fig. 3.3.5 and (16)) and has been suggested to 
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accumulate in perinuclear (49) or cytoskeletal compartments after signaling (35). This 
may ultimately lead to degradation of TRAF2 (36,46). Given TRAF2's association with 
lipid rafts and caveolae, a reasonable model suggests that, upon receptor enagement, 
TRAF2 first translocates to membrane rafts, where it can activate kinase cascades. It then 
may be internalized via caveolae, whereupon it is trafficked to cytoskeletal compartments 
and/or degraded. Since we found that only TRAF2 that is capable of raft translocation 
can bind to Filamin and that TRAFl can disrupt the interaction of TRAF2 and Filamin 
(Fig. 3.3.5), it appears that cytoskeletal trafficking of TRAF2 is a consequence of raft 
translocation. Furthermore, it is likely that TRAFl influences the intracellular trafficking 
of activated TRAF2 by solubilizing it not only from lipid rafts, but also from cytoskeletal 
structures. This may, in turn, prevent or reduce the degradation of activated TRAF2 
complexes, thereby increasing the available levels of soluble TRAF2 for subsequent 
signaling by engagement of multiple TNF receptor family proteins over time (Fig. 3.3.6). 
The implications of TRAFl's ability to regulate the solubility of TRAF2 leading to 
positive signaling outcomes are supported by several studies. Previously, we have found 
that transgenic overexpression of TRAFl in T cells leads to prolonged survival of 
activated CD8+ T cells that may otherwise be subject to TNF-a induced apoptosis (26). 
Others have shown that TRAFl, in concert with TRAF2, c-IAPl, and C-IAP2, contributes 
to the suppression of TNF-a induced caspase-8 activation and subsequent cytoprotection 
(25). In stable transfectants overexpressing full-length TRAFl, but not in transfectants 
expressing an N-terminal truncation of TRAFl, NF-kB and JNK activation was sustained 
(22). It has recently been observed that TRAFl is a target of caspases during apoptosis, 
which results in a decrease in its cytoprotective properties and a concomitant decrease in 
sustained antiapoptotic signaling by TRAF2 (27,28). During the preparation of this 
manuscript, it was reported that TRAFl deficiency results in "positive"' modulation of 
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TNF-a signaling in T lymphocytes (50). The increased TNF-induced skin necrosis 
observed in those TRAFl-/- mice is reminiscent of the "feed-forward" TNF-induced TNF 
overproduction in TRAF2-/- cells (51), and thus may point to a "negative" role of TRAFl 
in one aspect of TNF signaling but that "negative" role is in terms of a "positive" role in 
TRAF2 regulation. 
In this study, in TRAFl-/- DCs, CD40 signaling in the short term (up to 20 minutes) on 
immature cells is intact and comparable to that of wild-type cells, enabling NF-kB 
activation and functional maturation, as well as depletion of TRAF2 from the soluble 
fraction (Fig. 3.3.6). Since the signaling and functional outcomes in immature wild-type 
and TRAFl-/- DCs are indistinguishable, and since immature wild-type DCs express low 
levels of TRAFl, it is likely that the initial stimulation is TRAFl-independent. However, 
after 24 hours of stimulation by CD40L and a brief starvation period followed by 
restimulation, there is a marked difference between wild-type and TRAFl-/- cells. 
Despite similar CD40L-dependent induction of CD40 expression in wild-type and 
TRAFl-/- DCs (data not shown), CD40L can re-activate NF-kB in wild-type cells, but 
NF-kB activation in TRAFl-/- cells is greatly attenuated. This correlates directly with the 
level of pre-existing TRAF2 in the soluble fraction. These signaling events correlate 
strongly with substantially reduced DC survival mediated by the TRAF2-dependent 
factors TNF-a and CD40L in TRAFl-/- DCs matured in CD40L as compared to those 
matured in LPS, a TRAF2-independent factor. In TRAFl-/- DCs matured in CD40L, 
TNF-a provided virtually no survival effect, while CD40L was able to promote survival, 
albeit to a lesser extent than in wild-type DCs, and TRANCE promoted similar survival 
levels in wild-type and TRAFl-/- DCs. This is consistent with the fact that TRAF2 is the 
predominant TRAF protein that mediates survival signaling downstream of TNFR1, 
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while CD40 and TRANCE-R can signal through TRAF6 as well as through TRAF2 
(7,43). 
The role of TNF family ligand signaling in dendritic cell homeostasis is well 
documented. Dendritic cells residing in peripheral tissues become activated by the 
presence of inflammatory mediators, including IL-1, LPS, and TNF-a, or the presence of 
activated T cells, which may express TNF-a, CD40L, or TRANCE (52). Recently, it has 
been shown that transgenic overexpression of CD40L in epidermis leads to chronic skin 
inflammation and autoimmunity, mediated in large part by the excessive activation and 
maturation of Langerhans cells, which are epidermal DCs (53). TNF-a deficient mice 
have attenuated antiviral responses, in part due to deficiencies in maturation and 
upregulation of costimulatory factors due to a lack of auctocrine TNF-a production (54). 
There are two receptors for TNF-a: TNFR1 and TNFR2. TNFR1 can activate both the 
apoptotic caspase cascade and, via the interaction of TRADD with TRAF2, it can activate 
pro-survival signaling, while TNFR2 lacks a death domain and cannot activate caspases 
(1). The spontaneous apoptosis of mature DCs appears to be at least partially due to 
autocrine activation of TNFR1, as TNFR1-/- DCs in culture are highly resistant to 
spontaneous apoptosis (55). Given that TRAFl is highly expressed in DCs (21) and it 
regulates the availability of TRAF2 for anti-apoptotic signaling, it is likely that the 
balance between caspase activation and pro-survival signals is regulated to some extent in 
DCs by TRAFl. This hypothesis is consistent with our finding in TRAFl-/- DCs that 
maturation of DCs by CD40L tilts the balance of TNF-a signaling from survival to 
apoptosis due to a depletion of soluble TRAF2. 
What remains unclear is the mechanism of action of the RING finger that enables 
translocation of TRAF2 and the associated receptor complex. One potential mechanism 
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has emerged recently in studies examining a non-classical polyubiquitination mechanism 
mediated by the RING finger of TRAF6 (18,19). In these elegant in vitro studies, a 
protein complex that can activate IKK, leading to NF-kB activation, was biochemically 
purified. It was found that TRAF6 associates with the ubiquitin-conjugating enzymes 
Ubcl3 and UevlA, which results in polyubiquitination on K63 of ubiqutin (as opposed to 
proteasome-targeting K48 polyubiquitination), which is attached to TRAF6 itself, in a 
process dependent on the RING finger and oligomerization of TRAF6. This 
ubiquitination step, in turn, activates a complex consisting of the TAK1 (a MAP3K), 
TAB1, and TAB2, which can subsequently activate the IKK complex upstream of NF-kB 
as well as MKK6, which is upstream of JNK. Interestingly, TAB2 has been shown to 
translocate from membrane-associated fractions to the cytoplasm upon activation of the 
TAK1/TAB1/TAB2 complex (56). While it is unclear whether TRAF2 undergoes the 
same process as TRAF6, it is tempting to speculate that the formation of K63-linked 
polyubiquitinated complexes is tied to the translocation of TRAF2 to lipid rafts. This is a 
particularly intriguing hypothesis in light of the fact that various forms of ubiquitination 
have been tied to trafficking between cellular compartments (57). It is possible, then, that 
ubiquitinated TRAF2 can then interact with raft-associated proteins, possibly including 
the TAK1/TAB1/TAB2 complex or an analog of this complex with similar function, 
displacing them into the cytoplasm where they can phosphorylate substrates leading to 
NF-kB and JNK activation. Clearly, the role of ubiquitination in RING-dependent raft 
translocation and kinase activation merits further investigation. 
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4. Recycling of TRAF2 leading to 
sustained signaling/availability to 
other TNFR family members 
Figure 3.3.7. Proposed model of the mechanism of TRAF2 signaling and its regulation by TRAFl. 
Upon ligand engagment, a TNFR family protein recruits TRjAF2 and various kinases via the C-terminal 
TRAF domain of TRAF2. The receptor complex assembles in the soluble fraction. Upon complex 
assembly, the N-terminal RING finger of TRAF2 mediates translocation of the receptor complex into 
detergent-resistant lipid rafts. This translocation event simultaneously activates and releases the kinases, 
while isolating TRj\F2 in an insoluble complex that may be internalized and/or degraded. The activated 
kinases ultimately activate transcription factors such as NF-kB and AP-1, which upregulate the expression 
of TRAFl. TRAFl then releases TRAF2 from insoluble complexes by hetero-oligomerization with TRAF2 
or competing for receptor binding sites. This results in an increase of soluble TRAF2 that is available for 
subsequent signaling events mediated by other TRAF2-dependent TNFR family proteins. 
Conclusion 
While previous reports have concluded that T R A F signaling takes place within the rafts, 
our results suggest a slightly altered model (Fig. 3.3.7). Since the receptor, T R A F 2 , and 
downstream signaling components can interact in soluble lysates, and especially since 
T2A87 cannot translocate to rafts but can still interact with both the receptor and 
downstream components, it appears that the act of translocation is coupled to the 
activating event. Thus, upon receptor engagement, the receptor, T R A F 2 , and downstream 
signaling molecules assemble in the soluble fraction. Subsequently, T R A F 2 translocates 
with the receptor to lipid rafts, simultaneously releasing and activating the downstream 
kinase. It is unclear what the exact mechanism of activation of the downstream kinase is, 
but it is possible that K63-linked polyubiquitination and/or raft-associated kinases such as 
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c-Src either directly or indirectly activate these kinases. TRAF2 is now sequestered in the 
rafts, unable to stimulate additional molecules of downstream kinases. As TRAF2 has 
been shown to interact with caveolin-1 (48) and the actin-binding protein Filamin (16), 
which is a raft translocation-dependent process (Fig. 3.3.6), it is possible that TRAF2 
and/or other components of the receptor complexes are internalized and degraded. As a 
result of this initial signaling, NF-kB and AP-1 are activated and TRAFl gene expression 
is turned on. TRAFl protein levels rise, and now TRAFl can relocate TRAF2 to the 
soluble cytoplasmic fraction and potentially protect it from degradation, where it can re-
assemble receptor signaling complexes and continue the cycle. This allows for what 
appears to be "sustained" signaling or restimulation through the same receptor, or 
stimulation through multiple TNFR family proteins that bind to TRAF2 over time. 
3.3.5 Ex.perimental Procedures 
3.3.5.1 Reagents 
Recombinant mouse TNF-a, ILA, and GM-CSF were from R&D Systems, LPS (E. 
Coli 055:B5) was from Sigma, soluble hCD8-TRANCE (TRANCE) was purified from 
insect cells as described (58), and soluble mCD8-CD40L (CD40L) was generated in 
insect cells and supernatant was used at a 1:200 dilution as described (59). 
Antibodies (Abs) specific for lKB-a were from New England Biolabs; TRAF2 (N-19 and 
C-20), TRAFl (N-19), Lyn (44), JNK1 (N-19), MEKK1 (C-22), and ASK1 (H-300) were 
from Santa Cruz Biotechnology; P-actin (Ab-1) was from Calbiochem; HA (12CA5) 
from Boehringer Mannheim; the Flag epitope (M2) was from Sigma; and TRAF6 was 




Mouse CD40 was cloned by RT-PCR from whole spleen mRNA and inserted into the 
pFLAG-CMVl cloning vector (Sigma). Mouse TRAF2 and T2A87 in pcDNA3.1 have 
been previously described (60). To make M/P-T2A87, complementary oligonucleotides 
encoding the N-terminal 12 residues of Lck (MGCVCSSNPEDD) with appropriate 
flanking restriction sites were annealed, digested, and ligated into the expression vector 
encoding T2A87 at the 5' end of T2A87. To make TRAF2-GFP, cDNA encoding EGFP 
from the EGFP-N3 vector (Clontech) was ligated into pcDNA3.1. TRAF2 was amplified 
by PCR using a C-terminal primer that fused sequence encoding a flexible linker 
(GGGS)2 to the C-terminus and eliminated the stop codon, and this product was ligated in 
frame upstream of EGFP. ASK1 in pcDNA3 was generously provided by Dr. James 
Woodgett (Ontario Cancer Institute, University of Toronto) and HA-tagged Filamin (a.a. 
1644-2118) was generously provided by Dr. Ulrich Siebenlist (NIAID, NIH). MEKK1 in 
pCFL and Flag-tagged mouse TRAFl, TRAF5, and HA- and Flag-tagged TRAF6 have 
been previously described (43). Site-directed mutagenesis of CD40 was performed on the 
indicated residues by the Ex-Site method (Stratagene). All constructs were confirmed by 
sequencing. 
3.3.5.3 Dendritic cells 
Dendritic cells were generated from bone marrow precursors via a modification of 
existing protocols (61,62). Bone marrow precursors were plated in 24-well tissue culture 
plates at a density of 106/ml, 1 ml/well, in RPMI-1640 medium containing 5% heat-
inactivated FBS, 10 mM HEPES (pH 7.0), (3-mercaptoethanol, penicillin, streptomycin, 
and rmGM-CSF (25 ng/ml) and rmIL-4 (5 ng/ml) for 7 days in a 37°, 5% C02 incubator, 
with replacement of 800 fil of medium on days 2 and 4 and the addition of 500 jil of 
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medium on day 6. On day 7, cells were left alone or stimulated overnight with CD40L 
(1:200) or LPS (100 ng/ml). On day 8, cells were removed for FACS analysis, transferred 
to a new 24 well plate for restimulation (see below), or transferred into 96-well plates 
(105 cells/well in 200 ul of medium without GM-CSF or IL-4, containing 5% serum and 
the indicated stimuli [TNF-a, 10 ng/ml; CD40L, 1:200; or TRANCE, 1 ug/ml] in 
triplicate) for survival assays. Maturation was assayed by FACS analysis of CD86, 
CD80, and I-Ab expression, gated on CDllc+ cells on a FACSCalibur (Becton-
Dickinson). Survival was assayed by FACS analysis of propidium iodide exclusion after 
48 h as described previously (58). 
3.3.5.4 Cell Stimulation, Transfection, and Analysis 
In vitro differentiated dendritic cells were extensively washed to remove exogenous 
growth factors, cultured in medium with low serum (0.5% FBS, 2-4 h), then stimulated 
by adding TNF-a, TRANCE, or CD40L as indicated. After stimulation, cells were 
washed with ice-cold PBS, lysed, and subject to SDS-PAGE and western blotting. In 
order to control for equal loading of each timepoint, the protein concentration of each 
sample was determined and samples were normalized for total protein content prior to 
further processing. 
293T cells were transfected in 6-well plates by calcium phosphate precipitation as 
described (43). The amount of transfected DNA was held constant to 1 fig by addition of 
empty vector DNA where necessary. Cells were processed for analysis 24-30 h after 
transfection. For NF-kB reporter assays, cells were transfected with the indicated 
amounts of expression constructs and mutants along with 75 ng of an NF-KB-luciferase 
reporter plasmid and 25 ng of a [3-galactosidase plasmid to control for transfection 
efficiency. Transfection amounts were kept constant at 1 ag by addition of empty 
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pFLAG-CMVl vector. Luciferase and [3-galactosidase activity was measured as 
described (43). In vitro JNK assays were performed on cell lysates as described (59). All 
transfection experiments were repeated at least three times and representative results are 
shown. 
Where indicated, cells were harvested in 1 ml ice-cold PBS, then lysed in a solution of 
150 mM NaCl, 20 mM HEPES (pH 7.0), 10% glycerol, and 0.75% Triton X-100 with 
protease and phosphatase inhibitors (1 mM PMSF, 1 u.g/ml leupeptin, 0.1 U/ml aprotinin, 
10 mM NaF, and 5 mM Na3V04). For lysis in NP-40, cells were lysed in HNE buffer (20 
mM HEPES, pH 7.0; 150 mM NaCl, 5 mM EDTA) with 0.5% NP-40 and protease 
inhibitors. Cell lysates were incubated on ice for 20-30 minutes, vortexed extensively, 
and centrifuged in a microfuge at maximum speed at 4° for 10 minutes. Soluble fractions 
were removed and subjected to SDS-PAGE or immunoprecipitation. Insoluble fractions 
were washed extensively in lysis buffer and solubilized via the addition of SDS gel-
loading buffer, vortexing, and boiling for 10 minutes. Immunoprecipitation was carried 
out by the addition of an antibody as indicated to the soluble fraction, rotation at 4° for 2-
3 h, followed by the addition of 15 ul protein G-sepharose equilibrated in lysis buffer and 
rotation at 4° for 1 h. The beads were washed 3 x in lysis buffer containing detergent and 
once in lysis buffer without detergent. SDS gel-loading buffer was added and samples 
were boiled and subjected to SDS-PAGE and western blotting. 
3.3.5.5 Sucrose density gradient centrifugation 
293T cells were transfected as indicated in 10 cm tissue culture plates with 4 ug total 
DNA. Six hours prior to harvesting, CD40L (1:200) was added to the culture medium. 
Cells were harvested in ice-cold PBS and lysed in 1 ml of HNE containing 0.25% Triton 
X-100, incubated on ice for 30 minutes, and vortexed extensively. One ml of an 80% 
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sucrose solution in HNE was mixed with the lysate, and this was overlaid with 2 ml of a 
30% sucrose solution in HNE, followed by 1 ml of a 5% sucrose solution in HNE. The 
samples were centrifuged in a Beckman SW55Ti rotor at 200,000 x g overnight at 4° as 
described (35). 0.5 ml fractions were taken from the top of the gradient to which 250 ul 
of 2x SDS gel-loading buffer was added. 30 ul of each fraction was subjected to SDS-
PAGE and western blotting. 
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3.4 SUPPLEMENTARY RESULTS 
The results presented in this section do not clearly fit anywhere into the three major 
results sections, but comprise some important observations about TRAF signaling that 
contribute to the continuity of this thesis. Although the results presented here are far from 
comprehensive, they are presented in support of ideas that will be addressed in the 
general discussion in section 4. These results pertain to TRAF-mediated activation of 
Src-family kinases, which represents a new TRAF-activated signaling pathway 
previously identified by our laboratory (1). 
3.4.1 Phosphorylation of TRANCE-R by c-Src downregulates the surface expression 
of TRANCE-R 
Joseph R. Arron, Masha Vologodskaia, and Yongwon Choi 
TRANCE and c-Src are essential components of the signaling processes that underlie 
osteoclast biology. Gene targeting experiments have demonstrated that TRANCE is 
required for the differentiation of osteoclasts from hematopoietic precursors (2). 
Although mice deficient in c-Src have osteoclasts, osteoclast function in c-Src-/- mice is 
severely impaired, leading to osteopetrosis (3). Osteoclasts from these mice fail to 
undergo cytoskeletal rearrangements such as the formation of ruffled borders and actin 
rings necessary for bone resorption (4). Since TRANCE is necessary to induce these 
morphological and functional changes in mature osteoclasts (5), we reasoned that 
TRANCE and c-Src acted in a shared biochemical pathway. We recently demonstrated 
that TRANCE treatment results in activation of Akt in osteoclasts and dendritic cells, and 
that this process is dependent upon c-Src activity. Exposure to TRANCE leads to the 
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association of c-Src with TRANCE-R and an increase in the kinase activity of Src-family 
kinases (1). Furthermore, as we have shown in Section 3.1, c-Src mediates tyrosine 
phosphorylation of TRANCE-R on a specific residue (Y468 in mouse TRANCE-R) (6). 
We therefore investigated the role of tyrosine phosphorylation of TRANCE-R in its 
expression and signaling. 
Although a Y468F mutation in mouse TRANCE-R abolished phosphorylation of 
TRANCE-R by c-Src, it did not affect the ability of TRANCE-R to interact with c-Cbl or 
Cbl-b (6). In order to further investigate the role of TRANCE-R tyrosine phosphorylation 
in TRANCE-mediated signaling, we attempted to generate cell lines that stably expressed 
wild-type TRANCE-R or TRANCE-R with a Y468F mutation (TR-wt or TR-Y468F). 
Using the pMI retroviral vector, we generated retroviruses containing a construct driving 
the expression of TR-wt or TR-Y468F followed by an internal ribosomal entry site 
(IRES) and cDNA encoding human CD2. Using these retroviruses, we infected 
KMls8.3.5.1 (K8) T cell hybridomas, which do not ordinarily express TRANCE-R on 
their surface as determined by FACS analysis (data not shown). Two days after infection, 
FACS analysis of the bulk cell population revealed the presence of hCD2+, TRANCE-R+ 
cells infected with wild-type TR-wt and TR-Y468F viruses (Figure 3.4.1, left panels). 
Ten days after infection and selection in 500 Ug/ml G418, the bulk population of cells 
contained hCD2+, TRANCE-R+ cells only in the sample infected with TR-Y468F. In 
samples infected with TR-wt, there were no TRANCE-R+ cells despite the presence of 
hCD2+ cells (Figure 3.4.1, middle panels), suggesting that, despite the presence of TR-wt 
mRNA, cell surface expression of TR-wt was impaired. Infected cells were cloned by 
















v o -t 








Wild-type o o. 
'5S :• 
£21; 













10" 10' 10' 10" 10" 
CD2FITC 
2 d post-infection 
o o -
*m 











"••I • ) ' " " * 
10" 10' IO* 10J 10' 
FL1-H 
*n" «n' */yt tn-S tri*i 
10 d post-infection Representative clones 
Figure 3.4.1. Phosphorylation of TRANCE-R on Y468 prevents stable cell surface expression of 
TRANCE-R. 
KMls8.3.5.1 T cell hybridoma cells (K8) were infected with retroviruses driving expression of wild-type 
TRANCE-R (TR-wt) or TR-Y468F upstream of an IRES-hCD2 insert. FACS analysis of infected K8 cells 
is shown 2 d after infection (left panels). 10 d after infection and G418 selection (middle panels), and 
representative clones obtained by limiting dilution (right panels). 
W e next determined whether TRANCE-mediated signaling leading to the activation of 
Src-family kinase dependent pathways is affected by the Y468F mutation in TRANCE-R. 
We have previously found that the activation of Akt by TRANCE is dependent on 
TRAF6 and Src-family kinases (1), so we investigated TRANCE-mediated Akt activation 
in K8/TR-Y468F stable cells. While K8 cells alone did not show activation of Akt or 
JNK in response to TRANCE stimulation, K8/TR-Y468 cells showed Akt and JNK 
activation in response to TRANCE (Figure 3.4.2). K8/TR-wt cells did not show 
activation of any signaling pathways in response to the addition of soluble TRANCE, 
consistent with the observation that they do not express TRANCE-R on their surface 
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Figure 3.4.2. Y468 of TRANCE-R is not 
required for TRANCE-activated signaling. 
Parental K8 cell line (left) or a stable clone 
expressing TR-Y468F (right) were starved in 
0.5% FBS for 2-3 h and stimulated for the 
indicated number of minutes with soluble 
T R A N C E (2 ng/ml). Cell lysates were 
immunoblotted with antibodies to phospho-Akt 
and total Akt (WCE, top), or subjected to an in 
vitro JNK kinase assay (bottom). 
Previously, w e have attempted to generate stable cell lines expressing wild-type full-
length TRANCE-R on the cell surface, and these attempts have failed in a wide variety of 
c o m m o n cell lines, including H E K 293, Cos, C H O , HeLa, and others (data not shown). 
While TRANCE-R mRNA expression has been detected in numerous cell types and 
tissues, including skeletal muscle, thymus, liver, colon, small intestine, and adrenal gland 
(7), high levels of cell surface expression of T R A N C E - R have only been observed on 
mature DCs. Notably, high surface expression of TRANCE-R has not been observed on 
immature DCs, macrophages, or naive lymphocytes (8). Osteoclasts and activated 
lymphocytes respond to T R A N C E stimulation, but cell surface expression of T R A N C E -
R on these cell types is very low relative to the expression of TRANCE-R on mature 
DCs. Taken together with the finding that TR-Y468 can be stably expressed on the cell 
surface, these observations suggest that tyrosine phosphorylation of T R A N C E - R on 
Y468 in most cell types may activate a strong internalization or degradation signal. 
Why, then, is TRANCE-R expressed at such high levels on mature DCs? As DCs mature, 
they downregulate endocytosis so as to express the highest possible levels of peptide -
M H C complexes and costimulatory molecules on their surface for efficient T cell priming 
(9). The downregulation of endocytosis by mature DCs appears to be tied to the 
regulation of Rho-family GTPases, particularly Cdc42 (10). Thus, the high levels of 
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surface TRANCE-R expression in mature DCs may be a by-product of low endocytic 
activity in mature DCs. The normal or elevated endocytic activity in the cell lines 
mentioned above or immature DCs may be sufficient to prevent high stable levels of 
surface TRANCE-R expression in those cells. Further investigation of the role of 
phosphorylation of Y468 in TRANCE-R and cytoplasmic factors that bind to phospho-
Y468 may reveal important regulatory processes that underlie the efficient endocytosis 
displayed by immature DCs. 
3.4.2 The N-terminus of TRAF6 has a unique role in c-Src activation 
Joseph R. Arron, Takashi Kobayashi, and Yongwon Choi 
TRAF6 and c-Src have overlapping roles in TRANCE signaling in osteoclasts, as 
determined by genetic and biochemical experiments (1,3,4,11-13). We have found that 
TRAF6 can interact with c-Src (1) and c-Cbl (6). Furthermore, while the interaction with 
c-Src and c-Cbl appears to be dependent only on the TRAF domain of TRAF6, 
expression of full-length TRAF6 leads to the activation of c-Src, resulting in the tyrosine 
phosphorylation of c-Cbl. Thus, similar to the activation of IKK and JNK signal cascades 
(14,15), there is a requirement for the N-terminal RING and Zn fingers of TRAF6 to 
activate c-Src. We have shown in that the RING finger of TRAF2 is necessary for its 
translocation to lipid rafts and the activation of IKK and JNK cascades (Section 3.3). It 
has been well established that acylated Src-family kinases localize to lipid rafts (16). In 
order to determine if the N-terminal RING and Zn fingers of TRAF2 and TRAF6 have 
unique roles, we generated chimeric TRAF proteins, comprising the N-terminus of one 
TRAF and the TRAF domain of another TRAF. This approach has been previously used 
to dissect the differential signals transduced by TRAF3 and TRAF5 (17). 
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W e generated two chimeric TRAF2-TRAF6 constructs: 1) Residues 1-240 of m T R A F 2 
fused to residues 289-530 of mTRAF6 (N2-C6), and 2) residues 1-288 of TRAF6 fused 
to residues 241-501 of TRAF2 (N6-C2). Overexpression of TRAF2, TRAF6, N2-C6, and 
N6-C2 induced NF-kB and JNK activation (Figure 3.4.3A and B), although the N2-C6 
construct activated NF-kB at 3-4-fold levels lower than did similar amounts of TRAF2, 
TRAF6, or N6-C2. When we transfected the various TRAF constructs with c-Cbl and 
limiting amounts of c-Src and examined tyrosine phosphorylation of c-Cbl, we found that 
TRAF6 and the N6-C2 construct could promote efficient phosphorylation of c-Cbl, but 
TRAF2 and N2-C6 could not, although there was a slight increase over background 
levels in phospho-c-Cbl in the presence of overexpressed TRAF2 (Figure 3.4.3C). Thus, 
while the TRAF domain is sufficient for TRAF6 to interact with c-Src and c-Cbl, the N-
termin.al RING and Zn fingers have a unique role in the activation of c-Src, and this 
function cannot be substituted by the N-terminal domain of TRAF2. Conversely, the N-
terminal RING and Zn fingers of TR.*AF6 are able to confer c-Src activating ability to the 
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Figure 3.4.3. Differential abilities of the N-
terminal RING and Zn fingers of TRAF2 and 
TRAF6 to activate c-Src. 
A. TRAF2, TRAF6, and chimeras consisting of 
the N-terminal half of TRAF2 fused to the C-
terminal half of TRAF6 (N2-C6) and the N-
terminal half of TRAF6 fused to the C-terminal 
half of TRAF2 (N6-C2) (0.5 jug) were transfected 
into 293T cells with an NF-KB-responsive 
reporter plasmid and luciferase activity was 
measured 24h after transfection. 
B. As in (A), but an in vitro JNK assay was 
performed on the cell lysates. 
C. TRAF6, T6.DN, TRAF2, T2.DN, N2-C6, and 
N6-C2 (0.5 ,ug) were co-transfected as indicated 
with HA-tagged c-Cbl (0.3 ng) and c-Src (10 ng). 
c-Cbl was immunoprecipitated with antibodies to 
HA and immunoprecipitates were immunoblotted 
with antibodies to phosphotyrosine (4G10). 
Despite numerous observations that T R A F 2 and T R A F 6 activate similar signaling 
pathways through the action of their RING and Zn fingers (18), our findings suggest that 
the functions of these domains may be divergent, and this may point to divergent 
mechanisms of action between TRAF2 and TRAF6. Thus, there are two potential 
mechanisms whereby TRAF2 and TRAF6 can achieve signaling specificity: 1) binding to 
different receptor sites (Section 3.2) and 2) differential ability to activate signaling 
cascades through the action of the N-terminal RING and Zn fingers. 
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4. GENERAL DISCUSSION 
This thesis investigates the proximal components of TNFR family protein signal 
transduction, specifically pertaining to the assembly and regulation of signaling 
complexes mediated by TRAF proteins. Evolutionary, structural, and functional studies 
have all established a distinction between the TRAF proteins that activate signal cascades 
downstream of TNFR family proteins. This distinction is exemplified in examination of 
TRAF2 and TRAF6. While TRAF2 and TRAF6 appear to interact with an overlapping 
subset of intracellular molecules and TNFR family proteins, there are key distinctions to 
be made. Not only do TRAF2 and TRAF6 interact with different receptor sequences via 
their TRAF domains, but the functions of their N-terminal domains are also divergent. 
While it has long been understood that TRAFs were crucial for assembling signaling 
complexes upon TNF family ligand engagement of TNFRs, the mechanism of action of 
TRAFs has not been well characterized. The work presented in this thesis, along with 
other recent reports, makes significant progress toward delineating a mechanism of action 
for TRAF proteins. Two emerging themes in the mechanisms of TRAF signaling are 
ubiquitination and lipid raft translocation. Another important consideration in TRAF 
signaling lies in the other, often-ignored side of signal transduction - the negative 
regulation of signaling. Mechanisms of negative regulation of TRAF signaling appear to 
be tied to the very things that are required for signal activation, and it will be interesting 
to examine these phenomena in the context of signaling in general. 
4.1 Distinctions between TRAF6 and other TRAFs 
Examples of the two major types of signal-activating TRAFs are TRAF6 and TRAF2. 
TRAFl, 3, and 5 have more in common with TRAF2 than with TRAF6, although there 
are some key differences between them. Of TRAFl, 3, and 5, only TRAF5 has been 
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shown to activate NF-kB and AP-1 similar to TRAF2 (1,2). However, while TRAF2 
interacts directly with many receptors, TRAF5 may interact only indirectly with some 
receptors via hetero-oligomerization with TRAF3 (3). TRAF3 does not activate NF-kB or 
AP-1, but it is apparently essential for normal development and immune regulation (4). 
This essential role of TRAF3 may lie in its ability to recruit TRAF5 to receptors, or there 
may be additional regulatory roles for it that have not yet been identified. TRAFl is 
highly homologous to TRAF2 in its TRAF domain, but it lacks the N-terminal structures 
(RING and multiple Zn fingers) that enable TRAF2 to activate signals (5). Nonetheless, 
as we have seen in section 3.3, TRAFl is a key regulator of TRAF2-mediated signaling, 
most likely due to its ability to hetero-oligomerize with TRAF2 and regulate its 
subcellular distribution. TRAFl, 2, 3, and 5 all interact with similar receptor sites, albeit 
with slightly different affinity/avidity profiles (6). 
TRAF6 has the most evolutionarily divergent TRAF domain, although its 
oligomerization appears to activate NF-kB and AP-1 very similarly to TRAF2. TRAF6 
binds to a distinct receptor sequence from TRAF2, as we have defined in section 3.2. 
Thus, one obvious level of specificity that may be conferred by TRAF6 is that it can 
potentially interact with a completely different array of receptors. Furthermore, TRAF6 
can interact with IRAK proteins, which, unlike TNFR proteins, are intracellular adaptors 
for non-TNFR family receptors (7,8). The IL-l/TLR family of receptors is very important 
in general inflammation and innate immunity, thus TRAF6 is a bridge between innate and 
adaptive immunity. Not only does TRAF6 have key roles in immunity, but the same 
inflammatory factors and repetitive sequences that mediate innate immunity can also 
affect bone homeostasis (section 2.3.2). TRAF6 has been shown to be vital for osteoclast 
physiology, and we have recently found that dendritic cells, which arise from the same 
hematopoietic precursors as osteoclasts, are also dependent on TRAF6 for their 
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maturation (T. Kobayashi et al., unpublished data). Thus, by virtue of the fact that DCs 
and OCs come from the same precursors, and the same factors are responsible for the 
final stage of their maturation and activation, and these factors are all dependent on 
TRAF6 for signal transduction, it is apparent that TRAF6 plays a central role in 
osteoimmunology. Figure 4.1 details the roles of TRAF6 in the parallel development of 
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Figure 4.1. Parallel lifecycles of dendritic cells and osteoclasts and the role of T R A F 6 in 
osteoimmunology. 
D C s and O C s differentiate from c o m m o n myeloid hematopoietic precursors. Factors mediating D C 
differentiation include G M - C S F , IL-4, and TNF. D C differentiation is dependent on the combination of the 
NF-kB subunits p50 and RelA (F. Ouaaz, J. Arron, Y. Zhang, Y. Choi, and A. Beg, manuscript submitted). 
O C differentiation is dependent on M - C S F , T R A N C E , and the transcription factors c-Fos and the 
combination of NF-kB subunits p50 and p52 (9). The maturation of D C s and O C s are both mediated by 
TRAF6-dependent factors, including LPS, C p G , and IL-1. C D 4 0 L also induces D C maturation, while 
T R A N C E induces O C maturation. Mature, activated D C s and O C s rapidly undergo apoptosis in the 
absence of survival signals provided by T R A N C E and C D 4 0 L . TRANCE-mediated D C survival is 
dependent on the combination of the NF-kB subunits p50 and cRel, while TRANCE-mediated O C survival 
is dependent on Akt. 
Since it appears likely that the T R A F domain of TRAF2 and TRAF6 is responsible for 
most protein-protein interactions (Sections 2.2 and 3.3), it might be reasonable to 
conclude that the specificity of signaling mediated by TRAF2 and TRAF6 is encoded in 
the T R A F domain, because it determines which upstream molecules are coupled to which 
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downstream molecules. For example, IRAK has three TRAF6 binding sites and no 
TRAF2 binding sites while TNFR2 has one TRAF2 binding site and no TRAF6 binding 
sites. Since TRAF2 and TRAF6 interact with overlapping but distinct subsets of 
intracellular signaling molecules, one would expect there to be a qualitative difference 
between the effects of IL-1 and TNF on a given cell. Nonetheless, the specificity of 
TRAF signaling does not appear to be localized exclusively to the TRAF domain. As we 
have shown in section 3.3, the RING finger of TRAF2 mediates its translocation to lipid 
rafts, and without TRAFl, TRAF2 remains in insoluble complexes after translocation. 
TRAF6, on the other hand, does not appear to accumulate in insoluble complexes ((10) 
and data not shown). While translocation appears to be necessary for the ability of 
TRAF2 to activate signaling cascades, it is unclear whether the same can be said for 
TRAF6. 
4.2 c-Src activation by TRAF6 
While the N-terminal RING and Zn fingers of both TRAF2 and TRAF6 mediate the 
activation of NF-kB and AP-1, the N-terminal half of TRAF6 can also strongly activate 
c-Src, while the N-terminal half of TRAF2 can only weakly activate c-Src, if at all 
(section 3.4). This result is particularly interesting in light of the fact that we previously 
observed that c-Src and c-Cbl interacted with TRAFl, TRAF3, and TRAF6, but not with 
TRAF2 or TRAF5 ((11) and data not shown). In fact, the pattern of co-
immunoprecipitation of c-Src and c-Cbl with various TRAFs correlates with the tendency 
of the TRAFs to localize in the soluble fraction of cells lysed in Triton X-100 (data not 
shown). Thus, it is possible that the reason we did not observe co-immunoprecipitation of 
c-Src and c-Cbl with TRAF2 is because that interaction may have taken place in the 
insoluble fraction, which, at the time, we ignored. In support of the notion that the TRAF 
domain of TRAF2 can in fact interact with c-Src and c-Cbl, the N6-C2 chimeric TRAF 
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construct could activate c-Src-mediated c-Cbl phosphorylation (section 3.4). 
Alternatively, while there is no doubt that the TRAF domain of TRAF6 can interact with 
c-Src, it may be possible that elements in the N-terminal half of TRAF6 can also interact 
with c-Src when oligomerized (as is the case in the N6-C2 construct, where the TRAF 
domain of TRAF2 mediates oligomerization). Previously, we did not observe interaction 
between c-Src with the N-terminal half of TRAF6 alone (11), but it is apparent that the 
N-terminal half of TRAF6 can activate signaling by itself if it is oligomerized artificially 
by some means other than the TRAF domain (12,13). However, our biochemical and 
strucutural studies (section 3.2) suggest that c-Src can interact with a specific part of the 
TRAF domain distal to the N-terminal half of TRAF6. Thus, if c-Src can interact with 
only the TRAF domain, then there is a unique ability of the RING and Zn fingers of 
TRAF6 to mediate c-Src activation. If c-Src can also interact with the oligomerized 
RING and Zn fingers of TRAF6 but not TRAF2, then the specific ability of the N-
terminal half of TRAF6 to interact with c-Src may mediate c-Src activation. While the 
currently available data do not completely rule out either possibility, the fact that c-Src 
can interact with the TRAF domain alone of TRAF6 favors the first possibility. 
4.3 Ubiquitination as a mechanism of TRAF signaling 
If the RING finger of TRAF proteins is not required for the interaction of TRAFs and any 
other proteins known to interact with TRAFs (section 3.3), how does it activate signaling 
cascades? One established function of RING finger domains is the ability to mediate 
ubiquitination of other proteins by acting as E3 ubiquitin ligases (14). For example, we 
(section 3.1) and others (15-17) have shown that Cbl family proteins mediate the 
degradation of activated signaling molecules in a RING finger-dependent manner, which 
is accomplished by the ubiquitination of target proteins. Recently, the RING fingers of 
TRAF2 and TRAF6 have been shown in vitro to mediate a novel form of 
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polyubiquitination (13,18). The well-characterized degradative pathway of ubiquitination 
involves polyubiquitination wherein ubiquitin chains are formed with covalent linkage of 
one ubiquitin molecule to the target protein and further molecules of ubiquitin are 
covalently linked to K48 of the previous ubiquitin. K48-linked polyubiquitination leads 
to proteasomal degradation of the targeted protein. The novel form of ubiquitination 
mediated by TRAF proteins involves the formation of polyubiquitin chains linked 
through K63 of ubiquitin. This does not appear to mediate degradation of the target 
proteins. However, TRAF6-mediated K63-linked polyubiquitination appears to be 
required for the activation of the IKK complex leading to NF-kB activation. In addition 
to ubiquitinating downstream signaling molecules, TRAF6 itself is polyubiquitinated 
through a K63 linkage. It is thought that TRAF2 undergoes a similar process. 
While K63-linked polyubiquitination appears to be required for NF-kB activation, our 
findings in section 3.3 demonstrate that the RING finger is dispensable for the activation 
of JNK by TRAF2 if raft translocation of TRAF2 is artificially induced. Taken together 
with the findings that K63-linked polyubiquitination leads to the activation of NF-kB as 
well as JNK (13), our observations that M/P-T2A87 can activate JNK but not NF-kjB 
(Fig. 3.3.4) suggest that RING finger-mediated polyubiquitination of TRAF2 may 
mediate its translocation into lipid rafts. Although translocation is sufficient for JNK 
activation, the ubiquitination process is likely to be required in addition to translocation 
for NF-kB activation. A caveat to this hypothesis is that the RING fingers on various 
TRAF proteins may function differently. TRAF3 does not translocate to insoluble 
complexes or activate JNK upon overexpression, but replacement of the RING finger of 
TRAF3 with the RING finger of TRAF5 has been shown to induce its translocation and 
its ability to activate JNK (19). However, endogenous TRAF3 has been shown to be 
strongly recruited to lipid rafts upon CD40 engagement or LMP1 expression (20-22), 
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which may be mediated by its hetero-oligomerization with TRAF5. The murine splice 
variant of TRAF2, TRAF2A, can activate JNK but not NF-kB (23), so it is possible that 
TRAF2A possesses an intrinsic property of the RING finger that enables raft 
translocation, but is not capable of mediating K63-linked polyubiquitination leading to 
NF-kB activation. 
While the possibility remains that the RING finger mediates ubiqutination and raft 
translocation as completely separate processes, it is simpler and more likely that the 
RING finger mediates one process, which results in the other process. Thus, RING-
mediated K63-linked polyubiquitination of TRAF proteins may increase the affinity of 
TRAFs for lipid rafts either intrinsically or by mediating the interaction of 
polyubiquitinated TRAFs with raft-specific proteins. Alternatively, the RING finger of 
oligomerized TRAF proteins may mediate translocation into rafts, where proteins 
mediating polyubiquitination reside, thus the co-localization of TRAFs and ubiquitinating 
enzymes enables their activation. Given that enforced raft localization of M/P-T2A87 can 
activate JNK signaling but not NF-kB activation in the absence of the RING finger, it 
seems likely that ubiquitination may precede raft translocation, since there is no evidence 
that raft translocation is absolutely necessary for NF-kB activation. However, 
ubiquitination is required for NF-kB activation. Therefore, an orderly progression of 
TRAF signaling may proceed as follows: 1) ligand-mediated receptor trimerization, 2) 
TRAF recruitment and trimerization, 3) recruitment of TRAF-interacting signaling 
molecules in the soluble fraction, 4) RING finger-mediated polyubiquitination of the IKK 
complex and TRAFs (leading to NF-kB activation), and 5) polyubiquitin-mediated TRAF 
translocation to lipid rafts leading to JNK activation (Figure 4.2). Clearly, the role of 
ubiquitination in RING-dependent raft translocation and kinase activation merits further 
investigation. 
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Figure 4.2. Proposed 
model of ubiqutin-
mediated signaling by 
TRAF proteins. See 
text for details. 
of. 
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4.4 Raft translocation as a mechanism of T R A F signaling 
The role of lipid rafts has been an emerging theme in signal transduction in recent years 
(24-26). Because of the differential affinities of various proteins for lipid-ordered 
microdomains, these domains may serve to concentrate certain proteins in close 
proximity to one another while excluding other proteins. Recently, rafts have also been 
suggested to be involved in cell polarity, by redistributing relative amounts of 
transmembrane and raft-associated proteins on different sides of a cell (27). W e have 
observed a crucial role of raft translocation in TRAF2-mediated signaling (section 3.3). 
Of particular interest is that, while raft translocation of T R A F 2 is necessary for its ability 
to activate certain signals, once it has translocated to lipid rafts, it does not relocalize to 
the soluble cytoplasmic fraction in the absence of T R A F l . Furthermore, when T R A F 2 is 
trapped in insoluble complexes as a result of an initial receptor engagement, it cannot 
activate signals in response to subsequent receptor engagements. Thus, the translocation 
of T R A F 2 to rafts appears to simultaneously activate downstream signals and inactivate 
T R A F 2 . While T R A F 2 does accumulate in lipid rafts to some extent during steady-state 
signaling, it appears that a majority of insoluble T R A F 2 may not be raft-associated. 
T R A F l , which is not expressed in naive cells, is upregulated by TRAF2-dependent 
signals, and its function appears to be to regulate steady-state levels of soluble T R A F 2 . It 
also prevents the steady-state association of T R A F 2 with the cytoskeletal protein Filamin. 
T R A F 2 must be able to translocate to rafts in order to associate with Filamin. It appears 
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that TRAF2 undergoes a cycle of raft translocation, internalization (possibly mediated by 
interactions with caveolin), and sequestration in insoluble cytoskeletal complexes and/or 
degradation. While raft translocation is necessary for the positive effects of TRAF2 
(activation of signaling cascades), it appears that raft translocation downregulates the 
ability of activated TRAF2 to activate further signaling cascades in the absence of 
TRAFl. Therefore, raft translocation serves a positive and negative role in TRAF2 
signaling. 
The temporally regulated positive and negative roles of raft translocation in TRAF2 
signaling is reminiscent of the temporally regulated positive and negative roles of Cbl 
proteins in TRAF6-mediated Akt activation (section 3.1). In each case, the association of 
components of a TNFR protein signaling complex with a regulatory factor (Cbl in the 
case of TRAF6 and c-Src and lipid rafts in the case of TRAF2) is necessary for both the 
activation of a signaling pathway and the ultimate quenching of that signal. This type of 
complex regulation is seen in other examples of Cbl signaling, such as from the EGF 
receptor (16), and in Src-family kinase signaling (28), where only activated kinases are 
susceptible to degradation by ubiquitination or inactivation by phosphatases. It is striking 
that in all of these cases, downregulation of a given component takes place as a direct 
consequence of the component's activation. 
Since TRAF2's solubility is regulated by TRAFl, how is TRAF6 regulated? While we 
have found that TRAF2 becomes insoluble in the steady state in the absence of TRAFl, 
we have not found the same to be true for TRAF6. Furthermore, while TRAF2 can 
induce steady-state raft translocation of CD40, TRAF6 appears to inhibit steady-state raft 
translocation of CD40 (Figure 3.3.2). TRAFl or TRAF3 alone do not localize to 
insoluble complexes upon overexpression, while TRAF2 and TRAF5 do localize to 
155-
4. General Discussion 
insoluble complexes (data not shown). This appears to directly correlate to the ability of 
overexpressed TRAF2 and TRAF5 to activate NF-kB and JNK, while overexpressed 
TRAFl and TRAF3 cannot. Although it can activate NF-kB and JNK, TRAF6 does not 
accumulate in insoluble complexes upon overexpression, and it been suggested that 
TRAF6 does not translocate to lipid rafts upon CD40 stimulation (10). However, the 
methods used to identify raft-associated TRAFs are based on relative detergent solubility. 
It is possible that TRAF6 is in fact raft associated upon ligand stimulation, but not as 
strongly as TRAF2 and it was therefore not detected in defined "raft fractions." 
In the case of LMP1 expression, it was found that TRAF2 and TRAF3 could be either 
detected or not detected in defined "raft fractions," depending on the lysis conditions 
(22). TRAF6 can interact with and is a potent activator of c-Src, a dually acylated raft-
associated kinase. Given these observations, it appears likely that TRAF6 may be able to 
translocate to lipid rafts in order to activate kinase cascades in the same manner as 
TRAF2, but it is able to easily dissociate from rafts, whereupon it can activate subsequent 
signals. TRAF2, on the other hand, becomes stuck in rafts and/or other insoluble 
fractions, and its solubility is regulated by an additional factor, TRAFl. In order to 
thoroughly examine these possibilities, real-time fluorescence imaging of TRAF2 and 
TRAF6 in live cells may be necessary. Additionally, the regulation of TRAF6 after its 
activation should be closely examined. TRAF2 can interact with caveolin (29) and 
Filamin (30), thus it is possible that TRAF2 is internalized and sequestered in the 
cytoskeleton after raft translocation. It has been suggested that Filamin plays a role in 
TRAF6 signaling (30), but a direct interaction has not been demonstrated. A mode of 
activation-induced TRAF6 downregulation through degradative ubiquitination has been 
shown, and this pathway may be unique to TRAF6, while sequestration in insoluble 
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complexes (and possible subsequent degradation) may be unique to the downregulation 
ofTRAF2. 
4.5 Physiological regulation of TRAF signaling 
Ultimately, the answers to many remaining questions about TRAF signaling lie in the 
observation of different cell types in the context of the whole organism. While TRANCE 
can activate a variety of signaling pathways in DCs and OCs, the functional roles of these 
signaling pathways are divergent. We have previously shown that the TRANCE-
R/TRAF6/c-Src/PI3-K pathway leading to the activation of Akt is an important survival 
signal for OCs (11). Others have implicated this pathway in TRANCE-mediated survival 
of ductal epithelial cells in breast tissue (31). However, this pathway appears to be less 
crucial in TRANCE-mediated DC survival, as Cbl-b-/- DCs are deficient in TRANCE-
mediated Akt activation, but have no survival defects relative to wild-type DCs (section 
3.1). Recently, we have found that TRANCE-mediated survival in mature DCs is 
specifically dependent upon the NF-kB subunits p50 and cRel in combination (F. Ouaaz, 
J. Arron, Y. Zhang, Y. Choi, and A. Beg, manuscript submitted). While recent evidence 
has suggested that PI3-K activation may regulate NF-kB transcriptional activity (32), the 
cross-talk between these pathways appears to be highly cell type-specific, and in fact may 
be specific to the RelA NF-kB subunit. Another level of cell type specificity in TRAF 
signaling comes from the transcriptional regulation of TNFR proteins. It has recently 
been shown that there are numerous alternatively spliced forms of CD40 in different cell 
types that may have differential abilities to interact with TRAFs (33). Given the 
observations that tyrosine phosphorylation on a particular residue of TRANCE-R 
regulates its cell surface expression (section 3.4) and that TRAF6 deficiency completely 
abrogates TRANCE-mediated signal activation despite the ability of full-length 
TRANCE-R to signal through TRAF2 (34), it is possible that TRANCE-R is similarly 
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alternatively spliced. In addition to the specific effects of proximal components of the 
signaling complex, it is likely that other, TRAF-independent signals that are activated 
within the cell may affect signals downstream of TRAFs. For example, IFN-y stimulation 
of OC precursors has been shown to induce the degradation of TRAF6 (35). Taken 
together, these and many other observations demonstrate that an understanding of TRAF 
signaling must be at a level deeper than simple protein-protein interactions. 
4.6 Conclusions 
It is clear is that the fine regulation of TRAF signaling in primary cells is dependent upon 
multiple factors, including: 1) the relative levels of various TRAFs within a given cell, 2) 
the availability of soluble TRAFs for ligand-dependent signaling, 3) the availability of 
downstream signaling components that interact with TRAFs, and 4) the recent history of 
TRAF-dependent signals in a given cell. These all contribute to the differential activation 
of various signaling pathways, ultimately leading to different gene expression profiles 
and cellular effects. While the work presented here has made considerable progress 
toward elucidating structural and functional features of the mechanisms of TRAF 
signaling, it has raised a number of further questions. What are the individual roles of the 
RING and each Zn finger in TRAF2 and TRAF6? While it is structurally similar to 
TRAF2, TRAF3 does not appear to regulate signaling in the same way as TRAF2 - what 
does TRAF3 do? What does TRAF4 do? We have identified a biochemical role for 
TRAFl, but there do not appear to be a strong phenotype in TRAFl-/- mice. What are 
some physiological situations in which TRAFl-mediated TRAF2 regulation might be 
important? TRANCE-R, a TNFR family protein, has three TRAF6 binding sites and two 
TRAF 1/2/3/5 binding sites. These account for about 10% of its cytoplasmic tail. CD40, 
which binds to the same TRAFs, has a considerably shorter cytoplasmic tail. What does 
the rest of TRANCE-R do? What non-TRAF proteins does it interact with, in TRAF 
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dependent and independent fashions? Ultimately the observations about the molecular 
phenomena that underlie TNF family signaling must be extrapolated into a 
comprehensive understanding of and ability to manipulate the wide range of 
physiological processes linked to inflammation and immunity. 
4.7 References 
1. Ishida, T. K., Tojo, T., Aoki, T., Kobayashi, N., Ohishi, T., Watanabe, T., 
Yamamoto, T., and Inoue, J. (1996) TRAF5, a novel tumor necrosis factor 
receptor-associated factor family protein, mediates CD40 signaling. Proc Natl 
Acad Sci USA93(l 8), 9437-42. 
2. Nakano, H., Oshima, H., Chung, W., Williams-Abbott, L., Ware, C. F., Yagita, 
H., and Okumura, K. (1996) TRAF5, an activator of NF-kappaB and putative 
signal transducer for the lymphotoxin-beta receptor. J Biol Chem 271(25), 14661-
4. 
3. Pullen, S. S., Miller, H. G., Everdeen, D. S., Dang, T. T., Crute, J. J., and Kehry, 
M. R. (1998) CD40-tumor necrosis factor receptor-associated factor (TRAF) 
interactions: regulation of CD40 signaling through multiple T R A F binding sites 
and TRAF hetero-oligomerization. Biochemistry 37(34), 11836-45. 
4. Xu, Y., Cheng, G., and Baltimore, D. (1996) Targeted disruption of TRAF3 leads 
to postnatal lethality and defective T-dependent immune responses. Immunity 
5(5), 407-15. 
5. Rothe, M., Wong, S. C , Henzel, W . J., and Goeddel, D. V. (1994) A novel family 
of putative signal transducers associated with the cytoplasmic domain of the 75 
kDa tumor necrosis factor receptor. Cell 78(4), 681-92. 
6. Pullen, S. S., Labadia, M. E., Ingraham, R. H., McWhirter, S. M., Everdeen, D. 
S., Alber, T., Crute, J. J., and Kehry, M. R. (1999) High-affinity interactions of 
tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require 
T R A F trimerization and CD40 multimerization. Biochemistry 38(31), 10168-77. 
7. Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D. V. (1996) TRAF6 
is a signal transducer for interleukin-1. Nature 383(6599), 443-6. 
8. Cao, Z., Henzel, W . J., and Gao, X. (1996) IRAK: a kinase associated with the 
interleukin-1 receptor. Science 271(5252), 1128-31. 
9. Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., 
Leonardi, A., Tran, T., Boyce, B. F., and Siebenlist, U. (1997) Requirement for 
NF-kappaB in osteoclast and B-cell development. Genes Dev 11(24), 3482-96. 
159-
4. General Discussion 
10. Hostager, B. S., Catlett, I. M., and Bishop, G. A. (2000) Recruitment of CD40 and 
tumor necrosis factor receptor-associated factors 2 and 3 to membrane 
microdomains during CD40 signaling. J Biol Chem 275(20), 15392-8. 
11. Wong, B. R., Besser, D., Kim, N., Arron, J. R., Vologodskaia, M., Hanafusa, H., 
and Choi, Y. (1999) T R A N C E , a T N F family member, activates Akt/PKB 
through a signaling complex involving TRAF6 and c-Src. Mol Cell 4(6), 1041-9. 
12. Baud, V., Liu, Z. G., Bennett, B., Suzuki, N., Xia, Y., and Karin, M. (1999) 
Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 
is sufficient for JNK and IKK activation and target gene induction via an amino-
terminal effector domain. Genes Dev 13(10), 1297-308. 
13. Wang, C , Deng, L., Hong, M., Akkaraju, G. R., Inoue, J., and Chen, Z. J. (2001) 
TAK1 is a ubiquitin-dependent kinase of M K K and IKK. Nature 412(6844), 346-
51. 
14. Joazeiro, C. A., and Weissman, A. M. (2000) RING finger proteins: mediators of 
ubiquitin ligase activity. Cell 102(5), 549-52. 
15. Levkowitz, G., Waterman, H., Zamir, E., Kam, Z., Oved, S., Langdon, W . Y., 
Beguinot, L., Geiger, B., and Yarden, Y. (1998) c-Cbl/Sli-1 regulates endocytic 
sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 
12(23), 3663-74. 
16. Levkowitz, G., Waterman, H., Ettenberg, S. A., Katz, M., Tsygankov, A. Y., 
Alroy, I., Lavi, S., Iwai, K., Reiss, Y., Ciechanover, A., Lipkowitz, S., and 
Yarden, Y. (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie 
suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4(6), 1029-40. 
17. Yokouchi, M., Kondo, T., Houghton, A., Bartkiewicz, M., Home, W . C , Zhang, 
H., Yoshimura, A., and Baron, R. (1999) Ligand-induced ubiquitination of the 
epidermal growth factor receptor involves the interaction of the c-Cbl RING 
finger and UbcH7. J Biol Chem 274(44), 31707-12. 
18. Deng, L., Wang, C , Spencer, E., Yang, L., Braun, A., You, J., Slaughter, C , 
Pickart, C , and Chen, Z. J. (2000) Activation of the IkappaB kinase complex by 
TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique 
polyubiquitin chain. Cell 103(2), 351-61. 
19. Dadgostar, H., and Cheng, G. (2000) Membrane localization of T R A F 3 enables 
JNK activation. J Biol Chem 275(4), 2539-44. 
20. Brown, K. D., Hostager, B. S., and Bishop, G. A. (2001) Differential signaling 
and tumor necrosis factor receptor-associated factor (TRAF) degradation 
mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane 
protein 1 (LMP1). J Exp Med 193(8), 943-54. 
160 
4. General Discussion 
33. Tone, M., Tone, Y., Fairchild, P. J., Wykes, M., and Waldmann, H. (2001) 
Regulation of CD40 function by its isoforms generated through alternative 
splicing. Proc Natl Acad Sci U S A 98(4), 1751-6. 
34. Kobayashi, N., Kadono, Y., Naito, A., Matsumoto, K., Yamamoto, T., Tanaka, S., 
and Inoue, J. (2001) Segregation of TRAF6-mediated signaling pathways clarifies 
its role in osteoclastogenesis. Embo J 20(6), 1271-80. 
35. Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., 
Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., Nakamura, K., and Taniguchi, T. 
(2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross- talk 
between R A N K L and IFN-gamma. Nature 408(6812), 600-5. 
162 
